





# **Photochemistry**

How to cite: *Angew. Chem. Int. Ed.* **2021**, *60*, 23827–23834 International Edition: doi.org/10.1002/anie.202110257 German Edition: doi.org/10.1002/ange.202110257

# Direct Photoexcitation of Ethynylbenziodoxolones: An Alternative to Photocatalysis for Alkynylation Reactions\*\*

Stephanie G. E. Amos<sup>+</sup>, Diana Cavalli<sup>+</sup>, Franck Le Vaillant, and Jerome Waser\*

Abstract: Ethynylbenziodoxolones (EBXs) are commonly used as radical traps in photocatalytic alkynylations. Herein, we report that aryl-substituted EBX reagents can be directly activated by visible light irradiation. They act as both oxidants and radical traps, alleviating the need for a photocatalyst in several reported EBX-mediated processes, including decarboxylative and deboronative alkynylations, the oxyalkynylation of enamides and the C-H alkynylation of THF. Furthermore, the method could be applied to the synthesis of alkynylated quaternary centers from tertiary alcohols via stable oxalate salts and from tertiary amines via aryl imines. A photocatalytic process using 4CzIPN as an organic dye was also developed for the deoxyalkynylation of oxalates.

#### Introduction

Alkynes have found broad applications in synthetic and medicinal chemistry, chemical biology, and materials science. [1] They can be used either as an inert and rigid connecting element or as a reactive unit. [2] Therefore, it is not surprising that synthetic methods for accessing alkynes are the focus of intensive research. In addition to alkynylations of nucleophiles and electrophiles, the alkynylation of carbon radicals has emerged as an attractive complementary route for the synthesis of alkynes, enabling in particular the synthesis of highly sterically hindered systems, such as quaternary centers. [3,4] These compounds have found numerous applications in the total synthesis of natural products and medicinal chemistry. [5] Recently, particular attention has been placed on visible light mediated alkynylations with a photo-


catalyst as they enable the generation of highly reactive openshell species such as radicals avoiding the use of strong UV irradiation or toxic precursors (Scheme 1 A). However, finetuning of the photocatalyst is required for each new alkynylation process.

Among possible radical traps, Ethynylbenziodoxolones (EBXs, 1) hypervalent iodine reagents have been especially successful.<sup>[3,6]</sup> Photomediated alkynylations with EBXs (1) follow usually a reductive quenching mechanism,<sup>[7]</sup> in which an excited state photocatalyst (PC\*) is required to generate a carbon radical by oxidation of the substrate (Scheme 1B). The reaction of the radical with EBXs (1) gives then the


#### A. Photocatalyzed alkynylation of radicals with visible light



B. Simplified mechanism for photocatalytic alkynylation with EBXs



C. This work: direct photoactivation of EBXs with visible light



**Scheme 1.** Photomediated alkynylation and use of EBX reagents as radical traps with or without photocatalyst. PC = photocatalyst, AG = activating group.

[\*] S. G. E. Amos,<sup>[+]</sup> D. Cavalli,<sup>[+]</sup> Prof. Dr. J. Waser Laboratory of Catalysis and Organic Synthesis and National Centre

Laboratory of Catalysis and Organic Synthesis and National Centre of Competence in Research (NCCR) Catalysis, Institut des Sciences et Ingénierie Chimique, Ecole Polytechnique Fédérale de Lausanne CH-1015, Lausanne (Switzerland)

E-mail: jerome.waser@epfl.ch

Dr. F. Le Vaillant

Max-Planck-Institut für Kohlenforschung Mülheim an der Ruhr 45470 (Germany)

- [+] These authors contributed equally to this work.
- [\*\*] A previous version of this manuscript has been deposited on a preprint server (https://doi.org/10.33774/chemrxiv-2021-56f12).
- Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under: https://doi.org/10.1002/anie.202110257.

© 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.



alkynylation product and iodanyl radical **I**. For an efficient catalytic process, the reduced photocatalyst  $PC^-$  needs to be reoxidized by iodanyl radical **I** to give the ground state photocatalyst and benzoate **II**. When considering that several steps in the catalytic cycle involve reactive species present in low concentration, it is not surprising that fine-tuning of both catalyst structure and reaction conditions is required for success.

Herein, we report the serendipitous discovery of a different alkynylation approach via the visible light photoexcitation of aryl-EBX reagents, alleviating the need for a fine-tuned photocatalyst (Scheme 1 C). Visible light irradiation can promote the excitation of a variety of hypervalent iodine reagents through spin forbidden transitions. Nevertheless, to the best of our knowledge, this activation mode has never been reported for EBXs. We now demonstrate that the excited state ArEBX\* (1\*) of ArEBX (1) can be used as a photooxidant to activate a variety of oxidizable functional groups, allowing deboronative and decarboxylative fragmentation of oximes, the diffunctionalisation of enamides and the alkynylation of C—H ether bonds. All these processes were reported only in the presence of a photocatalyst previously.

Furthermore, this direct excitation strategy allowed the deoxygenation/deamination-alkynylation of broadly available tertiary alcohols and amines via cesium oxalate salts<sup>[10]</sup> or aryl imines<sup>[11]</sup> respectively, giving access to valuable alkynes connected to quaternary centers. These radical precursors have not yet been used to access alkynes. Only one approach used alcohols as precursors, exploiting a reductive substrate activation strategy with unstable and non-isolable N-phthalimidoyl oxalates as precursors.[12] We especially focused on easily available oxalate salts and developed in addition for these substrates a photocatalytic method with the organic dye 4CzIPN (2,4,5,6-tetrakis(9H-carbazol-9-yl) isophthalonitrile, 2a). Whereas the direct photoactivation method stands out for its operational simplicity, the photocatalytic approach usually proceeded in higher yields and tolerate a broader range of alkynes.

#### Results and Discussion

When attempting the photocatalytic deoxyalkynylation of cesium oxalate  $3a (3a/3a^- = 1.3 \text{ V vs. SCE})^{[10a]}$  with PhEBX (1a) and 4CzIPN (2a) as photocatalyst, we discovered in a control experiment that the desired deoxyalkynylated product 4a could be obtained in 50% yield In DCM with 1.5 equiv of **1a** in absence of **2a** (Table 1, entry 1). We also observed the formation of ketones 5a and 5b in 17 and 12% yield, respectively (entry 1). For this experiment, we used 2 high-intensity Kessil lamps (40 W each) with a broad bandwidth irradiation around 440 nm as the light source. When frequently used blue LED strips with a lower intensity (8 W) and an irradiation centered around 460 nm were applied, the formation of 4a was not observed (entry 2). This is in agreement with previous reports using blue LED strips in which no background reaction is observed in absence of a photocatalyst. [6b-h] With blue LED strips, we still did see conversion of cesium oxalate 3a and PhEBX (1a) to compounds 5a and 5b (entry 2). When the reaction was performed in the dark at 50°C, ketones 5a and 5b were obtained in 45% and 20% yield (entry 3). This suggests a thermal pathway for the formation of 5a and 5b. These ketones originated from the formal hydration of 1a and the incorporation of a nucleophile (iodobenzoate or oxalate). Using a larger excess of PhEBX (1a) resulted in an increase of yield to 57% (entry 4). We then turned to screening the irradiation wavelength using a single lamp. [13] A drop in yield was detected at 440 nm yielding 4a in 41 % despite a longer reaction time (entry 5). Irradiation centered at 427 nm led to no significant change (entry 6), whereas a lower conversion of 3a and PhEBX (1a) and a lower yield of product 4a were observed at 390 nm (entry 7). Finally, 2 lamps at 440 nm and a longer reaction time afforded 4a in 63% yield. However, a more careful monitoring of the reaction over time showed that no further conversion was observed after 8 hours, and the observed small increase is not significant.<sup>[14]</sup>

The irradiation of a solution of PhEBX (1a) led to non-negligible degradation (60% in 16 h) with formation of diyne 6 in 40% yield (Scheme 2A), whereas cesium salt 3a did not

Table 1: Optimization of the direct excitation deoxyalkynylation.


Entry <sup>[a]</sup>	la (equiv)	reaction time	Light source	λ [nm]	residual 3 a (equiv)	residual 1a (equiv)	Yield <b>4a</b> <sup>[b]</sup>	Yield <b>5 a</b> <sup>[b]</sup>	Yield <b>5 b</b> <sup>[b]</sup>
1	1.5	18 h	2 Kessil lamps	440	0.25	0.12	50	17	12
<b>2</b> ]	1.5	24 h	LED strips	460	0.70	0.66	nd	36	23
3 <sup>[c]</sup>	1.5	24 h	none	dark	0.75	0.60	nd	45	23
4	2.5	18 h	2 Kessil lamps	440	0.05	0.40	57	50	23
5	2.5	24 h	1 Kessil lamp	440	0.25	0.40	41	43	19
6	2.5	24 h	1 Kessil lamp	427	0.15	0.40	43	25	16
7	2.5	24 h	1 Kessil lamp	390	0.30-0.40	0.60	34	23	17
8	2.5	24 h	2 Kessil lamps	440	0.08	0.40	63	33	18

[a] 3a (0.1 mmol) and 1a were dissolved in DCM [3a] = 0.1 M and irradiated with two lamps (40 W, 440 nm) or LED strips (8 W, 460 nm) at a temperature of 30–35 °C. [b] <sup>1</sup>H NMR yield was determined using 1 equiv of  $CH_2Br_2$  as internal standard. [c] Reaction was run at 50 °C. nd = not detected.



# Research Articles






Scheme 2. Control experiments supporting the direct photoactivation of PhEBX (1a) and the stability of cesium oxalate 3a in absence of 1a. The reactions were performed at 0.1 mmol or 0.2 mmol scale and yields were determined by <sup>1</sup>H NMR by addition of 1 equiv of CH<sub>2</sub>Br<sub>2</sub> as an internal standard.

show any degradation when irradiated separately (Scheme 2B). These experiments confirmed a possible direct light excitation of PhEBX (1a) to PhEBX\* (1a\*) independent of the cesium oxalate.

With the optimized conditions in hand, we first investigated the scope of the alkynylation of cesium oxalates

(Scheme 3A). The model substrate 3a could be converted into 4a in 60% isolated yield, while the tert-butanol derivative **3b** afforded **4b** with 57 % yield. The same reaction conditions were applied to 5-, 6-, and 12-membered rings 3c-e, delivering the products **4c-e** in 54, 61 and 37% yield. Alkynylated heterocyclic 4f was obtained in 62% yield. With pTolEBX (1b) as an alkynylating reagent, 4g was obtained in 70% yield. However, the use of halogen-substituted aryl EBX reagents lead to low yields.<sup>[15]</sup> We then wondered if this direct excitation strategy could be extended to other decarboxylation processes. We first investigated the decarboxylative alkynylation of carboxylic acids 7  $(7b^{+}/7b^{-} = 1.2 \text{ V} \text{ vs.}$ SCE). [6c-e] By simply increasing the reagent and base loading when compared to the photocatalytic procedure, the decarboxylation proceeded in 18 hours affording the desired alkynylation products 8 (Scheme 3B). This gave access to ynone 8a in 81 % yield, as well as aliphatic alkynes 8b and 8c in 51% and 41% yield, respectively.

We then examined the potential of PhEBX\* (1a\*) in a decarboxylative oxime fragmentation-alkynylation (oxime'/  $oxime^- \approx 1.5 \text{ V}$  vs. SCE). [6f] In this case, 2.5 equivalents of PhEBX (1a) instead of the reported 2.0 equivalents gave the




Scheme 3. Scope of functional group activation. For A, B, C D, and F: Reactions were performed on 0.3 mmol, E: the reaction was performed on 0.1 mmol scale, the yield was determined by 1H NMR using CH<sub>2</sub>Br<sub>2</sub> (1 equiv) as an internal standard and G: Reaction was performed on 0.2 mmol scale, the yield was determined by <sup>1</sup>H NMR using CH<sub>2</sub>Br<sub>2</sub> (1 equiv) as an internal standard.



desired fragmentation products 10 a-c in 74, 69 and 53 % yield with no other changes to the reaction conditions (Sche-

With these results, it appeared that PhEBX\* was a potent oxidant activating substrates with potentials up to 1.5 V vs. SCE. It should be therefore able to oxidize other functional groups beside carboxylates. We turned first to the deboronative alkynylation of alkyl trifluoroborate salts 11 (11 c'/11  $c^-=$ 1.5 V vs. SCE). [6b,16] In the reported procedure, 0.5 equiv of a hypervalent iodine additive (hydroxybenziodoxolone, BI-OH, 19a) were required. The direct light activation of PhEBX (1a) in excess alleviated the need for both the photocatalyst and the additive (Scheme 3D). The alkynylated products 12a-c were obtained in 72%, 61% and 47% yield, respectively. Furthermore, the direct activation of PhEBX could be used for the difunctionalization of enamide 13 (enamide<sup>+</sup>/ enamide  $\approx 1.3 \text{ V}$  vs. SCE) without any change in the reaction conditions, leading to the formation of 14 in 35% yield (Scheme 3E). [6h] A new alkynylation reaction was attempted next. Inspired by the deamination-alkylation of Rovis, we wondered if we could perform a deaminative alkynylation reaction of imine 15 (imine\* $^+$ /imine  $\approx 1.4$  vs. SCE).[11] Indeed, the conversion of 15 into 16 occurred in 57 % yield via direct photoexcitation of PhEBX (1a) in the presence of Cs<sub>2</sub>CO<sub>3</sub> (Scheme 3F). Finally, the C–H alkynylation of THF (17) gave alkyne **18** in 80 % <sup>1</sup>H NMR yield (Scheme 3 G).

Having demonstrated that alkynylation was possible for a broad scope of oxidizable substrates, we attempted to gain a better understanding of the transformation. To rationalize our results, we envisaged three main reaction pathways. First, based on the photoinduced degradation of PhEBX (1a, Scheme 2A) we postulated the direct excitation of PhEBX (1a) to give a strong oxidant 1a\* able to oxidize the substrates to give radical intermediate I (Scheme 4A). Then, based on the broad use of aromatic ketones as photosensitizers, [17] we considered the possibility that the aromatic ketone 5a formed during the reaction (Table 1) could act as a photocatalyst and/ or a photooxidant (Scheme 4B). Finally, a residual HIR(III)




Scheme 4. Alternative mechanisms for the oxidative activation of substrates 3-8 to give radical I.

species BIOX from the synthesis of PhEBX (1a) could be the oxidant (Scheme 4C). For the special case of decarboxylative procedures, the formation of a covalent adduct II between the carboxylate and BIOX, such as BIOH (19a) and BIOAc (19b), could be expected based on literature precedence. [4,18] Especially 19a could be present in small amounts as impurity in PhEBX (1a), as it is used for its synthesis. Under visible light irradiation, homolytic cleavage of the hypervalent iodine I<sup>III</sup>-O would form the O-centered radical, which then undergoes double decarboxylation to give radical I.

To gain support for PhEBX\* (1a\*) as photooxidant, further experiments were performed (Table 2). Interestingly, when TIPS-EBX (TIPS = triisopropylsilyl, 1c) was used as an alkynylation reagent in absence of photocatalyst, no product was observed and both 1c and cesium oxalate 3a remained untouched (Table 2, entry 1). 1c has been reported to not undergo direct excitation at 400 nm, [9c] but is known to work as a radical trap. [6d] When we performed the reaction with 3a and 1c with 4CzIPN (2a) as a photocatalyst, we obtained 25% of alkynylation product **4h** confirming that **1c** is able to react with the tertiary radical formed from cesium oxalates, even if the overall reaction is not very efficient (entry 2). This result confirmed that the aryl substituent on PhEBX (1a) was required for the reaction to proceed in absence of photocatalyst, but it still did not allow us to distinguish between our possible reaction pathways.

We then turned to the role of the side product ketone 5a. We first explored the possibility of **5a** acting as photocatalyst and performed the alkynylation with 0.2 equivalents of 5a and TIPS-EBX (1c) (entry 3). Only traces of alkynylation product were observed. In presence of one equivalent of 5a,

Table 2: Control experiments for the determination of the oxidative species in the deoxyalkynylation.



Entry <sup>[a]</sup>	Reagent	Additive (equiv)	Residual <b>3 a</b> [b] [%]	Yield <sup>[b]</sup> [%]
1	1 c	_	100	nd
2	1 c	2a (0.05)	30	25
3	1 c	5 a (0.2)	98	2
4	_	5a (1.0)	100	_
5	1 c	<b>19a</b> (0.2)	92	5
6	1 c	<b>19b</b> (0.2)	92	5
7	-	<b>19a</b> (1.5)	90	_
8	_	<b>19b</b> (1.5)	100	_
9	1 c	1 a (0.2)	80	8–13 <sup>[c]</sup>

[a] 3 a (0.1 mmol), 1 c (1.5 equiv) and the additive were dissolved in DCM [3 a] = 0.1 M and irradiated with two lamps (40 W, 440 nm) for 18 h. [b] <sup>1</sup>H NMR yield was determined using 1 equiv of CH<sub>2</sub>Br<sub>2</sub> as internal standard. [c] Overall yield of deoxy-alkynylation, 4a:4h=1:1.



no degradation of cesium oxalate 3a or 5a was observed under irradiation (entry 4). These results showed that 5a was not competent to catalyze the alkynylation process. 5b was also subjected to the same control experiments with no alkynylation products detected (see the Supporting Information).[19] We then investigated the potential effect of traces of hypervalent iodine species 19a and 19b. When the reaction was performed with 0.2 equivalents of either additive, nearly no product formation was obtained with 1c (entries 5 and 6). Even with 1.5 equivalents of additive in absence of 1c, very little degradation of the starting material was observed upon irradiation (entries 7 and 8). Finally, we performed the alkynylation with 0.2 equivalents of PhEBX (1a) and 1.5 equivalents of TIPS-EBX (1c). In this case, 20% conversion of the cesium salt was observed with 8-13% deoxyalkynylation with phenyl and TIPS alkyne products 4a and 4h formed in a 1:1 ratio based on <sup>1</sup>H NMR analysis (entry 9), giving support for 1a only acting as photooxidant, whereas both **1a** and **1c** can act as radical traps.

With these results in hand, we turned to UV/Vis absorption and fluorescence spectroscopy to have further support for the photoactivity of PhEBX (1a) under our reaction conditions (Figure 1). We observed absorption until 460 nm (plain blue line) and fluorescence at 485 nm (dashed red line) (Figure 1A). Fluorescence excitation spectroscopy (dotted grey line) showed that irradiation of 1a from 300 nm




Figure 1. A) Normalized absorption of 1a (blue plain line), emission (red dashed line, excitation at  $\lambda = 390$  nm,  $\lambda_{max} = 485$  nm) and fluorescence excitation (gray dotted line, for emission at 485 nm,  $\lambda_{max}$  = 362 nm). B) Beer-Lambert linear regression for 420 nm (blue dotted line) and 440 nm (red plain line).  $A = \varepsilon l[1 \text{ a}], l = 1 \text{ cm}$ ),  $\varepsilon_{420\,\mathrm{nm}} = 0.54\,\mathrm{Lmol}^{-1}\,\mathrm{cm}^{-1}$  and  $\varepsilon_{440\,\mathrm{nm}} = 0.33\,\mathrm{Lmol}^{-1}\,\mathrm{cm}^{-1}$ .

to 440 nm was responsible for the emission at 485 nm. Specifically, we observed two excitation bands ( $\lambda_{max,1}$  = 380 nm,  $\lambda_{\text{max},2} = 430 \text{ nm}$ ) confirming the possibility of the photoexcitation of 1a with a broad band light source with emission centered around 440 nm. To identify the molar extinction coefficient  $\varepsilon$  of 1a, we performed a Beer–Lambert linear regression at 420 nm and 440 nm providing  $\varepsilon_{420\text{nm}}$  =  $0.54 \, \mathrm{L} \, \mathrm{mol}^{-1} \, \mathrm{cm}^{-1}$ and  $\varepsilon_{440\text{nm}} = 0.33 \text{ Lmol}^{-1} \text{cm}^{-1}$ ure 1B).[20] This is coherent with the weak absorption we observe in the 390 nm-460 nm range, even at high concentrations. These low molar extinction coefficients suggest that the absorption at 420 nm and 440 nm could result from a spin forbidden electronic transition.<sup>[21]</sup>

Having confirmed that PhEBX (1a) was absorbing under our irradiation conditions, it was important to estimate its strength as an oxidant in the excited state, in particular considering the broad scope of substrates that could be oxidized with 1a\*. First, cyclic voltammetry allowed us to determine the redox potential of the ground state  $E_{1/2}(1a)$  $\mathbf{1a}^{-}$ ) = -0.87 V vs. SCE (Figure 2). We could then calculate an estimate of the excited state  $E_{1/2}(\mathbf{1a^*/1a^{-}}) = +1.8 \text{ V vs.}$ SCE, [22] thus confirming the thermodynamic feasibility of the SET oxidation of the substrates (potentials ranging from +1.3to +1.5 V, see above).




Figure 2. Cyclic voltammogram of 1a (50 mV s<sup>-1</sup>, 1.0 μM in MeCN).

We then performed UV/Vis of three other EBXs (Figure 3). Interestingly, pTolEBX (1b) absorbed more in the region of irradiation than PhEBX (1a). We believe that this could explain the higher yield of deoxyalkynylated 4g (70% instead of 60% for PhEBX). TIPS-EBX (1c) absorbed less than the ArEBXs although the absorption band did still tail off into the visible light region. Finally, mFPhEBX (1d) absorbed similarly to PhEBX (1a). mFPhEBX (1d) did indeed undergo degradation under visible light irradiation. However, the alkynylation was less efficient (30% by <sup>1</sup>H NMR).<sup>[15]</sup>

With the results obtained in our work together with literature precedence, [4,6,9,16] we propose the following speculative mechanism for our alkynylation method (Scheme 5). Our experimental data (Figures 1, 2 and 3) suggest that ArEBX (1) undergoes direct photoexcitation to generate a highly oxidant excited state 1\* (+1.8 V vs. SCE), the latter can then perform a SET oxidation of cesium salt 3 ( $\pm$  1.3 V vs.







Figure 3. Absorption spectra of 1a, 1b, 1c, and 1d at 0.1 M in DMSO.



Scheme 5. Speculative mechanism.

SCE). The resulting O-centered radical I fragments to the acyl radical II and finally the tertiary alkyl radical III releasing two molecules of carbon dioxide. The latter can then add to a second EBX reagent 1 affording the final product 4 and the iodanyl radical IV. IV  $(+0.25 \text{ V vs. SCE})^{[6e]}$  would most likely not be capable of performing the oxidation of the cesium salt as it is thermodynamically unfavored. Following the oxidation of oxalate 3, we suspect that the reduced 1a<sup>--</sup> would be highly unstable and degrade resulting in side products such as the observed 1,4-diphenylbutadiyne (6). Additionally, we cannot exclude the possibility of diyne formation from the excited state 1\*. The formation of ketones 5a and 5b seems to be a background process occurring under thermal conditions.

These ketones impact the yield slightly due to the consumption of the starting materials, however, they do not seem to play a role in the reaction mechanism.

Considering the synthetic utility of a photomediated method for accessing alkynylated quaternary centers, we turned back to photocatalysis to improve the yields of our deoxyalkynylation strategy. Using 5 mol % of 4CzIPN (2a)  $(2a*/2a^- = +1.35 \text{ V vs. SCE})$ , [6f] under light irradiation at 440 nm with only 1.5 equivalent of PhEBX (1a) in DCM, the desired product (4a) was observed in 75 % NMR yield (94 % based on remaining starting material, Scheme 6).


Scheme 6. Optimized conditions for the photocatalyzed deoxyakynylation.

With the optimized reaction conditions established, we proceeded to explore the scope of cesium oxalates. The model substrate 3a afforded the desired alkyne 4a in 75% yield (compared to 60% for the direct photoexcitation) (Scheme 7). Substrates 3b-f already examined for the direct photoexcitation gave the products 4b-f in improved yields (63-91%). Cycloheptane-derived alkyne 4i was isolated in 74% yield. The adamantyl alkyne 4j was obtained with an expectable drop in yield when considering the unfavored bridged carbon radical. [23] Aliphatic alkynes 4k and 4l were isolated in 72% yield. Homobenzylic scaffolds yielded compounds 4m and 4n in 55 and 30% yield, respectively. A variety of benzyl and silyl protected alcohols afforded alkynes 40-q in up to 61% yield. Having established the scope of alcohols, we turned to explore different ArEBX reagents. pTolEBX afforded the desired product in 64% yield, which was slightly lower than using the direct excitation approach (70%). Nevertheless, the catalytic method tolerated a greater panel of reagents than the direct excitation approach: electron-poor fluorinated reagents afforded the corresponding alkynes 4r and 4s in 56% and 58% yield. Brominated and chlorinated aryl alkynes 4t-v were obtained in 45 to 78% yield. Silyl- and alkyl- EBX reagents however gave the product in only very low yield.

Finally, we were delighted to see that both the direct excitation and photocatalytic methods could be applied for the diastereoselective deoxyalkynylation of (-)-cedrol oxalate 3w (Scheme 8A). Both the direct excitation and the photocatalytic methods provided products in over 50% yield and 20:1 diastereoselectivity based on NMR analysis. NO-ESY analysis supported that the isomer obtained is of (S)configuration at C<sub>8</sub>. Interestingly, when (-)-terpinen-4-olderived oxalate 3x was used, a different outcome was observed: the 5-exo-trig cyclization of the intermediate acyl radical II onto the double bond was observed followed by







Scheme 7. Scope of the photocatalytic deoxyalkynylation. Reactions were performed on 0.3 mmol scale using the corresponding cesium oxalate 3 (1 equiv) and ArEBX 2 (1.5 equiv) with 4CzIPN (2a, 5 mol%) in DCM (0.1 M). [a] Reaction was performed on 0.24 mmol scale with 1.9 equiv of 2a.

alkynylation of the formed tertiary carbon radical (Scheme 8B). Both methods resulted in the formation of product 4x in 47% and 53% yield, respectively. This indicated that the decarboxylations are stepwise and that the acyl radical II formed from the oxalate radical after the release of CO<sub>2</sub> is long-lived enough to undergo cyclization before the second decarboxylation. The remotely alkynylated product 4x was also obtained in over 20:1 diastereoselectivity.

#### Conclusion

We have discovered the direct photoexcitation of aryl EBX reagents in the context of the deoxyalkynylation of cesium oxalates. The broad applicability of the direct excitation of ArEBXs was then exemplified in alkynylation processes requiring a photocatalyst before, including decarboxylative and deboronative alkynylations, the oxyalkynyla-

Scheme 8. Alkynylation of A. (-)-Cedrol oxalate 3 w and B. (-)-Terpinen-4-ol oxalate 3 x. Reactions were performed on 0.3 mmol scale under blue LED irradiation. Method A: 3w or 3x (1 equiv), 1a (1.5 equiv), 2a (5 mol%) in DCM (0.1 M), 50°C. Method B: 3w or 3x (1 equiv), 1a (2.5 equiv) in DCM (0.1 M).


tion of enamides and the C-H alkynylation of THF. The direct excitation of ArEBXs has also enabled a first example of deaminative alkynylation via an aryl imine. In the case of the deoxyalkynylation of oxalates, we also developed a photocatalytic approach using 4CzIPN (2a) as organophotocatalyst and accessed an extended scope of alkynylated quaternary centers. [24] The direct excitation approach discovered in our work results in simplified reaction design and will therefore facilitate the discovery of new alkynylation reactions using ArEBX reagents, as demonstrated in the case of deoxy- and  $deamino-alkynylation. ^{[25]} \\$ 

#### **Acknowledgements**

We thank the ERC (European Research Council, Starting Grant iTools4MC, number 334840) and EPFL for financial support. This publication was created as part of NCCR Catalysis, a National Centre of Competence in Research funded by the Swiss National Science Foundation. We thank Cristian Pezzato and Cesare Berton from the Laboratory of Supramolecular Chemistry, Ecole Polytechnique Fédérale de Lausanne for enabling us to run our absorption and fluorescence studies and Ophélie Planes from the same laboratory for her help in the cyclic voltammetry studies. Open access funding provided by Ecole Polytechnique Federale de Lausanne.

#### Conflict of Interest

The authors declare no conflict of interest.







**Keywords:** alkynes · hypervalent iodine · photochemistry · quaternary centers · synthetic methods

- [1] a) Acetylene Chemistry: Chemistry, Biology, and Material Science (Eds.: F. Diederich, P. J. Stang, R. R. Tykwinski), Wiley-VCH, Weinheim, 2005; b) I. A. Maretina, J. C. Tebby, Alkynes in Cycloadditions, Wiley, Chichester, 2014; c) Modern Alkyne Chemistry: Catalytic and Atom-Economic Transformations (Eds., B.M. Trost, C.-J. Li), Wiley-VCH, Weinheim, 2015; d) Y. Jiang, R. E. McNamee, P. J. Smith, A. Sozanschi, Z. Tong, E. A. Anderson, *Chem. Soc. Rev.* **2021**, *50*, 58–71.
- [2] a) P. Thirumurugan, D. Matosiuk, K. Jozwiak, Chem. Rev. 2013, 113, 4905-4979; b) T. T. Talele, J. Med. Chem. 2020, 63, 5625-
- [3] F. Le Vaillant, J. Waser, Chem. Sci. 2019, 10, 8909-8923.
- [4] Selected examples: Radical generated from alkenes: a) Y. Shen, B. Huang, J. Zheng, C. Lin, Y. Liu, S. Cui, Org. Lett. 2017, 19, 1744–1747; b) S. Zhou, T. Song, H. Chen, Z. Liu, H. Shen, C. Li, Org. Lett. 2017, 19, 698-701; c) H. Jiang, Y. He, Y. Cheng, S. Yu, Org. Lett. 2017, 19, 1240-1243; d) Y. Li, R. Lu, S. Sun, L. Liu, Org. Lett. 2018, 20, 6836-6839; e) H. Jiang, A. Studer, Chem. Eur. J. 2019, 25, 516-520; Radical generated via HAT: f) T. Hoshikawa, S. Kamijo, M. Inoue, Org. Biomol. Chem. 2013, 11, 164-169; g) L. Wang, Y. Xia, K. Bergander, A. Studer, Org. Lett. **2018**, 20, 5817 – 5820; h) S. P. Morcillo, E. M. Dauncey, J. H. Kim, J. J. Douglas, N. S. Sheikh, D. Leonori, Angew. Chem. Int. Ed. **2018**, 57, 12945 – 12949; Angew. Chem. **2018**, 130, 13127 – 13131; Other approaches: i) D. Wang, L. Zhang, S. Luo, Org. Lett. 2017, 19, 4924 – 4927; j) S. Tang, Y. Liu, X. Gao, P. Wang, P. Huang, A. Lei, J. Am. Chem. Soc. 2018, 140, 6006-6013; k) Y. Xia, A. Studer, Angew. Chem. Int. Ed. 2019, 58, 9836-9840; Angew. Chem. 2019, 131, 9941 - 9945.
- [5] Selected examples: a) T. J. A. Graham, E. E. Gray, J. M. Burgess, B. C. Goess, J. Org. Chem. 2010, 75, 226-228; b) S. Zheng, Y. R. Santosh Laxmi, E. David, A. T. Dinkova-Kostova, K. H. Shiavoni, Y. Ren, Y. Zheng, I. Trevino, R. Bumeister, I. Ojima, W. C. Wigley, J. B. Bliska, D. F. Mierke, T. Honda, J. Med. Chem. 2012, 55, 4837 – 4846; c) K. Sugimoto, K. Toyoshima, S. Nonaka, K. Kotaki, H. Ueda, H. Tokuyama, Angew. Chem. Int. Ed. 2013, 52, 7168-7171; Angew. Chem. 2013, 125, 7309-7312; d) S. Yoshioka, M. Nagatomo, M. Inoue, Org. Lett. 2015, 17, 90-93.
- [6] Selected examples: a) X. Liu, Z. Wang, X. Cheng, C. Li, J. Am. Chem. Soc. 2012, 134, 14330 – 14333; b) H. Huang, G. Zhang, L. Gong, S. Zhang, Y. Chen, J. Am. Chem. Soc. 2014, 136, 2280-2283; c) Q. Zhou, W. Guo, W. Ding, X. Wu, X. Chen, L. Lu, W. Xiao, Angew. Chem. Int. Ed. 2015, 54, 11196-11199; Angew. Chem. 2015, 127, 11348-11351; d) F. Le Vaillant, T. Courant, J. Waser, Angew. Chem. Int. Ed. 2015, 54, 11200-11204; Angew. Chem. 2015, 127, 11352-11356; e) F. Le Vaillant, M. D. Wodrich, J. Waser, Chem. Sci. 2017, 8, 1790-1800; f) F. Le Vaillant, M. Garreau, S. Nicolai, G. Gryn'ova, C. Corminboeuf, J. Waser, Chem. Sci. 2018, 9, 5883 – 5889; g) M. Garreau, F. Le Vaillant, J. Waser, Angew. Chem. Int. Ed. 2019, 58, 8182-8186; Angew. Chem. 2019, 131, 8266-8270; h) S. G. E. Amos, S. Nicolai, J. Waser, Chem. Sci. 2020, 11, 11274-11279.
- [7] An oxidative quenching catalytic cycle has also been proposed; see Ref. [6b].

- [8] M. Nakajima, S. Nagasawa, K. Matsumoto, T. Kuribara, A. Muranaka, M. Uchiyama, T. Nemoto, Angew. Chem. Int. Ed. 2020, 59, 6847-6852; Angew. Chem. 2020, 132, 6914-6919.
- [9] Selected examples: a) R.-Y. Zhang, L.-Y. Xi, L. Zhang, S. Liang, S.-Y. Chen, X.-Q. Yu, RSC Adv. 2014, 4, 54349-54353; b) E. Voutyritsa, M. Garreau, M. G. Kokotou, I. Triandafillidi, J. Waser, C. G. Kokotos, Chem. Eur. J. 2020, 26, 14453-14460; c) K. Matsumoto, M. Nakajima, T. Nemoto, J. Org. Chem. 2020, 85, 11802-11811.
- [10] a) C. C. Nawrat, C. R. Jamison, Y. Slutskyy, D. W. C. MacMillan, L. E. Overman, J. Am. Chem. Soc. 2015, 137, 11270-11273; b) X. Zhang, D. W. C. MacMillan, J. Am. Chem. Soc. 2016, 138, 13862-13865; c) S. Y. Abbas, P. Zhao, L. E. Overman, Org. Lett. **2018**, 20, 868 – 871; d) J. Y. Su, D. C. Grünenfelder, K. Takeuchi, S. E. Reisman, Org. Lett. 2018, 20, 4912-4916.
- [11] M. A. Ashley, T. Rovis, J. Am. Chem. Soc. 2020, 142, 18310-18316.
- [12] C. Gao, J. Li, J. Yu, H. Yang, H. Fu, Chem. Commun. 2016, 52, 7292 - 7294.
- [13] This was due for practical reasons, as only a single lamp was available at other wavelengths in our laboratory.
- [14] See the Supporting Information, Table S3 and Figure S2 for details.
- [15] 15–30% by NMR. See the Supporting Information for details.
- [16] Converted from V vs. Fc to V vs. SCE, taken from: Y. Yasu, T. Koike, M. Akita, Adv. Synth. Catal. 2012, 354, 3414-3420.
- [17] "Diaryl Ketones as Photoactivators": J. Pérez-Prieto, R. E. Galian, M. A. Miranda in Mini-Reviews in Organic Chemistry, Vol. 3, Bentham Science, Sharjah, **2006**, pp. 117 – 135.
- [18] "Photochemistry of Hypervalent Iodine Compounds": K. Jia, Y. Chen in PATAI'S Chemistry of Functional Groups, American Cancer Society, Hoboken, 2018, pp. 1-42.
- [19] Irradiation of 3a (1 equiv) and 5b (1 equiv) in DCM led to no observable degradation. Irradiation of 3a (1 equiv), 5b (0.7 equiv) with 1c (1.5 equiv) led to less than 5% product formation. Irradiation of 5b (1 equiv) and 1a (1.5 equiv) in DCM led to no product formation confirming that 5b is most likely not a reaction intermediate.
- [20] The reproducibility of the measurement was verified by 3 repetitions of the sample.
- [21] Photochemistry of Organic Compounds, 1st ed., Wiley, Hoboken, 2009.
- [22]  $E_{1/2}(\mathbf{1} \mathbf{a}^*/\mathbf{1} \mathbf{a}^{-}) = E_{0.0} + E_{1/2}(\mathbf{1} \mathbf{a}/\mathbf{1} \mathbf{a}^{-})$ .  $E_{0.0}$  was determined experimentally from the position of the long wavelength tail of the absorption spectrum at 460 nm, as described in: L. Buzzetti, A. Prieto, S. R. Roy, P. Melchiorre, Angew. Chem. Int. Ed. 2017, 56, 15039-15043; Angew. Chem. 2017, 129, 15235-15239.
- [23] G. L. Lackner, K. W. Quasdorf, L. E. Overman, J. Am. Chem. Soc. 2013, 135, 15342-15345.
- [24] During the revision process of this manuscript, Xie and coworkers also reported a photocatalytic method for the deoxyalkynylation of cesium oxalates: M. Li, T. Liu, J. Li, H. He, H. Dai, J. Xie, J. Org. Chem. 2021, 86, 12386-12393.
- [25] Raw data for NMR, IR, and MS are available at zenodo.org, https://doi.org/10.5281/zenodo.5205584.

Manuscript received: July 31, 2021 Accepted manuscript online: August 17, 2021 Version of record online: September 21, 2021

# **Supporting Information**

# Direct Photoexcitation of EthynylBenziodoXolones: An Alternative to Photocatalysis for Alkynylation Reactions

Stephanie G. E. Amos,<sup>‡</sup> Diana Cavalli,<sup>‡</sup> Franck Le Vaillant, Jérôme Waser\*

Laboratory of Catalysis and Organic Synthesis, Institut des Sciences et Ingénierie Chimique, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland

# Contents

1.	. General methods					
2.		Synt	thesis of starting materials	5		
	2.	1.	Synthesis of hypervalent iodine reagents	5		
		1-H	ydroxy-1,2-benziodoxol-3-(1 <i>H</i> )-one ( <b>19a</b> )	5		
		1-A	cetoxy-1,2-benziodoxol-3-(1H)-one ( <b>19b</b> )	5		
		1-[P	Phenylethynyl]-1,2-benziodoxol-3(1H)-one (PhEBX, <b>1a</b> )	6		
		1-(p-Tolylethynyl)-1,2-benziodoxol-3(1H)-one (1b)				
		Tri <i>iso</i> propylsilyl trimethylsilylacetylene ( <b>21c</b> )				
		1-[(Tri <i>iso</i> -propylsilyl)ethynyl]-1,2-benziodoxol-3(1 <i>H</i> )-one (TIPS-EBX, <b>1c</b> )				
		1-[3-Fluorophenylethynyl]-1,2-benziodoxol-3(1H)-one (1d)				
		1-[4	I-Trifluoromethylphenylethynyl]-1,2-benziodoxol-3(1H)-one (1e)	9		
		1-[4	I-Bromophenylethynyl]-1,2-benziodoxol-3(1H)-one (1f)	9		
		1-[2	P-Bromophenylethynyl]-1,2-benziodoxol-3(1 <i>H</i> )-one ( <b>1g</b> )	10		
		1-[2	2-Chlorophenylethynyl]-1,2-benziodoxol-3(1H)-one (1h)	11		
	2.	2.	Synthesis of the photocatalysts	11		
	2.	3.	General procedure A: Synthesis of the photocatalysts	11		
		2,4,	5,6-Tetra(9 <i>H</i> -carbazol-9-yl)isophthalonitrile (4CzIPN, <b>2a</b> )	12		
		(2r,	4s,5r)-2,4,5,6-Tetrakis(3,6- <i>d</i> ichloro-9 <i>H</i> -carbazol-9-yl)isophthalonitrile (4ClCzIPN, <b>2b</b> )	12		
	2.	4.	Synthesis of tertiary alcohols	13		
		Gen	neral procedure B: Synthesis of tertiary alcohols from ketones	13		
		Gen	neral procedure C: Synthesis of tertiary alcohols from esters	14		
	2.	5.	Synthesis of cesium salts	15		
		Gen	neral procedure D: Synthesis of cesium salts from tertiary alcohols	15		
		•	thetic and characterization data for alkyl ethyl oxalate intermediates <b>28a-x</b> and cesium s			
	2		K			
		6.	Synthesis of oximes			
2		7.	Synthesis of potassium trifluoroboronates			
3.			tochemical experimental set-up			
4.		•	imization of the photomediated deoxygenation-alkynylation			
	4.		Optimization studies method B (Excited state PhEBX 1a)			
_		2.	Optimization studies of the 4CzIPN photocatalyzed deoxyalkynylation			
5.			tomediated Alkynyation Reactions:			
	٥.	<ol> <li>5.1.</li> </ol>				
		5.1.	Z. General procedure G. Decarboxylative alkynylation	35		

	5.1.	3.	General procedure H: Oxime fragmentation-alkynylation	. 36			
	5.1.	4.	General procedure I: Deboronative alkynylation	. 36			
	5.1.	5.	Difunctionalization	. 36			
	5.1.	6.	Deaminative alkynylation	. 37			
5.1.7. 5.1.8.		7.	HAT	. 38			
		8.	General procedure J: 4CzIPN catalyzed deoxyalkynylation	. 38			
	5.2.	Yield	ds and characterization data	. 39			
	5.2.	1.	Deoxyalkynylated products	. 39			
5.2.2. 5.2.3.		2.	Decarboxylation alkynylation	. 53			
		3.	Oxime fragmentation	. 54			
	5.2.	4.	Deboronative alkynylation	. 55			
6.	Med	chanis	stic studies	. 57			
	6.1.	Mor	nitoring of the reaction by <sup>1</sup> H NMR	. 57			
	6.2. Sic		product formation and reaction with TIPS-EBX (1c) monitored by ${}^{1}\text{H}$ NMR	. 57			
6.3. Sy		Synt	hesis and characterization of <b>5a</b> , <b>5b</b> and <b>4h</b>	. 59			
	2-0	,xo-2	phenylethyl 2-iodobenzoate ( <b>5a</b> )	. 59			
	2-m	2-methyl-4-phenylbutan-2-yl (2-oxo-2-phenylethyl) oxalate (5b)					
	(3,3	(3,3-Dimethyl-5-phenylpent-1-yn-1-yl)triisopropylsilane (4h)					
6.4.		Cont	ontrol experiments				
6.5.		UV-\	Vis absorption and fluorescence studies	. 62			
	Abs	osorption and fluorescence studies of PhEBX 1a and the cesium oxalate 3a					
	Abs	Absorption and Beer-Lambert linear regression at 420 nm and 440 nm of PhEBX (					
	6.6.	Cycl	ic voltammetry of PhEBX ( <b>1a</b> )	. 65			
7.	NM	R spe	ctra of new compounds	. 66			

# 1. General methods

All reactions that were carried out in oven dried glassware and under an atmosphere of nitrogen is stated at the start of the reaction conditions. For flash chromatography, distilled technical grade solvents were used. THF,  $CH_3CN$ , toluene,  $Et_2O$  and  $CH_2Cl_2$  were dried by passage over activated alumina under nitrogen atmosphere ( $H_2O$  content < 10 ppm, Karl-Fischer titration). The solvents were degassed by Freeze-Pump-Thaw method when mentioned. All chemicals were purchased from Acros, Aldrich, Fluka, VWR, TCI, Merck and used as such unless stated otherwise. Chromatographic purification was performed as flash chromatography using Macherey-Nagel silica 40-63, 60 Å, using the solvents indicated as eluent with 0.1-0.5 bar pressure. TLC was performed on Merck silica gel 60 F254 TLC glass plates and visualized with UV light and p-anisaldehyde stain (EtOH: $H_2SO_4$ :AcOH:p-anisaldehyde 135:5:1.5:3.7 V:V:V:V).

 $^{1}$ H-NMR spectra were recorded on a Brucker DPX-400 400 MHz spectrometer in CDCl3, acetonitrile- $d_3$ , DMSO- $d_6$  or acetone- $d_6$ , all signals Are reported in ppm with the internal chloroform signal at 7.26 ppm, the internal acetonitrile signal at 1.94 ppm, the internal methanol signal at 3.30 ppm, the internal DMSO signal at 2.50 ppm or the internal acetone signal at 2.05 ppm as standard. The data is reported as (s = singlet, d = doublet, t= triplet, q = quadruplet, qi = quintet, m = multiplet or unresolved, br = broad signal, app = apparent, coupling constant(s) in Hz, integration, interpretation).  $^{13}$ C-NMR spectra were recorded with  $^{1}$ H-decoupling on a Brucker DPX-400 100 MHz spectrometer in CDCl3, acetonitrile- $d_3$  CD $_3$ OD, DMSO- $d_6$  or acetone- $d_6$ , all signals Are reported in ppm with the internal chloroform signal at 77.0 ppm, the internal acetonitrile signal at 1.3 ppm the internal methanol signal at 49.0 ppm, the internal DMSO signal at 39.5 ppm or the internal acetone signals at 29.84 and 206.26 ppm as standard. Diastereoiomeric ratios has been determined after purification and stereochemistry has been assigned based on  $^{1}$ H NMR analysis.

Infrared spectra were recorded on a JASCO FT-IR B4100 spectrophotometer with an ATR PRO410-S and a ZnSe prisma and is reported in  $cm^{-1}$  (w = weak, m = medium, s = strong).

High resolution mass spectrometric measurements were performed by the mass spectrometry service of ISIC at the EPFL on a MICROMASS (ESI) Q-TOF Ultima API.

All photocatalyzed reactions were carried out in oven dried glassware and under inert atmosphere (freeze pump thaw solvent stored on molecular sieves and under argon for maximum one week) unless specified otherwise. They were performed in screw cap dram vials (0.5 - 7,5 mL) which were stuck to a glass plate that was placed on a stirring plate with 2 Kessil lamps (440 nm, 40 W) irradiating from both sides (the hood was free and coated with aluminum foil for personal protection). The distance between the Kessil lamps and the vials was approximatively 10 cm. Long irradiation resulted in temperature increasing up to 50 °C during overnight reactions unless a fan was used in which case the temperature raised to 30-35°C. Photos have been provided.

UV/Vis spectroscopy was performed on an Agilent Cary 60 UV-Vis and steady-state luminescence spectroscopy was recorded on a Varian Cary Eclipse spectrophotometer.

# 2. Synthesis of starting materials

## 2.1. Synthesis of hypervalent iodine reagents

The synthesis of reagents **19a-b** and **1a-g** had already been described before. <sup>1,2,3,4,5,6,7,8</sup> Some of the procedures for accessing the ArEBX species have evolved slightly and have been updated with corresponding modifications, the modifications only apply to work-ups and purifications.

## 1-Hydroxy-1,2-benziodoxol-3-(1*H*)-one (**19a**)

Following a reported procedure,  $^1$  NaIO<sub>4</sub> (40.5 g, 189 mmol, 1.05 equiv) and 2-iodobenzoic acid (**20**, 44.8 g, 180 mmol, 1.0 equiv) were suspended in 30% (v:v) aq. AcOH (350 mL). The mixture was vigorously stirred and refluxed for 5 h. The reaction mixture was then diluted with cold water (250 mL) and allowed to cool to rt, protecting it from light. After 1 h, the crude product was collected by filtration, washed on the filter with ice water (3 x 150 mL) and acetone (3 x 150 mL), and air-dried in the dark overnight to afford 1-Hydroxy-1,2-benziodoxol-3-(1H)-one (**19a**, 44.3 g, 168 mmol, 93% yield) as a white solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO- $d_6$ ) δ 8.02 (dd, J = 7.7, 1.4 Hz, 1H, ArH), 7.97 (m, 1H, ArH), 7.85 (dd, J = 8.2, 0.7 Hz, 1H, ArH), 7.71 (td, J = 7.6, 1.2 Hz, 1H, ArH).

<sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  167.7, 134.5, 131.5, 131.1, 130.4, 126.3, 120.4.

Consistent with reported data.1

# 1-Acetoxy-1,2-benziodoxol-3-(1H)-one (19b)

O—I—OH
$$Ac_2O$$
reflux, 30 min
$$19a$$

$$19b$$

Following a reported procedure,  $^9$  compound **19a** (3.00 g, 11.3 mmol, 1.00 equiv) was heated in  $Ac_2O$  (10 mL) to reflux until the solution turned clear (without suspension, ca. 30 min). The mixture was then left to cool down and white crystals started to form. The crystallization was continued at -18 °C.

<sup>&</sup>lt;sup>1</sup> Brand, J. P.; Chevalley, C.; Scopelliti, R.; Waser, J. Chem. – Eur. J. **2012**, *18*, 5655–5666.

<sup>&</sup>lt;sup>2</sup> Amos, S. G. E.; Nicolai, S.; Waser, J. *Chem. Sci.* **2020**, *11*, 11274–11279.

<sup>&</sup>lt;sup>3</sup> Lu, B.; Wu, J.; Yoshikai, N. J. Am. Chem. Soc. **2014**, 136, 11598.

<sup>&</sup>lt;sup>4</sup> Jia, K.; Zhang, F.; Huang, H.; Chen, Y. J. Am. Chem. Soc **2016**, 138, 1514.

<sup>&</sup>lt;sup>5</sup> Le Vaillant, F.; Courant, T.; Waser, J. *Angew. Chem. Int. Ed.* **2015**, *54*, 11200.

<sup>&</sup>lt;sup>6</sup> Le Vaillant, F.; Garreau, M.; Nicolai, S.; Gryn'Ova, G.; Corminboeuf, C.; Waser, J. Chem. Sci. 2018, 9, 5883.

<sup>&</sup>lt;sup>7</sup> Brand, J. P.; Waser, J. Angew. Chem. Int. Ed. **2010**, 49, 7304.

<sup>&</sup>lt;sup>8</sup> Huang, H.; Zhang, G.; Gong, L.; Zhang, S.; Chen, Y. J. Am. Chem. Soc. **2014**, 136, 2280–2283.

<sup>&</sup>lt;sup>9</sup> Eisenberger, P.; Gischig, S.; Togni, A. Chem. Eur. J. 2006, 12, 2579

The crystals were then collected and dried overnight under high vacuum to give compound **5a** (3.06 g, 10.0 mmol, 86%).

<sup>1</sup>H NMR (400 MHz, Chloroform- $d_3$ ) δ 8.25 (dd, 1 H, J = 7.6, 1.4 Hz, ArH), 8.00 (dd, 1 H, J = 8.3, 0.5 Hz, ArH), 7.92 (dt, 1 H, J = 7.0, 1.7 Hz, ArH), 7.71 (td, 1 H, J = 7.6, 0.9 Hz, ArH), 2.25 (s, 3 H, COC $H_3$ ). NMR data correspond to the reported values.

1-[Phenylethynyl]-1,2-benziodoxol-3(1H)-one (PhEBX, 1a)

Following a reported procedure, trimethylsilyltriflate (9.1 mL, 50 mmol, 1.1 equiv) was added dropwise to a suspension of 2-iodosylbenzoic acid (**19a**, 12.1 g, 45.8 mmol, 1.0 equiv) in  $CH_2Cl_2$  (120 mL) at 0 °C. The mixture was stirred for 1 h, followed by the dropwise addition of trimethyl(phenylethynyl)silane (**21a**, 8.8 mL, 50 mmol, 1.1 equiv) (slightly exothermic). The resulting suspension was stirred for 6 h at RT, during this time a white solid was formed. A saturated solution of NaHCO<sub>3</sub> (120 mL) was added and the mixture was stirred vigorously for 30 min. The two layers of the mother liquors were separated and the organic layer was washed with sat. NaHCO<sub>3</sub> (2x50 mL), dried over MgSO<sub>4</sub>, filtered and evaporated under reduced pressure. The resulting solid was recrystalized in EtOAc:MeOH (7:3 v:v) (ca. 20 mL). The solution was left to cool to RT then in the freezer ovenight, filtered and dried under high vacuum to afford PhEBX (**1a**, 6.8 g, 25 mmol, 43% yield) as colorless crystals.

**Mp** (Dec.) 155 – 160 °C.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.46 (m, 1H, Ar*H*), 8.28 (m, 1H, Ar*H*), 7.80 (m, 2H, Ar*H*), 7.63 (m, 2H, Ar*H*), 7.48 (m, 3H, Ar*H*).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 163.9, 134.9, 132.9, 132.5, 131.6, 131.3. 130.8, 128.8, 126.2, 120.5, 116.2, 106.6, 50.2.

Consistent with reported data.<sup>2</sup>

1-(p-Tolylethynyl)-1,2-benziodoxol-3(1H)-one (1b)

Following a reported procedure,  $^8$  trimethylsilyl triflate (1.0 mL, 5.5 mmol, 1.1 equiv) was added to a suspension of 2-iodosylbenzoic acid (**19a**) (1.32 g, 5.00 mmol, 1.00 equiv) in  $CH_2Cl_2$  (15 mL) at room temperature. The resulting suspension was stirred for 3 h, followed by the drop wise addition of trimethyl(p-tolylethynyl)silane (**21b**) (1.04 g, 5.50 mmol, 1.10 equiv). The resulting suspension was stirred for 6 h at room temperature. A saturated solution of NaHCO<sub>3</sub> (20 mL) was then added and the mixture was stirred vigorously for 30 minutes, the two layers were separated and the organic layer

was washed with saturated solution of NaHCO<sub>3</sub> (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. The resulting solid was recrystallized from EtOAc:MeOH 7:3 (ca 20 mL). The mixture was cooled down, filtered and dried under high vacuum to afford **1b** (0.620 g, 1.71 mmol, 45%) as a white crystals.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.43 (dd, J = 6.1, 2.9 Hz, 1H, ArH), 8.30–8.14 (m, 1H, ArH), 7.77 (dd, J = 6.9, 3.1 Hz, 2H, ArH), 7.50 (d, J = 7.8 Hz, 2H, ArH), 7.25 (d, J = 7.6 Hz, 2H, ArH), 2.43 (s, 3H, Ar $CH_3$ ).

<sup>13</sup>C NMR (100 MHz, CDCl3): δ 166.6, 141.5, 134.9, 132.8, 132.5, 131.6, 131.3, 129.5, 126.2, 117.4, 116.2, 107.25, 49.1, 21.7. The characterization data corresponded to the reported values.<sup>8</sup>

Tri*iso*propylsilyl trimethylsilylacetylene (21c)

Following a reported procedure,  $^{10}$  n-butyllithium (2.5 M in hexanes, 28 mL, 70 mmol, 0.98 equiv) was added dropwise to a stirred solution of ethynyltrimethylsilane (22, 7.0 g, 71 mmol, 1.0 equiv) in THF (100 mL) at -78 °C. The mixture was warmed to 0 °C and stirred for 5 min. The mixture was then cooled back to -78 °C and chlorotri*iso* propylsilane (15 mL, 71 mmol, 1.0 equiv) was added dropwise. The mixture was then allowed to warm to room temperature and stirred overnight. A saturated solution of ammonium chloride (100 mL) was added, and the reaction mixture was extracted with diethyl ether (2 x 100 mL). The combined organic layers were washed with water and brine, then dried over MgSO4, filtered and concentrated under reduced pressure to obtain a colorless liquid which was further purified by filtration on silica eluting with pentane (500 mL) to yield 21g (16 g, 64 mmol, 90% yield) as a colorless liquid.

<sup>1</sup>**H NMR** (400 MHz, Chloroform-*d*)  $\delta$  1.08 (m, 21H, TIPS), 0.18 (s, 9H, TMS).

Consistent with reported data. 10

1-[(Triiso-propylsilyl)ethynyl]-1,2-benziodoxol-3(1H)-one (TIPS-EBX, 1c)

This compound can also be accessed in one pot from commercially available *o*-iodobenzoic acid and the free TIPS alkyne, however in the context of this study it was synthesized in the 2 step fashion.<sup>11</sup>

Following a reported procedure,<sup>7</sup> 2-iodosylbenzoic acid (**19a**, 8.0 g, 30 mmol, 1.0 equiv) was charged in an oven-*d*ried round-bottomed 250 mL flask equipped with a magnetic stirrer. The solid was placed under a nitrogen atmosphere and anhydrous acetonitrile (100 mL) was added. The mixture was cooled to 0 °C. Trimethylsilyltriflate (6.0 mL, 33 mmol, 1.1 equiv) was added dropwise. After 15 min,

<sup>&</sup>lt;sup>10</sup> Helal, C. J.; Magriotis, P. A.; Corey, E. J. J. Am. Chem. Soc. **1996**, 118, 10938.

<sup>&</sup>lt;sup>11</sup> Hari, D. P.; Caramenti, P.; Schouwey, L.; Chang, M.; Nicolai, S.; Bachert, D.; Wright, T.; Orella, C.; Waser, J. *Org. Process Res. Dev.* **2020**, *24*, 106–110.

(trimethylsilyl)(tri*iso*propylsilyl)acetylene (**21c**, 8.5 g, 33 mmol, 1.1 equiv) was added dropwise. After 30 min, the suspension became an orange solution. Pyridine (2.7 mL, 33 mmol, 1.1 equiv) was added dropwise. After 15 min, the reaction mixture was transferred in a one-neck 500 mL flask and concentrated under vacuum to afford a yellow solid. The solid was dissolved in  $CH_2Cl_2$  (100 mL) and transferred in a 500 mL separatory funnel. The organic layer was washed with a 1 M HCl solution (50 mL) and the aqueous layer was extracted with  $CH_2Cl_2$  (100 mL). The organic layers were combined, washed with a saturated solution of  $NaHCO_3$  (2 x 100 mL), dried over  $MgSO_4$ , filtered and the solvent was evaporated under reduced pressure. Recrystallization from acetonitrile (40 mL) afforded TIPS-EBX (1c, 9.2 g, 21.5 mmol, 71% yield) as colorless crystals.

Mp (Dec.) 170-176 °C.

<sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  8.44 (m, 1H, Ar*H*), 8.29 (m, 1H, Ar*H*), 7.77 (m, 2H, Ar*H*), 1.16 (m, 21H, TIPS).

<sup>13</sup>C NMR (100 MHz, Chloroform-d) δ 166.4, 134.6, 132.3, 131.4, 131.4, 126.1, 115.6, 114.1, 64.6, 18.4, 11.1.

**IR** v 2943 (m), 2865 (m), 1716 (m), 1618 (m), 1604 (s), 1584 (m), 1557 (m), 1465 (m), 1439 (w), 1349 (m), 1291 (m), 1270 (w), 1244 (m), 1140 (m), 1016 (m), 999 (m), 883 (m), 833 (m), 742 (m), 702 (s), 636 (m).

Consistent with reported data.7

1-[3-Fluorophenylethynyl]-1,2-benziodoxol-3(1H)-one (1d)

Following a slightly modified reported procedure,  $^6$  trimethylsilyl triflate (0.44 mL, 2.5 mmol, 1.1 equiv) was added to a suspension of 2-iodosylbenzoic acid (**19a**, 0.589 g, 2.23 mmol, 1.00 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (6.8 mL) at RT The resulting suspension was stirred for 1 h, followed by the dropwise addition of ((3-fluorophenyl)ethynyl)trimethylsilane (**21d**, 0.50 mL, 2.5 mmol, 1.1 equiv). The resulting suspension was stirred for 6 h at RT. A saturated solution of NaHCO<sub>3</sub> (10 mL) was then added and the mixture was stirred vigorously for 30 minutes, resulting in a suspension. The mixture was diluted with chloroform (10 mL), water (5 mL) and MeOH (ca. 0.5 mL) resulting in two clear layers. The two layers were separated, and the organic layer was washed with sat. NaHCO<sub>3</sub> (7 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. The resulting solid was recrystallized in EtOAc:MeOH (7:3 v:v) (ca. 20 mL). The solution was left to cool to RT then was placed in the freezer (-20 °C) overnight. The crystals were filtered and washed with Et<sub>2</sub>O to afford **1d** (787 mg, 2.15 mmol, 43% yield) as colorless crystals.

<sup>1</sup>**H NMR** (400 MHz, DMSO- $d_6$ ) δ 8.33 (dd, J = 8.2, 0.8 Hz, 1H, ArH), 8.13 (dd, J = 7.4, 1.7 Hz, 1H, ArH), 7.91 (ddd, J = 8.2, 7.2, 1.7 Hz, 1H, ArH), 7.81 (td, J = 7.3, 0.9 Hz, 1H, ArH), 7.64 – 7.59 (m, 1H, ArH), 7.58 – 7.53 (m, 2H, ArH), 7.47 – 7.37 (m, 1H, ArH).

<sup>13</sup>C NMR (101 MHz, DMSO- $d_6$ )<sup>12</sup> 166.3, 161.8 (d, J = 245.6 Hz), 135.3, 131.9, 131.3, 131.2 (d, J = 8.7 Hz), 129.0 (d, J = 2.9 Hz), 127.7, 122.4 (d, J = 9.6 Hz), 119.2 (d, J = 23.4 Hz), 118.1 (d, J = 21.1 Hz), 116.4, 102.5 (d, J = 3.3 Hz), 53.8.

<sup>19</sup>**F NMR** (376 MHz, DMSO- $d_6$ ) δ -111.7.

Consistent with reported data.5

1-[4-Trifluoromethylphenylethynyl]-1,2-benziodoxol-3(1H)-one (1e)

Following a reported procedure, <sup>3</sup> trimethylsilyl triflate (1.0 mL, 5.5 mmol, 1.1 equiv) was added to a suspension of 2-iodosylbenzoic acid (**19a**, 1.3 g, 5.0 mmol, 1.0 equiv) in  $CH_2Cl_2$  (15 mL) at RT The resulting suspension was stirred for 1 h, followed by the dropwise addition of trimethyl((4-(trifluoromethyl)phenyl)ethynyl)silane (**21e**, 1.3 mL, 5.5 mmol, 1.1 equiv), which was dissolved in  $CH_2Cl_2$  (1 mL). The resulting suspension was stirred for 6 h at RT A saturated solution of NaHCO<sub>3</sub> (20 mL) was then added and the mixture was stirred vigorously for 30 min, the two layers were separated and the organic layer was washed with sat. NaHCO<sub>3</sub> (20 mL), dried over MgSO<sub>4</sub>, filtered and evaporated under reduced pressure. The resulting solid was boiled in  $CH_3CN$  (20 mL). The mixture was cooled down, filtered and dried under high vacuum to afford **1e** (1.3 g, 3.2 mmol, 64% yield) as a pale yellow solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.46 – 8.38 (m, 1H, Ar*H*), 8.28 – 8.19 (m, 1H, Ar*H*), 7.84 – 7.74 (m, 2H, Ar*H*), 7.74 – 7.65 (m, 4H, Ar*H*).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.6, 135.0, 133.0, 132.6, 132.2 (q, J = 33.0 Hz), 131.7, 131.2, 126.3, 125.7 (q, J = 3.6 Hz), 124.4, 123.4 (q, J = 272.6 Hz), 116.1, 104.2, 53.7.

Consistent with reported data.3

### 1-[4-Bromophenylethynyl]-1,2-benziodoxol-3(1H)-one (1f)

Following a reported procedure,  $^4$  trimethylsilyl triflate (1.0 mL, 5.5 mmol, 1.1 equiv) was added to a suspension of 2-iodosylbenzoic acid (**19a**, 1.3 g, 5.0 mmol, 1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) at RT The resulting suspension was stirred for 1 h, followed by the dropwise addition of ((4-bromophenyl)ethynyl)trimethylsilane (**21f**, 1.2 g, 5.5 mmol, 1.1 equiv), which was dissolved in CH<sub>2</sub>Cl<sub>2</sub>

<sup>&</sup>lt;sup>12</sup> One carbon is not resolved.

(1 mL). The resulting suspension was stirred for 6 h at RT A saturated solution of NaHCO<sub>3</sub> (20 mL) was then added and the mixture was stirred vigorously for 30 min, the two layers were separated and the organic layer was washed with sat. NaHCO<sub>3</sub> (20 mL), dried over MgSO<sub>4</sub>, filtered and evaporated under reduced pressure. The resulting solid was boiled in CH<sub>3</sub>CN (20 mL). The mixture was cooled down, filtered and dried under high vacuum to afford **1f** (1.4 g, 3.3 mmol, 66% yield) as a pale yellow solid.

Mp 158-163 °C (decomposition).

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 8.51 – 8.30 (m, 1H, Ar*H*), 8.30 – 8.13 (m, 1H, Ar*H*), 7.84 – 7.72 (m, 2H, Ar*H*), 7.58 (d, 2H, J = 8.5 Hz, Ar*H*), 7.46 (d, 2 H, J = 8.5 Hz, Ar*H*).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.6, 135.1, 134.3, 132.7, 132.3, 131.9, 131.4, 126.3, 125.7, 119.6, 116.3, 105.4, 52.1.

Consistent with reported data.4

1-[2-Bromophenylethynyl]-1,2-benziodoxol-3(1H)-one (1g)

Following a slightly modified reported procedure,  $^5$  trimethylsilyl triflate (0.42 mL, 2.4 mmol, 1.1 equiv) was added to a suspension of 2-iodosylbenzoic acid (**19a**, 0.562 g, 2.13 mmol, 1.00 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL) at RT The resulting suspension was stirred for 1 h, followed by the drop wise addition of ((2-bromophenyl)ethynyl)trimethylsilane (**21g**, 0.50 mL, 2.4 mmol, 1.1 equiv). The resulting suspension was stirred for 6 h at RT. A saturated solution of NaHCO<sub>3</sub> (10 mL) was then added and the mixture was stirred vigorously for 1 h resulting in a persistent emulsion/suspension. The mixture was diluted with CHCl<sub>3</sub> (10 mL), water (5 mL) and MeOH (ca. 2 mL) to afford 2 distinct layers. The two layers were separated, and the organic layer was washed with sat. NaHCO<sub>3</sub> (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. The resulting solid was recrystallized in EtOAc:MeOH (7:3 v:v) (ca. 20 mL). The solution was left to cool to RT then was placed in the freezer (-20 °C) overnight. The crystals were filtered and washed with Et<sub>2</sub>O afford **1g** (1.50 g, 3.51 mmol, 70% yield) as colorless crystals.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.44 (td, J = 7.3, 2.1 Hz, 2 H, ArH), 7.84 – 7.74 (m, 2 H, ArH), 7.68 (d, J = 1.1 Hz, 1 H, ArH), 7.61 (dd, J = 7.6, 1.7 Hz, 1 H, ArH), 7.36 (m, 2 H, ArH).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)<sup>7</sup> δ 166.6, 135.2, 134.7, 133.0, 132.7, 131.8, 131.3, 127.6, 126.8, 126.4, 123.2, 116.5, 104.3, 55.4.

Consistent with reported data.<sup>5</sup>

# 1-[2-Chlorophenylethynyl]-1,2-benziodoxol-3(1H)-one (1h)

Following a slightly modified reported procedure, <sup>6</sup> trimethylsilyl triflate (0.40 mL, 2.2 mmol, 1.2 equiv) was added to a suspension of 2-iodosylbenzoic acid (**19a**, 0.548 g, 2.08 mmol, 1.1 equiv) in DCE (5.8 mL) at RT The resulting suspension was stirred for 1 h, followed by the drop wise addition of (2-chlorophenyl)acetylene (**21h**, 0.26 mL, 0.19 mmol, 1.0 equiv). The resulting suspension was stirred for 15 h at 40 °C A saturated solution of NaHCO<sub>3</sub> (20 mL) was then added and the mixture was stirred vigorously for 30 minutes resulting in a persistent emulsion/suspension. Water (5 mL) was added, followed by chloroform (15 mL) and MeOH (ca. 0.5 mL) resulting in 2 clear layers. The two layers were seperated and the organic layer was washed with sat. NaHCO<sub>3</sub> (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. The resulting solid was recrystallized from EtOAc:MeOH (7:3 v:v, ca. 10 mL). The mixture was cooled down overnight in the freezer (-20 °C), filtered and washed with Et<sub>2</sub>O to afford **1h** (0.217 g, 0.567 mmol, 30% yield) as a white crystalline solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.46 – 8.38 (m, 2H, Ar*H*), 7.84 – 7.73 (m, 2H, Ar*H*), 7.62 (dd, J = 7.6, 1.7 Hz, 1H, Ar*H*), 7.50 (dt, J = 8.2, 1.2 Hz, 1H, Ar*H*), 7.46 – 7.37 (m, 1H, Ar*H*), 7.33 (td, J = 7.6, 1.3 Hz, 1H, Ar*H*).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.6, 137.2, 135.2, 134.5, 132.7, 131.8, 131.7, 131.3, 129.9, 127.0, 126.7, 121.0, 116.4, 102.7, 56.0.

Consistent with reported data<sup>13</sup>

# 2.2. Synthesis of the photocatalysts


# 2.3. General procedure A: Synthesis of the photocatalysts

**S11** 

<sup>&</sup>lt;sup>13</sup> Li, M.; Li, W.; Lin, C.-D.; Wang, J.-H.; Wen, L.-R. J. Org. Chem. **2019**, 84 (11), 6904–6915.

Sodium hydride (60% suspension in mineral oil, 8.0 equiv) was added slowly to a stirred solution of substituted-carbazole 23 (5.0 equiv) in dry THF (0.05 M) under a nitrogen atmosphere at RT After 30 min, 2,4,5,6-tetrafluoroisophthalonitrile 24 (1.0 mmol, 1.0 equiv) was added. After stirring at RT for 15 h, 2 mL water was added to the reaction mixture to quench the excess of NaH. The resulting mixture was then concentrated under reduced pressure. The crude product was purified by recrystallization from hexane:CH<sub>2</sub>Cl<sub>2</sub> then filtered. The brown liquid filtrate was concentrated and recrystallized as before. The combined solids were then purified by column chromatography on silica gel with CH<sub>2</sub>Cl<sub>2</sub>:Hexane.

## 2,4,5,6-Tetra(9*H*-carbazol-9-yl)isophthalonitrile (4CzIPN, **2a**)



Following general procedure A and starting from 9H-carbazole 23a (X = H, 1.67 g, 10.0 mmol, 5.00 equiv), sodium hydride (0.60 g, 15 mmol, 7.5 equiv) and 2,4,5,6-tetrafluoroisophthalonitrile 24 (0.40 g, 2.0 mmol) in 40 mL of THF. Recrystallization (Hexanes:CH<sub>2</sub>Cl<sub>2</sub> (1:1, 90 mL)) afforded the crude product as a yellow powder. Column chromatography afforded 2,4,5,6tetra(9H-carbazol-9-yl)isophthalonitrile (2a) as a bright yellow crystalline solid (1.14 g, 1.45 mmol, 73 % yield).


Rf (Hexane; $CH_2Cl_2$  1:1) = 0.29. (yellow spot on TLC).

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 8.2 (d, J = 7.7 Hz, 2H, ArH), 7.8 – 7.6 (m, 8H, ArH), 7.5 (ddd, J = 8.0, 6.6, 1.6 Hz, 2H, ArH), 7.3 (d, J = 7.5 Hz, 2H, ArH), 7.2 (dd, J = 8.4, 1.5 Hz, 4H, ArH), 7.2 – 7.0 (m, 8H, ArH), 6.8 (t, J = 7.8 Hz, 4H, ArH), 6.6 (td, J = 7.6, 1.2 Hz, 2H, ArH).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  145.2, 144.6, 140.0, 138.2, 136.9, 134.7, 127.0, 125.8, 124.9, 124.7, 124.5, 123.8, 122.4, 121.9, 121.4, 121.0, 120.4, 119.6, 116.3, 111.6, 109.9, 109.5, 109.4.

<sup>1</sup>H NMR shift in CDCl<sub>3</sub> are consistent with reported data. <sup>14</sup>

# (2r,4s,5r)-2,4,5,6-Tetrakis(3,6-dichloro-9H-carbazol-9-yl)isophthalonitrile (4ClCzIPN, 2b)



Following general procedure A and starting from 3,6-dichloro-9Hcarbazole 23b (1.96 g, 6.00 mmol, 6.0 equiv), sodium hydride 8.00 mmol, equiv) (0.320)8.0 and tetrafluoroisophthalonitrile 24 (200 mg, 1.00 mmol) in 20 mL of THF. Recrystallization (Hexanes:CH<sub>2</sub>Cl<sub>2</sub> (1:2, 80 mL)) gave 900 mg of yellow powder, then second recrystallization gave 325 mg of brown powder. Column chromatography of the combined solid (2r,4s,5r)-2,4,5,6-tetrakis(3,6-dichloro-9H-carbazol-9yl)isophthalonitrile (2b) as a bright yellow crystalline solid (830 mg, 0.780 mmol, 87 % yield).

Rf (Hexane:CH<sub>2</sub>Cl<sub>2</sub> 1:1): 0.25. (yellow spot on TLC).

<sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) δ 8.60 (d, J = 2.1 Hz, 2H, ArH), 8.15 (d, J = 2.1 Hz, 4H, ArH), 8.08 (d, J = 8.8 Hz, 2H, ArH), 7.87 (dd, J = 8.8, 2.1 Hz, 2H, ArH), 7.80 (d, J = 2.2 Hz, 2H, ArH), 7.69 (d, J = 8.8 Hz, 4H, ArH), 7.46 (d, J = 8.8 Hz, 2H, ArH), 7.32 (dd, J = 8.8, 2.2 Hz, 4H, ArH), 6.93 (dd, J = 8.8, 2.2 Hz, 2H, ArH).

<sup>13</sup>C NMR (101 MHz, DMSO- $d_6$ )  $\delta$  145.0, 144.5, 138.5, 137.4, 136.5, 135.8, 134.5, 127.8, 127.0, 126.4, 125.7, 125.3, 124.2, 123.8, 123.3, 121.6, 120.9, 120.3, 116.8, 112.6, 112.5, 112.3, 111.7.

<sup>&</sup>lt;sup>14</sup> Uoyama, H.; Goushi, K.; Shizu, K.; Nomura, H.; Adachi, C. *Nature* **2012**, *492*, 234.

<sup>1</sup>H NMR shift in CDCl<sub>3</sub> are consistent with reported data.<sup>6</sup>


# 2.4. Synthesis of tertiary alcohols

Alcohols for substrates **3a-d**, **3k-m**, **3p**, **3w** and **3x** were purchased from commercial sources (Sigma-Aldrich, Acros, TCI, abcr) and used directly without prior purification.

General procedure B: Synthesis of tertiary alcohols from ketones

An oven dried two-necked flask, equipped with a magnetic stirrer, was charged with the ketone **25e-f** (1.0 equiv) and dissolved in anhydrous THF or  $Et_2O$  (0.2 M). The reaction was cooled to 0 °C with an ice bath. The methylmagnesium bromide solution (3.0 M in  $Et_2O$ ) was diluted to 1 M and added dropwise to the cooled solution via a dropping funnel. The reaction was stirred at room temperature overnight (15 to 18 h) at this time the reaction was quenched with sat. aq.  $NH_4CI$ , followed by the addition of water and EtOAc. The layers were separated, the aqueous layer was extracted 3 times with EtOAc then the combined organic layers were washed with sat. aq. NaCI. The organic layer was then dried on  $MgSO_4$ , filtered and concentrated under reduced pressure. The compound was purified by column chromatography ( $SiO_2$ , pentane:EtOAc, p-Anisaldehyde stain) affording the desired alcohol.

Methylcyclododecan-1-ol (26e)



**26e** was synthesized following the *general procedure B* in  $Et_2O$  (25 mL, 0.2 M) from cyclododecanone (**25e**, 1.00 g, 5.49 mmol, 1.0 equiv) using methylmagnesium bromide (3.0 M in  $Et_2O$ , 2.0 mL, 6.00 mmol, 1.1 equiv) diluted with THF (4.0 mL).

Column chromatography ( $SiO_2$ , 10% EtOAC in Pentane) afforded methylcyclododecan-1-ol **26e** (609 mg, 3.07 mmol, 56 %) as a white amorphous solid. The NMR data was collected and the compound was used in the next step without further analysis.

Rf (pentane:EtOAc 9:1) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.59 – 1.52 (m, 2 H, CH<sub>2</sub>), 1.45 – 1.25 (m, 20 H, CH<sub>2</sub>), 1.17 (s, 3 H, CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 73.8, 36.3, 29.2, 26.6, 26.2, 22.7, 22.2, 20.1.

4-Methyltetrahydro-2*H*-pyran-4-ol (**26f**)



**26f** was synthesized following the *general procedure B* in THF (50 mL, 0.2 M) from tetrahydro-4*H*-pyran-4-one (**25f**, 0.94 mL, 10 mmol, 1.0 equiv) using methylmagnesium bromide (3.0 M in Et<sub>2</sub>O, 3.7 mL, 11 mmol, 1.1 equiv) diluted with THF (7.3 mL). Column chromatography (SiO<sub>2</sub>, 25% EtOAc in Pentane) afforded 4-methyltetrahydro-2*H*-pyran-4-ol **26f** (604 mg, 5.20 mmol, 52 %) as a colourless oil.

Rf (pentane:EtOAc 3:1) = 0.3.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 3.81 - 3.75 (m, 2H, OCH<sub>2</sub>), 3.72 - 3.76 (m, 2H, OCH<sub>2</sub>), 1.77 - 1.62 (m, 2H, CH<sub>2</sub>), 1.58 - 1.48 (m, 2H, CH<sub>2</sub>), 1.28 (s, 3H, CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 67.5, 64.4, 39.6, 30.3.

General procedure C: Synthesis of tertiary alcohols from esters

$$\begin{array}{c}
O \\
R^{1} \\
OR
\end{array}$$


$$\begin{array}{c}
MeMgBr (3.0 \text{ M in Et}_{2}O) (2.3 \text{ equiv}) \\
\hline
THF
\end{array}$$

$$\begin{array}{c}
R
\end{array}$$

$$\begin{array}{c}
OH
\end{array}$$

An oven dried two necked flask, equipped with a magnetic stirrer, was charged with the ester **27m-n** (1.0 equiv) and dissolved in anhydrous THF (1.0 M). The reaction was cooled to 0 °C with an ice bath. The methyl magnesium bromide solution was diluted to 1 M with THF and added dropwise to the cooled solution *via* syringe. The reaction was left to stir at room temperature overnight (15 to 18 h) at this time the reaction was quenched with sat. aq. NH<sub>4</sub>Cl. The aqueous layer was extracted 3 times with EtOAc then the combined organic layers were washed with sat. aq. NaCl. The organic layers were then dried on MgSO<sub>4</sub>, filtered and concentrated under reduced pressure. The compound was purified by column chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1, 4:1, *p*-Anisaldehyde stain blue to purple and black spots) affording the desired alcohol.

#### 1-(4-Methoxyphenyl)-2-methylpropan-2-ol (26m)



**26m** was synthesized following the *general procedure B*: in THF (60 mL, 0.1 M) using methyl 2-(4-methoxyphenyl)acetate (**27m** ,1.0 mL, 6.3 mmol, 1.0 equiv) and methyl magnesium bromide (3 M in Et<sub>2</sub>O) (4.8 mL, 14 mmol, 2.3 equiv) diluted with 10 mL of THF.

Column chromatography ( $SiO_2$  ca. 40 g, pentane:EtOAc 9:1 to 8:2) afforded 1-(4-methoxyphenyl)-2-methylpropan-2-ol **26m** (0.898 g, 4.98 mmol, 79%).


Rf (pentane:EtOAc 9:1) = 0.3

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.16 – 7.11 (m, 2H, Ar*H*), 6.88 – 6.83 (m, 2H, Ar*H*), 3.80 (s, 3H, OMe), 2.71 (s, 2H, ArCH<sub>2</sub>), 1.21 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.5, 131.5, 129.9, 113.8, 70.9, 55.4, 48.9, 29.2.

The reported NMR data are consitant with the reported data. 15

#### 1-(2-Fluorophenyl)-2-methylpropan-2-ol (26n)



**26n** was synthesized following the *general procedure B*: in THF (60 mL, 0.1 M) using methyl 2-(2-fluorophenyl)acetate (**27n**, 1.0 mL, 6.8 mmol, 1.0 equiv) and methyl magnesium bromide (3 M in Et<sub>2</sub>O) (5.2 mL, 16 mmol, 2.3 equiv) diluted with 10 mL of THF.

Column chromatography ( $SiO_2$  ca. 40g, pentane:EtOAc 9:1 to 8:2) afforded 1-(2-fluorophenyl)-2-methylpropan-2-ol **26n** (0.723 g, 4.30 mmol, 63%).

Rf (pentane:EtOAc 9:1) = 0.3.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.29 – 7.18 (m, 2H, Ar*H*), 7.13 – 7.00 (m, 2H, Ar*H*), 2.83 (d, J = 1.5 Hz, 2H, C*H*<sub>2</sub>), 1.48 (s, 1H, O*H*), 1.25 (d, J = 0.9 Hz, 6H, C(C*H*<sub>3</sub>)<sub>2</sub>).

<sup>&</sup>lt;sup>15</sup> Okamura, T.; Egoshi, S.; Dodo, K.; Sodeoka, M.; Iwabuchi, Y.; Kanoh, N. *Chem. – Eur. J.* **2019**, *25*, 16002–16006.

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 161.5 (d, J = 244.7 Hz), 132.8 (d, J = 4.7 Hz), 128.3 (d, J = 8.2 Hz), 124.9 (d, J = 16.0 Hz), 123.8 (d, J = 3.5 Hz), 115.4 (d, J = 23.0 Hz), 71.3, 42.3, 29.1.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -116.1.

IR  $(v_{max}, cm^{-1})$  3420 (m), 3061 (m), 2975 (m), 2963 (m), 2936 (m), 1583 (m), 1493 (s), 1455 (s), 1228 (s), 1184 (s), 1134 (s), 753 (s).

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M]^+$  Calcd for  $C_{10}H_{12}F^+$  151.0918; Found 151.0921.

## 2.5. Synthesis of cesium salts

General procedure D: Synthesis of cesium salts from tertiary alcohols

Step 1: Following a modified reported procedure,  $^{16}$  a two necked round bottomed flask, equipped with a magnetic stirrer, was charged with THF or  $CH_2Cl_2$  (0.1 or 0.2 M),  $^{17}$  DMAP (0.15 mmol, 5 mol%), the tertiary alcohol **26a-x** (3.00 mmol, 1.00 equiv) and triethylamine (1.05 - 1.2 equiv) were then added. Ethyl 2-chloro-2-oxoacetate (1.05 - 1.2 equiv) was then added dropwise and giving a yellowish solution. The reaction was then stirred for 1 h – 2 h at room temperature. Upon full conversion of the alcohol, indicated by TLC analysis, the reactions were quenched with sat. aq. NH<sub>4</sub>Cl. The layers were then separated and the organic layer was then washed twice with brine (ca. 10 mL). The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub> and filtered. A solid deposit for flash chromatography was prepared: (ca. 5-7 g SiO<sub>2</sub>) concentrated under reduced pressure. The compound was purified by flash chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1, 4:1, *p*-Anisaldehyde stain blue, green or purple spots) affording the desired alkyl ethyl oxalate **28a-x**.

<u>Step 2:</u> Following a modified reported procedure,  $^{13}$  a round-bottom flask was charged with ethyl oxoacetate **28a-x** (1.75 mmol, 1.00 equiv) followed by the addition of THF (1 M). To this solution, a 1 M stock solution of aq. CsOH (1.7 mmol, 1.00 equiv) was added dropwise (ca. 2 min). The mixture was stirred vigorously for 5 min at room temperature, then concentrated immediately under reduced pressure (T =  $55^{\circ}$ C -  $60^{\circ}$ C: P =  $300^{\circ}$  mbar to 20 mbar). The resulting solid was then dried under high vacuum for at least 4 hours affording a dry (rarely hygroscopic, some are soap-like) cesium salt **3a-x**.

-

<sup>&</sup>lt;sup>16</sup>Nawrat, C. C.; Jamison, C. R.; Slutskyy, Y.; MacMillan, D. W. C.; Overman, L. E. *J. Am. Chem. Soc.* **2015**, *137*, 11270–11273

 $<sup>^{17}</sup>$  We have not noticed particular changes of reactivity between THF and  $CH_2Cl_2$  or between 0.1 M or 0.2 M, use of  $CH_2Cl_2$  simplifies extraction.

<sup>&</sup>lt;sup>18</sup> Other hydrolysis products have been observed when the reaction is left longer or triturated in diethyl ether to attempt purification.

Synthetic and characterization data for alkyl ethyl oxalate intermediates **28a-x** and cesium salts **3a-x** 

#### Ethyl 2-(2-methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (28a)

**28a** was synthesized following step 1 of general procedure D in THF (90 mL, 0.1 M) using 2-methyl-4-phenylbutan-2-ol (**22a**, 1.6 mL, 9.1 mmol, 1 equiv), DMAP (0.055 g, 0.46 mmol, 5 mol%), triethylamine (1.3 mL, 9.6 mmol, 1.05 equiv) and ethyl chloro-oxoacetate (1.1 mL, 9.6 mmol, 1.05 equiv).

Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 85:15) afforded ethyl (2-methyl-4-phenylbutan-2-yl) oxalate (**28a**, 2.00 g, 7.57 mmol, 83%) as a colorless oil.

#### Rf (pentane:EtOAc 9:1) = 0.5

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38 – 7.29 (m, 2H, Ar*H*), 7.25 (d, J = 7.1 Hz, 3H, Ar*H*), 4.38 (q, J = 7.1 Hz, 2H, OC $H_2$ -CH<sub>3</sub>), 2.79 – 2.71 (m, 2H, Ph-C $H_2$ ), 2.25 – 2.16 (m, 2H, C $H_2$ ), 1.66 (s, 6H, dMe), 1.43 (t, J = 7.1 Hz, 3H, OCH<sub>2</sub>C $H_3$ ).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.6, 157.1, 141.6, 128.5, 128.4, 126.0, 86.6, 62.8, 42.5, 30.2, 25.7, 14.0.

**IR** (vmax, cm-1) 3087 (w), 3062 (w), 3029 (m), 2983 (m), 2949 (m), 2872 (w), 1761 (s), 1737 (s), 1327 (m), 1188 (s), 1163 (s), 1118 (s), 912 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{15}H_{20}NaO_4^+$  287.1254; Found 287.1256.

#### Cesium 2-(2-methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (3a)

**3a** was synthesized following step 2 of general procedure D in THF (6.5 mL, 0.1 M) using ethyl (2-methyl-4-phenylbutan-2-yl) oxalate (**28a**, 1.70 g, 6.43 mmol, 1.0 equiv) and 1 M aq. CsOH (6.4 mL, 6.4 mmol, 1.0 equiv), affording cesium 2-(2-methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 2.34 g, 6.36 mmol, 99%) as an off-white amorphous solid.

<sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 7.31 (m, 5H, Ar*H*), 2.73 – 2.64 (m, 2H, ArC*H*<sub>2</sub>), 2.20 – 2.11 (m, 2H, C*H*<sub>2</sub>), 1.55 (s, 6H, C(C*H*<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 165.2, 164.1, 142.5, 128.7, 128.5, 126.0, 86.0, 41.3, 29.7, 25.4. HRMS (ESI/QTOF) m/z: [M - Cs]<sup>-</sup> Calcd for  $C_{13}H_{15}O_4$ <sup>-</sup> 235.0976; Found 235.0979.

#### Ethyl (tert-butyl)oxy-2-oxoacetate (28b)

Following a reported procedure, <sup>19</sup> ethyl 2-chloro-2-oxoacetate (3.6 mL, 32 mmol, 1.2 equiv) was added to a solution of *tert*-butanol (**26b**, 2.0 g, 27 mmol, 1.0 equiv) and pyridine (3.26 mL, 40.5 mmol) in  $Et_2O$  (100 mL) and the resulting yellow solution was stirred at room temperature for 4 hours. The organic layer was washed with water (2 x 50 mL) and sat. aq. NaHCO<sub>3</sub> solution (50 mL), dried over MgSO<sub>4</sub> and

<sup>19</sup> Xu, Y.; McLaughlin, M.; Bolton, E. N.; Reamer, R. A. J. Org. Chem. **2010**, 75, 8666–8669.

concentrated under reduced pressure. The crude material was purified by flash column chromatography on a short column of silica gel (1:20 Et<sub>2</sub>O:pentane) to give *tert*-butyl ethyl oxalate (28b, 4.4 g, 25 mmol, 98%) as a colorless oil.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.31 (q, J = 7.1 Hz, 2H, OCH<sub>2</sub>), 1.55 (s, 9H, tBu), 1.36 (t, J = 7.1 Hz, 3H, CH<sub>2</sub>CH<sub>3</sub>).

 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  158.8, 157.3, 85.0, 62.9, 27.9, 14.1. The NMR data obtained are consistent with the reported literature data.  $^{16}$ 

#### Cesium (tert-butyl)oxy-2-oxoacetate (3b)

**3b** was synthesized following step 2 of general procedure D in THF (2.1 mL, 0.1 M) using tert-butyl ethyl oxalate (**28c**, 0.366 g, 2.10 mmol, 1.0 equiv) and 1 M aq. CsOH (2.1 mL, 2.1 mmol, 1.0 equiv), affording cesium (tert-butyl)oxy-2-oxoacetate (**3c** 0.505 g, 1.82 mmol, 86%) as a colorless amorphous solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO- $d_6$ ) δ 1.37 (s, 9H, C(C $H_3$ )<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO- $d_6$ )  $\delta$  167.5, 163.5, 78.0, 27.9.

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_6H_9CsNaO_4^+$  300.9448; Found 300.9451.

#### Ethyl 2-(1-methylcyclopent-1-yl)oxy-2-oxoacetate (28c)

**28c** was synthesized following step 1 of general procedure D in THF (16 mL, 0.2 M) using 1-methylcyclopentan-1-ol (**22c**, 337 mg, 3.36 mmol, 1.0 equiv), DMAP (21 mg, 0.17 mmol, 5 mol%), triethylamine (0.56 mL, 11 mmol, 1.2 equiv) and ethyl chlorooxoacetate (0.45 mL, 11 mmol, 1.2 equiv).

Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1 to 8:2) afforded ethyl (1-methylcyclopentan-1-yl) oxalate (**28c**, 596 mg, 2.98 mmol, 89%).

#### Rf (pentane:EtOAc 9:1) = 0.5.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.31 (q, J = 7.1 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 2.21 (ttd, J = 10.4, 4.8, 2.4 Hz, 2H, CH<sub>2</sub>), 1.83 – 1.71 (m, 4H, CH<sub>2</sub>), 1.71 – 1.58 (m, 5H, CH<sub>2</sub> + CH<sub>3</sub>), 1.36 (t, J = 7.1 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  158.8, 157.5, 94.2, 62.9, 39.0, 24.1, 23.8, 14.1.

**IR** ( $v_{max}$ , cm<sup>-1</sup>) 2984 (m), 2942 (m), 2910 (w), 1762 (s), 1737 (s), 1370 (m), 1324 (m), 1201 (s), 1139 (s), 1017 (m), 846 (m).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{10}H_{16}NaO_4^+$  223.0941; Found 223.0935.

#### Cesium 2-(1-methylcyclopent-1-yl)oxy-2-oxoacetate (3c)

**3c** was synthesized following step 2 of general procedure D in THF (1.2 mL, 0.1 M) using ethyl (1-methylcyclopent-1-yl) oxalate (**28c**, 0.37 g, 1.8 mmol, 1.0 equiv) and 1 M aq. CsOH (1.8 mL, 1.8 mmol, 1.0 equiv), affording cesium 2-(1-methylcyclopent-1-yl)oxy-2-oxoacetate (**3c**, 0.541 g, 1.78 mmol, 97%).

<sup>1</sup>**H NMR** (400 MHz, DMSO) δ 1.97 (dddt, J = 7.1, 5.3, 3.0, 1.8 Hz, 2H,  $CH_2$ ), 1.72 – 1.49 (m, 6H,  $CH_2$ ), 1.46 (s, 3H,  $CH_3$ ).

 $^{13}$ C NMR (101 MHz, DMSO) δ 167.5, 163.5, 87.3, 24.3, 23.3, 14.2. Consistent with reported data.  $^{16}$ 

#### Ethyl 2-(1-methylcyclohex-1-yl)oxy-2-oxoacetate (28d)

**28d** was synthesized following step 1 of general procedure *D* in THF (90 mL, 0.1 M) using 1-methylcyclohexan-1-ol (**22d**, 1.1 mL, 8.8 mmol, 1.0 equiv), DMAP (107 mg, 0.876 mmol, 0.1 equiv) triethylamine (1.50 mL, 10.5 mmol, 1.2 equiv) and ethyl chloro-oxoacetate (1.20 mL, 10.5 mmol, 1.2 equiv).

Column chromatography (SiO<sub>2</sub>, 2% EtOAc in Pentane) afforded ethyl (1-methylcyclohexyl) oxalate (**28d**, 1.18 g, 5.51 mmol, 63%) as a pale yellow oil.

**Rf** (pentane:EtOAc 98:2) = 0.3.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 4.30 (q, J = 7.12 Hz, 2H, CO<sub>2</sub>CH<sub>2</sub>), 2.21 – 2.18 (m, 2H, CH<sub>2</sub>), 1.58 – 1.44 (m, 8 H, CH<sub>2</sub>), 1.55 (s, 3H, CH<sub>3</sub>), 1.35 (t, J = 7.12 Hz, 3 H, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$ : 158.8, 157.2, 86.7, 62.8, 36.4, 25.3, 25.1, 22.1, 14.1.

IR (v<sub>max</sub>, cm<sup>-1</sup>): 2979 (w), 2938 (m), 2864 (w), 1743 (s), 1454 (w), 1326 (m), 1192 (s), 1146 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{11}H_{18}NaO_4^+$  237.1097; found 237.1094

#### Ethyl 2-(1-methylcyclohex-1-yl)oxy-2-oxoacetate (3d)


**3d** was synthesized following step 2 of general procedure D in THF (5.0 mL, 0.1 M) using ethyl (1-methylcyclohexyl) oxalate (**28d**, 1.07 g, 5.00 mmol, 1.0 equiv) and 1 M aq. CsOH (5.0 mL, 5.0 mmol, 1.0 equiv). Affording cesium 2-((1-methylcyclohexyl)oxy)-2-oxoacetate (**3d**, 1.4 g, 4.4 mmol, 88%) as a colorless amorphous solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO-d6) δ: 2.08 - 1.96 (m, 2H, CH<sub>2</sub>), 1.56 - 1.43 (m, 3H, CH<sub>2</sub>), 1.43 - 1.29 (m, 7H, CH<sub>2</sub> + CH<sub>3</sub>), 1.27 - 1.18 (m, 1H, CH<sub>2</sub>).

 $^{13}$ C NMR (101 MHz, DMSO)  $\delta$ : 167.7, 163.6, 79.2, 36.2, 25.3, 25.0, 21.5.

**HRMS** (ESI/QTOF) m/z:  $[M - Cs]^{-}$  Calcd for  $C_9H_{13}O_4^{-}$  185.0819; Found 185.0819.

#### Ethyl (1-methylcyclododecyl) oxalate 28e



**28e** was synthesized following step 1 of general procedure *D* in THF (25 mL, 0.1 M) using 1-methylcyclododecan-1-ol (**22e**, 500 mg, 2.52 mmol, 1.0 equiv), DMAP (31 mg, 0.25 mmol, 10 mol%), triethylamine (0.42 mL, 3.0 mmol, 1.2 equiv) and ethyl chlorooxoacetate (0.34 mL, 3.0 mmol, 1.2 equiv).

Column chromatography ( $SiO_2$ , 20% EtOAc in Pentane) afforded ethyl (1-methylcyclododecyl) oxalate (**28e**, 1.08 g, 4.25 mmol, 71 %) as an off-white amorphous solid.

Rf (pentane:EtOAc 4:1) = 0.5.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.31 (q, J = 7.2 Hz, 2H, CO<sub>2</sub>CH<sub>2</sub>), 2.10 – 1.98 (m, 2H, CH<sub>2</sub>), 1.74 – 1.61 (m, 2H, CH<sub>2</sub>), 1.55 (s, 3H, CH<sub>3</sub>), 1.49 – 1.23 (m, 21H, CH<sub>2</sub> + CH<sub>2</sub>CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 157.1, 90.8, 62.9, 32.9, 26.2, 26.2, 24.0, 22.5, 22.0, 19.5, 14.1.

**IR** (v<sub>max</sub>, cm<sup>-1</sup>): 2939 (s), 2861 (m), 1744 (s), 1467 (m), 1375 (m), 1325 (m), 1190 (s), 1152 (s)

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{17}H_{30}NaO_4^+$  321.2036; Found 321.2037.

Cesium 2-((1-methylcyclododecyl)oxy)-2-oxoacetate (3e)

**3e** was synthesized following step 2 of general procedure D in THF (1.0 mL, 0.1 M) using ethyl (1-methylcyclododecyl) oxalate (**28e**, 300 mg, 1.00 mmol, 1.0 equiv) and 1 M aq. CsOH (1.0 mL, 1.00 mmol, 1.0 equiv). Cesium 2-((1-methylcyclododecyl)oxy)-2-oxoacetate (**3e**, 300 mg, 0.745 mmol, 74 %) was obtained as an offwhite solid.

<sup>1</sup>H NMR (400 MHz, DMSO) δ: 1.90 - 1.77 (m, 2H, CH<sub>2</sub>), 1.56 - 1.42 (m, 2H, CH<sub>2</sub>), 1.38 (s, 3H, CH<sub>3</sub>), 1.34 - 1.18 (m, 18H, CH<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO) δ: 168.1, 164.0, 83.4, 33.21 26.3, 26.2, 24.4, 22.3, 22.0, 19.2. HRMS (ESI/QTOF) m/z: [M + Na]<sup>+</sup> Calcd for  $C_{15}H_{25}CsNaO_4$ <sup>+</sup> 425.0700; Found 425.0695.

#### Ethyl (4-methyltetrahydro-2H-pyran-4-yl) oxalate (28f)

**28f** was synthesized following step 1 of general procedure D in THF (45 mL, 0.1 M) using 4-methyloxan-4-ol (**22f**, 500 mg, 4.30 mmol, 1.0 equiv), DMAP (53 mg, 0.43 mmol, 10 mol%), triethylamine (0.72 mL, 5.2 mmol, 1.2 equiv) and ethyl chloro-oxoacetate (0.58 mL, 5.2 mmol, 1.2 equiv).

Column chromatography (SiO<sub>2</sub>, 15% EtOAc in Pentane) afforded ethyl (4-methyltetrahydro-2*H*-pyran-4-yl) oxalate (**28f**, 785 mg, 3.63 mmol, 84 %) as a pale yellow oil.

**Rf** (pentane:EtOAc 85:15) = 0.5.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 4.33 (q, J = 7.1 Hz, 2H, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 3.83 – 3.59 (m, 4H, OCH<sub>2</sub>), 2.27 – 2.17 (m, 2H, CH<sub>2</sub>), 1.78 (ddd, J = 14.6, 10.1, 5.0 Hz, 2H, CH<sub>2</sub>), 1.62 (s, 3H, CH<sub>3</sub>), 1.37 (t, J = 7.1 Hz, 3H, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$ : 158.4, 157.1, 83.2, 63.7, 63.1, 36.6, 25.0, 14.1.

IR (v<sub>max</sub>, cm<sup>-1</sup>): 2968 (w), 2864 (w), 1744 (s), 1462 (w), 1324 (m), 1192 (s), 1134 (s), 1023 (m).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{10}H_{16}NaO_5^+$  239.0890; Found 239.0894.

#### cesium (4-methyltetrahydro-2H-pyran-4-yl) oxalate (3f)



**3f** was synthesized following step 2 of general procedure D in THF (2.5 mL, 0.1 M) using ethyl (4-methyltetrahydro-2*H*-pyran-4-yl) oxalate (**28f**, 541 mg, 2.50 mmol, 1.0 equiv) and 1 M aq. CsOH (2.5 mL, 2.50 mmol, 1.0 equiv). Cesium 2-((3-methyl-1-phenylpentan-3-yl)oxy)-2-oxoacetate (**3f**, 725 mg, 2.27 mmol, 91%) was obtained as an off-white amorphous solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO) δ: 3.66 - 3.49 (m, 4H, OCH<sub>2</sub>), 2.04 - 1.93 (m, 2H, CH<sub>2</sub>), 1.67 - 1.53 (m, 2H, CH<sub>2</sub>), 1.45 (s, 3H, CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) δ: 167.6, 163.2, 76.5, 62.9, 36.6, 24.9.

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_8H_{11}CsNaO_5^+$  342.9553; Found 342.9553.

#### Ethyl 2-(1-methylcycloheptan-1-yl)oxy-2-oxoacetate (28i)

**28i** was synthesized following step 1 of general procedure *D* in DCM (35 mL, 0.1 M) using 1-methylcycloheptan-1-ol (**22i**, 0.30 mL, 3.4 mmol, 1 equiv), DMAP (42 mg, 0.34 mmol, 10 mol%), triethylamine (0.52 mL, 3.7 mmol, 1.1 equiv) and ethyl chloro-oxoacetate (0.42 mL, 3.8 mmol, 1.1 equiv).

Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1) afforded ethyl (1-methylcycloheptan-1-yl) oxalate (**28i**, 0.373 g, 1.84 mmol, 54%).

Rf (pentane:EtOAc 9:1) = 0.5.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.30 (q, J = 7.1 Hz, 2H, OC $H_2$ CH<sub>3</sub>), 2.20 (ddd, J = 14.9, 8.6, 1.7 Hz, 2H, cyclic-C $H_2$ ), 1.82 (ddd, J = 14.7, 9.8, 1.8 Hz, 2H, cyclic-C $H_2$ ), 1.70 – 1.39 (m, 11H, cyclic-(C $H_2$ ))<sub>4</sub> + CH<sub>3</sub>, 1.35 (t, J = 7.2 Hz, 3H, OCH<sub>2</sub>C $H_3$ ).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 157.3, 91.1, 62.8, 40.0, 29.5, 26.6, 22.6, 14.1.

**IR** (v<sub>max</sub>, cm<sup>-1</sup>) 3005 (w), 2929 (m), 2858 (m), 1760 (s), 1736 (s), 1459 (m), 1446 (m), 1371 (m), 1323 (m), 1205 (s), 1186 (s), 1159 (s), 1128 (s), 861 (m).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{12}H_{20}NaO_4^+$  251.1254; Found 251.1259.

#### Cesium 2-(1-methylcycloheptan-1-yl)oxy-2-oxoacetate (3i)




**3i** was synthesized following step 2 of general procedure D in THF (1.1 mL, 0.1 M) using ethyl (1-methylcycloheptan-1-yl) oxalate (**28i**, 0.250 g, 1.10 mmol, 1.0 equiv) and 1 M aq. CsOH (1.1 mL, 1.1 mmol, 1.0 equiv), affording cesium 2-(1-methylcycloheptan-1-yl)oxy-2-oxoacetate (**3i**, 0.332 g, 1.00 mmol, 91%). Amorphous solid.

<sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) δ 2.02 (ddd, J = 14.3, 8.6, 1.6 Hz, 2H, cyclic-C $H_2$ ), 1.67 (ddd, J = 14.4, 9.9, 1.9 Hz, 2H, cyclic-C $H_2$ ), 1.60 – 1.42 (m, 6H, cyclic-C $H_2$ ), 1.41 (s, 3H, C $H_3$ ), 1.40 – 1.28 (m, 2H, cyclic-C $H_2$ ).

<sup>13</sup>C NMR (101 MHz, DMSO- $d_6$ )  $\delta$  168.2, 164.1, 83.9, 29.3, 27.2, 22.5. 1 carbon is unresolved.

#### Ethyl 2-(((1S,3S)-adamantan-1-yl)oxy)-2-oxoacetate (28j)



**28j** was synthesized following <u>step 1</u> of *general procedure D* in DCM (25 mL, 0.1 M) using adamant-1-ol (**22j**, 378 mg, 2.48 mmol, 1.0 equiv), DMAP (30.4 mg, 248 mmol, 10 mol%), triethylamine (0.41 mL, 3.0 mmol, 1.2 equiv) and ethyl chloro-oxoacetate (0.34 mL, 3.0 mmol, 1.2 equiv).

Column chromatography ( $SiO_2$ , 15% EtOAc in Pentane) afforded ethyl 2-(((1S,3S)-adamantan-1-yl)oxy)-2-oxoacetate (28j, 442 mg, 1.75 mmol, 71 %) as a pale yellow oil.

Rf (pentane:EtOac 9:1) = 0.5.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.31 (q, J = 7.1 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 2.19 (d, J = 2.7 Hz, 9H, ad-CH<sub>x</sub>), 1.76 – 1.55 (m, 6H, ad-CH<sub>x</sub>), 1.36 (t, J = 7.1 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.8, 156.8, 85.1, 62.9, 41.0, 36.1, 31.1, 14.1.

IR (v<sub>max</sub>, cm<sup>-1</sup>) 2911 (m), 2854 (w), 1760 (s), 1733 (s), 1176 (s), 1155 (s), 1044 (m).

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M + Na]^+$  Calcd for  $C_{14}H_{20}NaO_4^+$  275.1254; Found 275.1256.

#### Cesium 2-(((1S,3S)-adamantan-1-yl)oxy)-2-oxoacetate (3j)



**3j** was synthesized following step 2 of general procedure D in THF (2.5 mL, 0.1 M) using ethyl 2-(((1*S*,3*S*)-adamantan-1-yl)oxy)-2-oxalate (**28j**, 252 mg, 1.00 mmol, 1.0 equiv) and 1 M aq. CsOH (2.5 mL, 2.5 mmol, 1.0 equiv). cesium 2-(((1*S*,3*S*)-adamantan-1-yl)oxy)-2-oxoacetate (**3j**, 0.32 g, 0.91 mmol, 91%) was obtained as an offwhite amorphous solid.

<sup>1</sup>H NMR (400 MHz, DMSO) δ: 2.12 - 2.07 (m, 3H, CH), 2.06 - 1.99 (m, 6H, CH<sub>2</sub>), 1.64 - 1.59 (m, 6H, CH<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO) δ: 167.3, 163.4, 78.0, 41.0, 35.8, 30.2.

**HRMS** (ESI/QTOF) m/z:  $[M - Cs]^{-}$  Calcd for  $C_{12}H_{15}O_4^{-}$  223.0976; Found 223.0974.

#### Ethyl (3-methyl-1-phenylpentan-3-yl) oxalate (28k)

**28k** was synthesized following step 1 of general procedure D in THF (60 mL, 0.1 M) using 3-methyl-1-phenylpentan-3-ol (**22k** 1.1 g, 6.0 mmol, 1.0 equiv), DMAP (73 mg, 0.60 mmol, 10 mol%), triethylamine (1.0 mL, 7.2 mmol, 1.2 equiv) and ethyl chloro-oxoacetate (0.80 mL, 7.2 mmol, 1.2 equiv).

Column chromatography (SiO<sub>2</sub>, 2% EtOAC in Pentane) afforded ethyl (3-methyl-1-phenylpentan-3-yl) oxalate (**28k**, 1.61 g, 5.78 mmol, 96 %) as a colourless oil.


Rf (pentane:EtOAc 98:2) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.33 – 7.24 (m, 2H, Ar*H*), 7.23 – 7.16 (m, 3H, Ar*H*), 4.32 (q, J = 7.1 Hz, 2H, CO<sub>2</sub>CH<sub>2</sub>C*H*<sub>3</sub>), 2.72 – 2.59 (m, 2H, ArC*H*<sub>2</sub>), 2.30 – 2.18 (m, 1H, C*H*<sub>2</sub>), 2.17 – 1.99 (m, 2H, C*H*<sub>2</sub>), 1.97 – 1.85 (m, 1H, C*H*<sub>2</sub>), 1.57 (s, 3H, C*H*<sub>3</sub>), 1.37 (t, J = 7.1 Hz, 3H, CO<sub>2</sub>C*H*<sub>2</sub>CH<sub>3</sub>), 0.95 (t, J = 7.5 Hz, 3H, CH<sub>2</sub>C*H*<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 158.7, 157.2, 141.8, 128.6, 128.5, 126.1, 89.6, 62.9, 39.7, 30.9, 30.1, 23.1, 14.1, 8.1.

IR ( $v_{max}$ , cm<sup>-1</sup>): 2979 (m), 2943 (w), 1739 (s), 1458 (m), 1323 (m), 1185 (s), 1115 (m), 1019 (m). HRMS (ESI/QTOF) m/z: [M + Na]<sup>+</sup> Calcd for  $C_{16}H_{22}NaO_4$ <sup>+</sup> 301.1410; Found 301.1412.

#### Cesium 2-((3-methyl-1-phenylpentan-3-yl)oxy)-2-oxoacetate (3k)



**3k** was synthesized following step 2 of general procedure D in THF (3.0 mL, 0.1 M) using ethyl (3-methyl-1-phenylpentan-3-yl) oxalate (**28k**, 835 mg, 3.00 mmol, 1.0 equiv) and 1 M aq. CsOH (3.0 mL, 3.00 mmol, 1.0 equiv). Cesium 2-((3-methyl-1-phenylpentan-3-yl)oxy)-2-oxoacetate (**3k**, 951 mg, 2.49 mmol, 83%) was obtained as an offwhite amorphous solid.

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ: 7.29 – 7.24 (m, 2H, ArH), 7.19 – 7.14 (m, 3H, ArH), 2.59 – 2.54 (m, 2H, Ar-CH<sub>2</sub>), 2.11 – 2.03 (m, 1H, CH<sub>2</sub>), 1.97 – 1.84 (m, 2H, CH<sub>2</sub>), 1.76 – 1.67 (m, 1H, CH<sub>2</sub>), 1.36 (s, 3H, CH<sub>3</sub>), 0.84 (t, J = 7.53 Hz, 3H, CH<sub>2</sub>CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) δ: 167.7, 163.5, 142.3, 128.3, 128.2, 125.6, 82.3, 64.8, 30.6, 29.3, 23.2, 7.8.

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{14}H_{17}CSNaO_4^+$  405.0074; Found 405.0075.

#### Ethyl (2,3-dimethylbutan-2-yl)oxy-2-oxoacetate (281)

**28I** was synthesized following <u>step 1</u> of *general procedure D* in DCM (24 mL, 0.1 M) using 2,3-dimethyl-2-butanol (**22I**, 0.30 mL, 2.4 mmol, 1.0 equiv), DMAP (30 mg, 0.24 mmol, 10 mol%), triethylamine (0.35 mL, 2.5 mmol, 1.05 equiv) and ethyl chloro-oxoacetate (0.3 mL, 2.5 mmol, 1.05 equiv).

Column chromatography ( $SiO_2$ , pentane:EtOAc 9:1) afforded ethyl (2,3-dimethylbutan-2-yl) oxalate (**28I**, 0.340 g, 1.68 mmol, 70%).

Rf (pentane:EtOAc 9:1) = 0.5.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 4.30 (q, J = 7.2 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 2.27 (hept, J = 6.9 Hz, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.49 (s, 6H, OC(CH<sub>3</sub>)<sub>2</sub>), 1.35 (t, J = 7.2 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>), 0.94 (d, J = 6.9 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 157.3, 90.4, 62.8, 36.3, 22.5, 17.4, 14.1.

IR  $(v_{max}, cm^{-1})$  2995 (m), 2983 (m), 2962 (w), 2946 (w), 2891 (w), 2878 (w), 2840 (w), 1763 (s), 1737 (s), 1467 (m), 1371 (m), 1324 (s), 1191 (s), 1130 (s), 1094 (s), 1017 (m).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{10}H_{18}NaO_4^+$  225.1097; Found 225.1099.

#### Cesium (2,3-dimethylbutan-2-yl)oxy-2-oxoacetate (31)

**3I** was synthesized following step 2 of general procedure D in THF (1.0 mL, 0.1 M) using ethyl (2,3-dimethylbutan-2-yl) oxalate (**28I**, 0.200 g, 0.989 mmol, 1.0 equiv) and 1 M aq. CsOH (0.99 mL, 0.99 mmol, 1.0 equiv), affording cesium (2,3-dimethylbutan-2-yl)oxy-2-oxoacetate (**3I**, 137 mg, 0.447 mmol, 45%) as a colorless amorphous solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO- $d_6$ ) δ 2.22 (hept, J = 6.9 Hz, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.30 (s, 6H, OC(CH<sub>3</sub>)<sub>2</sub>), 0.84 (d, J = 6.9 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO- $d_6$ )  $\delta$  167.6, 163.6, 83.0, 35.3, 22.7, 17.1.

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_8H_{13}CsNaO_4^+$  328.9761; Found 328.9768.

#### Ethyl (1-(4-methoxyphenyl)-2-methylpropan-2-yl)oxy-2-oxoacetate (28m)

**28m** was synthesized following step 1 of general procedure *D* in DCM (30 mL, 0.1 M) using 1-(4-methoxyphenyl)-2-methylpropan-2-ol (**22m**, 500 mg, 2.77 mmol, 1.0 equiv), DMAP (33 mg, 0.28 mmol, 10 mol%), triethylamine (0.40 mL, 2.9 mmol, 1.05 equiv) and ethyl chloro-oxoacetate (0.30 mL, 2.9 mmol, 1.05 equiv).

Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 4:1) afforded ethyl (1-(4-methoxyphenyl)-2-methylpropan-2-yl) oxalate (**28m**, 270 mg, 0.963 mmol, 35%) as a pale-yellow oil.

Rf (pentane:EtOAc 4:1) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.20 – 7.12 (m, 2H, Ar*H*), 6.87 – 6.79 (m, 2H, Ar*H*), 4.32 (q, J = 7.2 Hz, 2H, OC $H_2$ CH<sub>3</sub>), 3.79 (s, 3H, OC $H_3$ ), 3.03 (s, 2H, ArC $H_2$ ), 1.53 (s, 6H (C $H_3$ )<sub>2</sub>), 1.38 (t, J = 7.1 Hz, 3H, OC $H_2$ C $H_3$ ).

 $^{13}$ C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  158.6, 158.6, 157.2, 131.8, 128.5, 113.6, 86.8, 62.9, 55.3, 46.1, 25.4, 14.1

IR  $(v_{max}, cm^{-1})$  2995 (m), 2985 (m), 2953 (m), 2937 (m), 2909 (m), 2837 (m), 1761 (s), 1738 (s), 1612 (m), 1513 (s), 1465 (m), 1370 (m), 1321 (s), 1247 (s), 1189 (s), 1177 (s), 1164 (s), 1034 (s), 1019 (s), 851 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{15}H_{20}NaO_5^+$  303.1203; Found 303.1206.

#### Cesium (1-(4-methoxyphenyl)-2-methylpropan-2-yl)oxy-2-oxoacetate (3m)

**3m** was synthesized following step 2 of general procedure D in THF (0.7 mL, 0.1 M) using ethyl (1-(4-methoxyphenyl)-2-methylpropan-2-yl) oxalate (**28m**, 0.20 g, 0.71 mmol, 1.0 equiv) and 1 M aq. CsOH (0.7 mL, 0.7 mmol, 1.0 equiv), affording cesium (1-(4-methoxyphenyl)-2-methylpropan-2-yl)oxy-2-oxoacetate (**3m**, 251 mg, 0.653 mmol, 92%) as a coloroless amorphous solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO- $d_6$ ) δ 7.18 – 7.11 (m, 2H, ArH), 6.85 – 6.78 (m, 2H, ArH), 3.72 (s, 3H, OC $H_3$ ), 2.95 (s, 2H, ArC $H_2$ ), 1.31 (s, 6H, (C $H_3$ )<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO- $d_6$ ) δ 167.7, 163.3, 157.7, 131.5, 129.3, 113.2, 80.2, 54.9, 44.5, 25.8. HRMS (ESI/QTOF) m/z: [M - Cs] Calcd for C<sub>13</sub>H<sub>15</sub>O<sub>5</sub> 251.0925; Found 251.0936.

#### Ethyl (1-(2-fluorophenyl)-2-methylpropan-2-yl)oxy-2-oxoacetate (28n)

**28n** was synthesized following step 1 of general procedure D in DCM (30 mL, 0.1 M) using 1-(2-fluorophenyl)-2-methylpropan-2-ol (**26n**, 500 mg, 2.97 mmol, 1.0 equiv), DMAP (36 mg, 0.30 mmol, 10 mol%), triethylamine (0.44 mL, 3.1 mmol, 1.05 equiv) and ethyl chloro-oxoacetate (0.35 mL, 3.1 mmol, 1.05 equiv).

Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1 to 8:2) afforded ethyl (1-(4-fluorophenyl)-2-methylpropan-2-yl) oxalate (**28n**, 467 mg, 1.74 mmol, 59%) as a colorless oil.

Rf (pentane:EtOAc 9:1) = 0.35.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.30 (td, J = 7.6, 1.8 Hz, 1H, ArH), 7.26 – 7.20 (m, 1H, ArH), 7.12 – 6.99 (m, 2H, ArH), 4.32 (q, J = 7.2 Hz, 2H, OC $H_2$ CH<sub>3</sub>), 3.16 (d, J = 1.4 Hz, 2H, ArC $H_2$ ), 1.57 (d, J = 1.0 Hz, 6H, (C $H_3$ )<sub>2</sub>), 1.38 (t, J = 7.2 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.8, 160.4, 157.8 (d, J = 141.6 Hz), 133.2 (d, J = 4.4 Hz), 128.8 (d, J = 8.2 Hz), 123.9 (d, J = 3.5 Hz), 123.5 (d, J = 15.7 Hz), 115.4 (d, J = 23.0 Hz), 86.6, 62.9, 39.3, 25.4, 14.1. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ -115.9.

IR  $(v_{max}, cm^{-1})$  3004 (m), 2989 (m), 2965 (w), 2938 (m), 2899 (w), 1764 (s), 1737 (s), 1495 (m), 1456 (m), 1372 (m), 1319 (m), 1233 (s), 1190 (s), 1172 (s), 1120 (s), 759 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{14}H_{17}FNaO_4^+$  291.1003; Found 291.1002.

#### Cesium (1-(2-fluorophenyl)-2-methylpropan-2-yl)oxy-2-oxoacetate (**3n**)



**3n** was synthesized following step 2 of general procedure D in THF (1.5 mL, 0.1 M) using ethyl (1-(2-fluorophenyl)-2-methylpropan-2-yl) oxalate (**28n**, 0.40 g, 1.5 mmol, 1.0 equiv) and 1 M aq. CsOH (1.5 mL, 1.5 mmol, 1.0 equiv), affording cesium (1-(2-fluorophenyl)-2-methylpropan-2-yl)oxy-2-oxoacetate (**3n**, 469 mg, 1.26 mmol, 84%) as a coloroless amorphous solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO- $d_6$ ) δ 7.36 (td, J = 7.7, 1.9 Hz, 1H, ArH), 7.33 – 7.23 (m, 1H, ArH), 7.19 – 7.06 (m, 2H, ArH), 3.08 (s, 2H, Ar $CH_2$ ), 1.34 (d, J = 1.0 Hz, 6H, ( $CH_3$ )<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO- $d_6$ ) δ 167.6, 163.1, 160.9 (d, J = 243.4 Hz), 133.1 (d, J = 4.4 Hz), 128.5 (d, J = 8.2 Hz), 124.0 (d, J = 4.0 Hz), 124.0, 114.9 (d, J = 22.9 Hz), 80.0, 37.5, 25.7.

<sup>19</sup>**F NMR** (376 MHz, DMSO- $d_6$ ) δ -116.6.

**HRMS** (ESI/QTOF) m/z:  $[M - Cs]^{-}$  Calcd for  $C_{12}H_{12}FO_4^{-}$  239.0725; Found 239.0719.

#### 4-Methylbenzylation of 3-methylbutane-1,3-diol (260)

An oven dried 25 mL flask, equipped with a magnetic stirring bar, was flushed with nitrogen then charged with 3-methylbutane-1,3-diol (29, 0.26 mL, 2.4 mmol, 1.0 equiv) and anhydrous DMF (12.5 mL, 0.2 M). The solution was cooled to 0 °C and NaH (60% oil dispersion, 102 mg, 2.56 mmol, 1.05 equiv) was added portion-wise under nitrogen. The latter solution was stirred for 1 h at room

temperature. The solution was cooled back down to 0 °C and 1-(chloromethyl)-4-methylbenzene (411 mg, 2.92 mmol, 1.2 equiv) was added under nitrogen. The reaction was left to warm up to RT slowly and was stirred overnight. The reaction was quenched with sat. aq. NH<sub>4</sub>Cl (5 mL) then diluted with water (10 mL) and CH<sub>2</sub>Cl<sub>2</sub> (15 mL). The layers were separated, and the aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (15 mL). The organic layers were combined and washed with a (sat. aq. NaCl):water (1:1) solution (15 mL) three times. The organic layers were then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude oil was purified by column chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1 to 8:2) affording 2-methyl-4-((4-methylbenzyl)oxy)butan-2-ol (**26h**, 297 mg, 1.43 mmol, 59%) as a colorless oil with some trace impurities. After <sup>1</sup>H NMR and HRMS confirmation, the compound was used directly in next step with no further purification or analyses.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.21 (d, J = 8.0 Hz, 2H, ArH), 7.15 (d, J = 7.8 Hz, 2H, ArH), 4.48 (s, 2H, ArCH<sub>2</sub>), 3.70 (t, J = 5.9 Hz, 2H, CH<sub>2</sub>), 3.14 (bs, 1H, OH), 2.34 (s, 3H, ArCH<sub>3</sub>), 1.79 (t, J = 5.9 Hz, 2H, CH<sub>2</sub>), 1.23 (s, 6H, (CH<sub>3</sub>)<sub>2</sub>).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{13}H_{20}NaO_2^+$  231.1356; Found 231.1358.

Ethyl (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl)oxy-2-oxoacetate (280)

**280** was synthesized following step 1 of general procedure D in THF (11 mL, 0.1 M) using 2-methyl-4-((4-methylbenzyl)oxy)butan-2-ol (**220**, 220 mg, 1.06 mmol, 1.0 equiv), DMAP (13 mg, 0.11 mmol, 10 mol%), triethylamine (0.16 mL, 1.2 mmol, 1.1 equiv) and ethyl chloro-oxoacetate (0.16 mL, 1.2 mmol, 1.1 equiv).

Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1 to 8:2) afforded ethyl (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl) oxalate (**28o**, 224 mg, 0.726 mmol, 69%).

Rf (pentane:EtOAc 9:1) = 0.3.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.21 (d, J = 8.1 Hz, 2H, ArH), 7.18 – 7.11 (m, 2H, ArH), 4.44 (s, 2H, ArCH<sub>2</sub>), 4.28 (q, J = 7.1 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.59 (t, J = 6.6 Hz, 2H, CH<sub>2</sub>), 2.34 (s, 3H, ArCH<sub>3</sub>), 2.19 (t, J = 6.6 Hz, 2H, CH<sub>2</sub>), 1.57 (s, 6H, (CH<sub>3</sub>)<sub>2</sub>), 1.34 (t, J = 7.1 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.6, 157.2, 137.4, 135.3, 129.2, 127.8, 86.1, 73.0, 66.0, 62.9, 39.9, 26.3, 21.3, 14.1.

**IR**  $(v_{max}, cm^{-1})$  3048 (m), 3016 (m), 2991 (m), 2929 (m), 2876 (m), 2860 (m), 1760 (m), 1737 (s), 1370 (m), 1325 (m), 1187 (s), 1134 (s), 1112 (s), 1096 (s), 1018 (m), 802 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{17}H_{24}NaO_5^+$  331.1516; Found 331.1518.

Cesium (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl)oxy-2-oxoacetate (**3o**)

**3o** was synthesized following step 2 of general procedure D in THF (0.6 mL, 0.1 M) using ethyl (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl) oxalate (**28o**, 0.19 g, 0.60 mmol, 1.0 equiv) and 1 M aq. CsOH (0.6 mL, 0.6 mmol, 1.0 equiv), affording cesium (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl)oxy-2-oxoacetate (**3o**, 233 mg, 0.565 mmol, 94%) as a coloroless amorphous solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO- $d_6$ ) δ 7.23 – 7.17 (m, 2H, Ar*H*), 7.14 (d, J = 7.9 Hz, 2H, Ar*H*), 4.38 (s, 2H, Ar*CH*<sub>2</sub>), 3.54 – 3.45 (m, 2H, C*H*<sub>2</sub>), 2.28 (s, 3H, Ar*CH*<sub>3</sub>), 2.01 (t, J = 7.1 Hz, 2H, C*H*<sub>2</sub>), 1.37 (s, 6H, (C*H*<sub>3</sub>)<sub>2</sub>). <sup>13</sup>**C NMR** (101 MHz, DMSO- $d_6$ ) δ 168.0, 163.7, 136.9, 136.0, 129.3, 128.0, 79.6, 72.3, 66.3, 30.2 26.9, 21.2.

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{15}H_{19}CsNaO_5^+$  435.0179; Found 435.0183.

4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-ol (**26p**)

To a solution of 3-methylbutane-1,3-diol (**29**, 500 mg, 4.80 mmol, 1.00 equiv) and 1H-imidazole (654 mg, 9.60 mmol, 2.00 equiv) in *N*,*N*-dimethylformamide (25 mL), TBSOTf (1.4 g, 1.2 mL, 5.3 mmol, 1.1 equiv) was added dropwise. The reaction mixture was stirred at room temperature until TLC showed full conversion of the starting material. DCM and a 1:1 solution of brine and water were added, the layers were separated and the organic layer was washed with half brine (2x), dried over MgSO4 and solvent removed *in vacuo*. The crude was purified by flash chromatography (SiO<sub>2</sub>, 5% EtOAc in pentane) affording 4-((*tert*-butyldimethylsilyl)oxy)-2-methylbutan-2-ol (**26p**, 950 mg, 4.35 mmol, 91% yield) as a pale yellow oil. The NMR data was collected and the compound was used in the next step without further analyses.

Rf (pentane:EtOAc 95:5) = 0.4.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ: 3.91 (t, J = 5.8 Hz, 2H, OCH<sub>2</sub>), 3.83 (bs, 1H, OH), 1.70 (t, J = 5.8 Hz, 2H, CH<sub>2</sub>), 1.24 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 0.90 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 0.09 (s, 6H, Si(CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  71.0, 61.1, 43.0, 29.4, 26.0, 18.2, -5.5.

4-((tert-Butyldimethylsilyl)oxy)-2-methylbutan-2-yl ethyl oxalate (28p)

**28p** was synthesized following step 1 of general procedure *D* in THF (25 mL, 0.1 M) using 4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-ol (**26p**, 500 mg, 2.30 mmol, 1.0 equiv), DMAP (28 mg, 0.23 mmol, 10 mol%), triethylamine (0.40 mL, 2.8 mmol, 1.2 equiv) and ethyl chloro-oxoacetate (0.30 mL, 2.8 mmol, 1.2 equiv).

Column chromatography ( $SiO_2$ , 2% EtOAc in Pentane) afforded 4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl ethyl oxalate (28p, 517 mg, 1.62 mmol, 71 %) as a yellow oil.

Rf (pentane:EtOAc 98:2) = 0.2.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.31 (q, J = 7.2 Hz, 2H, COOC $H_2$ ), 3.75 (t, J = 6.7 Hz, 2H, OC $H_2$ ), 2.09 (t, J = 6.7 Hz, 2H, C $H_2$ ), 1.57 (s, 6H, C(C $H_3$ )<sub>2</sub>), 1.36 (t, J = 7.2 Hz, 3H, COOC $H_3$ ), 0.88 (s, 9H, C(C $H_3$ )<sub>3</sub>), 0.05 (s, 6H, Si(C $H_3$ )<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.7, 157.1, 86.4, 62.9, 59.0, 43.0, 26.3, 26.0, 18.4, 14.1, -5.3. IR ( $v_{max}$ , cm<sup>-1</sup>): 2944 (m), 2891 (m), 2863 (m), 1744 (s), 1468 (m), 1323 (m), 1256 (m), 1190 (s), 1133

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{15}H_{30}NaO_5Si^+$  341.1755; Found 341.1752.

Cesium 2-((4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)oxy)-2-oxoacetate (3p)

(s), 1098 (s).

**3p** was synthesized following step 2 of general procedure D in THF (1.1 mL, 0.1 M) using 4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl ethyl oxalate (**28p**, 350 mg, 1.10 mmol, 1.0 equiv) and 1 M aq. CsOH (1.1 mL, 1.1 mmol, 1.0 equiv). Cesium 2-((4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)oxy)-2-

oxoacetate (**3p**, 450 mg, 1.07 mmol, 97 %) was obtained as an off-white amorphous solid.

<sup>1</sup>H NMR (400 MHz, DMSO) δ 3.65 (t, J = 7.2 Hz, 2H, OC $H_2$ ), 1.94 (t, J = 7.2 Hz, 2H, C $H_2$ ), 1.37 (s, 6H, C(C $H_3$ )<sub>2</sub>), 0.85 (s, 9H, C(C $H_3$ )<sub>3</sub>), 0.03 (s, 6H, Si(C $H_3$ )<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO)  $\delta$  167.5, 163.3, 79.1, 58.7, 42.7, 26.5, 25.8, 17.8, -5.3.

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{13}H_{25}CsNaO_5Si^+$  445.0418; Found 445.0418.

4-((tert-butyldiphenylsilyl)oxy)-2-methylbutan-2-ol (**26q**)

To a solution of 3-methylbutane-1,3-diol (29, 500 mg, 4.80 mmol, 1.00 equiv) and 1H-imidazole (654 mg, 9.60 mmol, 2.00 equiv) in *N,N*-dimethylformamide (25.0 mL), TBDPSCI (1.45 g, 1.37 mL, 5.28 mmol, 1.10 equiv) was added dropwise. The reaction mixture was stirred at room temperature until TLC showed full conversion of the starting material. DCM and half brine were added, the layers were separated and the organic layer was washed with half brine (2x), dried over MgSO4 and solvent removed under vacuo. The crude product was purified by flash chromatography (SiO<sub>2</sub>, 5% EtOAc in pentane) affording 4-((*tert*-butyldiphenylsilyl)oxy)-2-methylbutan-2-ol (26q, 1.64 g, 4.80 mmol, 100% yield) as a fain yellow oil. The NMR data was collected and the compound was used in the next step without further analyses.

Rf (pentane:EtOAc 95:5) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.72 – 7.65 (m, 4H, Ar*H*), 7.47 – 7.36 (m, 6H, Ar*H*), 3.90 (t, J = 5.8 Hz, 2H, OCH<sub>2</sub>), 3.74 (bs, 1H, OH), 1.75 (t, J = 5.7 Hz, 2H, CH<sub>2</sub>), 1.27 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>OH), 1.05 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 135.7, 132.9, 130.03, 128.0, 71.1, 62.2, 43.2, 29.5, 26.9, 19.1.

4-((tert-Butyldiphenylsilyl)oxy)-2-methylbutan-2-yl ethyl oxalate (28q)

**28q** was synthesized following step 1 of general procedure *D* in THF (30 mL, 0.1 M) using 4-((tert-butyldiphenylsilyl)oxy)-2-methylbutan-2-ol (**26q**, 1.00 g, 2.92 mmol, 1.0 equiv), DMAP (36 mg, 0.29 mmol, 10 mol%), triethylamine (0.50 mL, 3.5 mmol, 1.2 equiv) and ethyl chloro-oxoacetate (0.40 mL, 3.5 mmol, 1.2 equiv).

Column chromatography (SiO<sub>2</sub>, 2% EtOAc in Pentane) afforded 4-((*tert*-butyldiphenylsilyl)oxy)-2-methylbutan-2-yl ethyl oxalate (**28q**, 1.06g, 2.40 mmol, 82 %) as a pale yellow oil.

**Rf** (pentane:EtOAc 98:2) = 0.15.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.69 – 7.64 (m, 4H, Ar*H*), 7.43 – 7.35 (m, 6H, Ar*H*), 4.27 (q, J = 7.1 Hz, 2H, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 3.78 (t, J = 6.7 Hz, 2H, OCH<sub>2</sub>), 2.16 (t, J = 6.7 Hz, 2H, CH<sub>2</sub>), 1.55 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 1.32 (t, J = 7.1 Hz, 3H, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.04 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 158.5, 157.0, 135.6, 133.6, 129.7, 127.7, 86.2, 62.8, 59.8, 42.6, 26.8, 26.2, 19.1, 13.9.

IR ( $v_{max}$ , cm<sup>-1</sup>): 3064 (w), 2939 (m), 2862 (m), 1743 (s), 1323 (m), 1190 (s), 1104 (s), 823 (m). HRMS (ESI/QTOF) m/z: [M + Na]<sup>+</sup> Calcd for  $C_{25}H_{34}NaO_{5}Si^{+}$  465.2068; Found 465.2076.

Cesium 2-((4-((tert-butyldiphenylsilyl)oxy)-2-methylbutan-2-yl)oxy)-2-oxoacetate (3q)

**3q** was synthesized following step 2 of general procedure D in THF (1.1 mL, 0.1 M) using 4-((tert-butyldiphenylsilyl)oxy)-2-methylbutan-2-yl ethyl oxalate (**28q**, 500 mg, 1.13 mmol, 1.0 equiv) and 1 M aq. CsOH (1.1 mL, 1.1 mmol, 1.0 equiv). Cesium 2-((4-((tert-butyldiphenylsilyl)oxy)-2-methylbutan-2-yl)oxy)-2-oxoacetate (**3q**, 600 mg, 1.10 mmol, 97 %) was obtained as an off-white amorphous solid.

<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.65 – 7.58 (m, 4H, Ar*H*), 7.48 – 7.41 (m, 6H, Ar*H*), 3.74 (t, J = 7.1 Hz, 2H, OC $H_2$ ), 2.03 (t, J = 7.1 Hz, 2H, C $H_2$ ), 1.34 (s, 6H, C $H_3$ ), 0.99 (s, 9H, C(C $H_3$ )<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO) δ 167.5, 163.2, 135.0, 133.2, 129.8, 127.9, 79.1, 59.9, 42.7, 26.7, 26.4, 18.7.

**HRMS** (ESI/QTOF) m/z:  $[M + H]^+$  Calcd for  $C_{23}H_{30}CsO_5Si^+$  547.0912; Found 547.0908.

Ethyl (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl) oxalate (28w)

**28w** was synthesized following step 1 of general procedure D in DCM (50 mL, 0.1 M) using Cedrol (**22w**, 1.00 g, 4.46 mmol, 1.0 equiv), DMAP (0.054 g, 0.45 mmol, 10 mol%), triethylamine (0.68 mL, 4.9 mmol, 1.1 equiv) and ethyl chloro-oxoacetate (0.55 mL, 4.9 mmol, 1.1 equiv).

Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1 to 8:2) afforded ethyl (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl) oxalate (**28w**, 0.343 g, 0.1.06 mmol, 24%).

Rf (pentane:EtOAc 9:1) = 0.45.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.30 (q, J = 7.1 Hz, 2H, OC $H_2$ CH<sub>3</sub>), 2.46 – 2.40 (m, 1H, aliphatic-CH or C $H_2$ ), 2.17 (ddt, J = 13.6, 5.8, 1.7 Hz, 1H, aliphatic-CH or C $H_2$ ), 2.13 – 2.00 (m, 1H, aliphatic-CH or C $H_2$ ), 1.94 – 1.78 (m, 2H, aliphatic-CH or C $H_2$ ), 1.74 – 1.64 (m, 2H, aliphatic-CH or C $H_2$ ), 1.62 (d, J = 1.0 Hz, 3H, C $H_3$ ), 1.59 – 1.47 (m, 2H, aliphatic-CH or C $H_2$ ), 1.46 – 1.33 (m, 6H, aliphatic-CH or C $H_2$  + OCH<sub>2</sub>C $H_3$ ), 1.32 – 1.23 (m, 1H, aliphatic-CH or C $H_2$ ), 1.18 (s, 3H, C $H_3$ ), 0.99 (s, 3H, C $H_3$ ), 0.84 (d, J = 7.1 Hz, 3H, C $H_2$ C $H_3$ ).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.8, 157.1, 91.2, 62.8, 57.0, 56.8, 54.0, 43.7, 41.4, 41.2, 37.1, 33.0, 31.4, 28.5, 27.1, 25.5, 25.4, 15.6, 14.1.

IR  $(v_{max}, cm^{-1})$  2990 (w), 2939 (w), 2876 (w), 1738 (s), 1373 (s), 1236 (s), 1186 (m), 1044 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{19}H_{30}NaO_4^+$  345.2036; Found 345.2029.

(-)-Cedrol derived cesium oxalate: cesium (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl)oxy-2-oxoacetate (**3w**)



**3w** was synthesized following step 2 of general procedure D in THF (0.78 mL, 0.1 M) using ethyl (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl) oxalate (**28w**, 0.250 g, 0.775 mmol, 1.0 equiv) and 1 M aq. CsOH (0.78 mL, 0.78 mmol, 1.0 equiv), affording cesium (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl)oxy-2-oxoacetate (**3w**, 0.330 g, 0.774 mmol, 100%). Amorphous white amorphous solid.

<sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) δ 2.34 (d, J = 5.1 Hz, 1H, aliphatic-CH), 1.90 – 1.71 (m, 4H, aliphatic-CH), 1.68 – 1.54 (m, 2H, aliphatic-CH or CH2), 1.45 (s, 4H, aliphatic-CH or CH2 + CH<sub>3</sub>), 1.42 – 1.19 (m, 5H, aliphatic-CH or CH2), 1.16 (s, 3H, CH<sub>3</sub>), 0.91 (s, 3H, CH<sub>3</sub>), 0.81 (d, J = 7.1 Hz, 3H, CHCH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>) δ 167.3, 163.5, 83.8, 56.4, 56.2, 53.6, 43.0, 40.7, 40.3, 36.4, 33.0, 30.6, 28.4, 27.3, 25.7, 24.9, 15.5.

**HRMS** (ESI/QTOF) m/z: [M - Cs] Calcd for C<sub>17</sub>H<sub>25</sub>O<sub>4</sub> 293.1758; Found 293.1751.

(R)-Ethyl (1-isopropyl-4-methylcyclohex-3-en-1-yl) oxalate (28x)

**28x** was synthesized following step 1 of general procedure *D* in THF (60 mL, 0.1 M) using (-)-terpinen-4-ol (**22x**, 1.00 mL, 6.00 mmol, 1.0 equiv), DMAP (73 mg, 0.60 mmol, 10 mol%), triethylamine (1.00 mL, 7.20 mmol, 1.2 equiv) and ethyl chloro-oxoacetate (0.80 mL, 7.2 mmol, 1.2 equiv).

Column chromatography (SiO<sub>2</sub>, 2% EtOAc in Pentane) afforded (*R*)-ethyl (1-isopropyl-4-methylcyclohex-3-en-1-yl) oxalate (**28x**, 1.08 g, 4.25 mmol, 71 %) as a pale yellow oil.

Rf (pentane:EtOAc 98:2) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.29 – 5.21 (m, 1H, C=CH), 4.29 (q, J = 7.1 Hz, 2H, CO<sub>2</sub>CH<sub>2</sub>), 2.71 (hept, J = 6.9 Hz, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 2.54 – 2.43 (m, 2H, CH<sub>2</sub>), 2.29 – 2.19 (m, 1H, CH<sub>2</sub>), 2.11 – 1.98 (m, 1H, CH<sub>2</sub>), 1.97 – 1.87 (m, 1H, CH<sub>2</sub>), 1.78 – 1.68 (m, 1H, CH<sub>2</sub>), 1.73 – 1.62 (m, 3H, CH<sub>3</sub>), 1.34 (t, J = 7.1 Hz, 3H, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 0.95 (d, J = 6.9 Hz, 3H, CH(CH<sub>3</sub>)<sub>2</sub>), 0.94 (d, J = 6.9 Hz, 3H, CH(CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 158.9, 157.6, 133.8, 117.2, 91.1, 62.7, 32.7, 29.9, 27.9, 27.3, 23.3, 17.7, 17.2, 14.1.

IR ( $v_{max}$ , cm<sup>-1</sup>): 2973 (m), 2933 (m), 1738 (s), 1444 (m), 1380 (m), 1324 (m), 1180 (s), 1014 (m). HRMS (ESI/QTOF) m/z: [M + Na]<sup>+</sup> Calcd for  $C_{14}H_{22}NaO_4$ <sup>+</sup> 277.1410; Found 277.1415.

(-)Terpinen-4-ol derived cesium oxalate: cesium (R)-2-((1-isopropyl-4-methylcyclohex-3-en-1-yl)oxy)-2-oxoacetate (<math>3x)

**3x** was synthesized following step 2 of general procedure D in THF (2.0 mL, 0.1 M) using (R)-ethyl (1-isopropyl-4-methylcyclohex-3-en-1-yl) oxalate (**28x**, 509 mg, 2.00 mmol, 1.0 equiv) and 1 M aq. CsOH (2.0 mL, 2.0 mmol, 1.0 equiv). Cesium (R)-2-((1-isopropyl-4-methylcyclohex-3-en-1-yl)oxy)-2-oxoacetate (**3x**, 661 mg, 1.85 mmol, 92 %) was obtained as an off-white amorphous solid.

<sup>1</sup>H NMR (400 MHz, DMSO) δ: 5.20 - 5.16 (m, 1H, C=CH), 2.66 (p, J = 7.0 Hz, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 2.40 - 2.31 (m, 1H, CH<sub>2</sub>), 2.23 - 2.04 (m, 2H, CH<sub>2</sub>), 2.04 - 1.90 (m, 1H, CH<sub>2</sub>), 1.86 - 1.71 (m, 1H, CH<sub>2</sub>), 1.60 (s, 3H, CH<sub>3</sub>), 1.59 - 1.50 (m, 1H, CH<sub>2</sub>), 0.86 (d, J = 7.0 Hz, 3H, CH(CH<sub>3</sub>)<sub>2</sub>), 0.84 (d, J = 7.0 Hz, 3H), CH(CH<sub>3</sub>)<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO) δ: 168.1, 163.5, 132.8, 117.9, 83.3, 32.0, 29.5, 27.7, 26.7, 23.2, 17.4, 16.7.

**HRMS** (ESI/QTOF) m/z:  $[M + H]^+$  Calcd for  $C_{12}H_{18}CsO_4^+$  359.0254; Found 359.0260.

#### 2.6. Synthesis of oximes

2-(Aminooxy)-2-methylpropanoic acid hydrochloride was purchased from commercial sources (ABCR)

2-(Aminooxy)propanoic acid hydrochloride (33a)

Following a reported procedure,  $^{20}$  N-hydroxybenzamide (**30**) (6.08 g, 44.3 mmol, 1.0 equiv) and finely ground NaOH (5.32 g, 133 mmol, 3.0 equiv) were suspended in absolute EtOH (66 mL). To the resulting thick, off-white suspension, 2-bromopropanoic acid (**31**) (4.1 mL, 44 mmol, 1.0 equiv) was added slowly via syringe under stirring. This resulted in the conversion of the homogeneous suspension into a pale brown solution, which was then heated to 80 °C. Once this temperature was reached, the mixture looked again as a homogeneous, off-white suspension, which was stirred overnight. The mixture was then concentrated under reduced pressure to provide a solid residue, which was dissolved in water (90 mL). The resulting aqueous solution was washed once with diethyl ether (100 mL) and then acidified by careful addition of aq. HCl (37 % w/w) until pH = 1. It was then extracted with EtOAc (3 x 100 mL) and the combined organic layers were dried over MgSO<sub>4</sub>, filtered and concentrated under vacuum to provide an off-white solid. Recrystallization from hexane (50 mL) and EtOAc (100 mL) afforded 2-(benzamidooxy)propanoic acid (**32**) (7.08 g, 33.9 mmol, 76% yield) as a colorless solid. The compound was used directly in next step with no further analyses.

2-(Benzamidooxy)propanoic acid (32) (7.08 g, 33.8 mmol, 1.0 equiv) was suspended in acetic acid (20.5 mL). Aq. HCl (5.0 M; 68 mL, 34 mmol, 10 equiv) was then added and the mixture was heated to reflux (110 °C), which resulted in the formation of a pale yellow, clear solution. The latter was refluxed for 18 hours. It was then allowed to cool down to room temperature. This led to the precipitation of a crystalline solid (benzoic acid), which was filtered off. The resulting solution was stored at 4 °C overnight, which permitted the precipitation of a further amount of benzoic acid. Upon removal of the latter (4.13 g, 33.8 mmol, 100% yield) through filtration, the so-obtained clear solution was concentrated under vacuum. The resulting wet solid was further dried under vacuum at 60 °C for 3 hours. It was then refluxed in a mixture of EtOAc (30 mL) and EtOH (1.5 mL) for 20 minutes, filtered, washed with pentane, and dried in the air. 2-(Aminooxy)propanoic acid hydrochloride (33a) was obtained as a colorless solid (4.15 g, 29.3 mmol, 87% yield). The compound was used directly in next step with no further analyses.

2-(Aminooxy)-2-methylpropanoic acid hydrochloride (33b) and cyclobutanones were commercially available and purchased.

\_

<sup>&</sup>lt;sup>20</sup> H. Jiang, A. Studer, *Angew. Chem. Int. Ed.* **2017**, *56*, 12273–12276.

#### General procedure E:

Following a reported procedure,  $^{21}$  a solution of cyclobutanone (34) (1.0 equiv) in MeOH (0.20 M) was treated with hydroxylamine 33a or 33b (1.2 equiv), sodium acetate (2.4 equiv) and heated to reflux until complete by TLC analysis (4.5 – 6.0 hours). The mixture was then allowed to cool to room temperature and aq. Na<sub>2</sub>CO<sub>3</sub> (2.0 M) was added. In some cases, the addition of a small volume of water was necessary to achieve the complete dissolution of the solids. The resulting aqueous solution was extracted once with Et<sub>2</sub>O and the organic layer was washed with aq. Na<sub>2</sub>CO<sub>3</sub> (2.0 M; 2 x). The combined aqueous extracts were then acidified by careful addition of aq. HCl solution (30% v/v) until pH < 2, and extracted with DCM (3 x). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under vacuum to provide the pure product.

2-(((1-(Tert-butoxycarbonyl)azetidin-3-ylidene)amino)oxy)propanoic acid (9a)

$$\begin{array}{c|c} & CO_2H \\ \hline & N & O \end{array}$$

**9a** was synthesized following *general procedure E* using tert-butyl 3-oxoazetidine-1-carboxylate (**34a**, 342 mg, 2.00 mmol, 1.0 equiv) and 2-(aminooxy)propanoic acid hydrochloride (**33a**, 340 mg, 2.40 mmol, 1.2 equiv) and NaOAc (394 mg, 4.80 mmol, 2.4 equiv). 2-(((1-(tert-butoxycarbonyl)azetidin-3-ylidene)amino)oxy)propanoic acid (**9a**, 517 mg, 2.00 mmol, 100%) was obtained as an off-white amorphous solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.70 (bs, 1H, CO<sub>2</sub>H) 4.72 – 4.58 (m, 5H, CH<sub>2</sub>-N + CH-O), 1.50 – 1.47 (m, 3H, Me), 1.45 (bs, 9H, tBu)..

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  177.3, 156.3, 149.9, 80.9, 77.3, 58.3, 28.3, 16.6.

IR  $(v_{max}, cm^{-1})$  3700 – 2800 (broad), 2981 (m), 2939 (m), 1705 (s), 1396 (s), 1134 (s), 1250 (m), 1828 (w), 960 (m)

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{11}H_{18}N_2NaO_5^+$  281.1108; Found 281.1112.

2-(((3-((tert-Butoxycarbonyl)amino)cyclobutylidene)amino)oxy)-2-methylpropanoic acid (**9b**)

**9b** was synthesized following *general procedure E* using tert-butyl (3-oxocyclobutyl)carbamate (**34b**) (250 g, 1.28 mmol, 1.0 equiv) and 2-(aminooxy)-2-methylpropanoic acid hydrochloride (**33b**, 252 mg, 1.62 mmol, 1.2 equiv) and NaOAc (266 mg, 3.24 mmol, 2.4 equiv). 2--(((3-((tert-Butoxycarbonyl)amino)cyclobutylidene)amino)oxy)-2-methylpropanoic acid (**9b**, 360 mg, 1.23 mmol, 98%) was obtained as an white amorphous solid.

<sup>21</sup> E. M. Dauncey, S. P. Morcillo, J. J. Douglas, N. S. Sheikh, D. Leonori, *Angew. Chem. Int. Ed.* **2018**, *57*, 744–748.

<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H, CO<sub>2</sub>H), 7.38 (d, J = 7.4 Hz, 1H, NH), 4.03 (q, J = 7.4 Hz, 1H, CHNHBoc), 3.19 – 2.98 (m, 2H, CH<sub>2</sub>), 2.83 – 2.66 (m, 2H, CH<sub>2</sub>), 1.39 (s, 9H, tBu), 1.36 (s, 3H, tCMe<sub>2</sub>), 1.35 (s, 3H, CMe<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, DMSO-d6) δ 175.0, 154.7, 153.3, 80.1, 78.0, 38.8, 28.2, 24.0. 1 carbon is not resolved.

Corresponds to literature data.6

2-(((Oxetan-3-ylidene)amino)oxy)propanoic acid (**9c**)

$$N_{O}$$
 Me

**9c** was synthesized following *general procedure E* using 3-oxetanone (**34c**, 72 mg, 1.0 mmol, 1.0 equiv) and 2-(aminooxy)propanoic acid hydrochloride (**33a**, 170 mg, 1.20 mmol, 1.2 equiv) and NaOAc (197 mg, 2.40 mmol, 2.4 equiv). 2-(((oxetan-3-ylidene)amino)oxy)propanoic acid (**9c**, 66 mg, purety 90%, 0.37 mmol, 37%) was obtained as an off-white amorphous solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.53 – 5.15 (m, 4H, OCH<sub>2</sub>), 4.70 (q, J = 7.1 Hz, 1H, OCHMe), 1.50 (d, J = 7.1 Hz, 3H, Me). CO<sub>2</sub>H is not detected.

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  176.9, 155.1, 79.2, 78.8, 29.9, 16.8, 0.1.

**IR** (v<sub>max</sub>, cm<sup>-1</sup>) 3556 – 2573 (broad), 3066 (w), 2939 (w), 2858 (w), 1720 (s), 1643 (w), 1442 (w), 1250 (m), 1300 (m), 1203 (m), 1138 (m), 1095 (m), 1041 (m), 976 (s), 864 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + H_{-1}]^{-}$  Calcd for C<sub>6</sub>H<sub>8</sub>NO<sub>4</sub><sup>-</sup> 158.0459; Found 158.0456.

#### 2.7.Synthesis of potassium trifluoroboronates

potassium 2,3-dihydro-1H-inden-2-yl-trifluoroborate (11a)

Following a reported procedure,  $^{22}$  a flame dried round bottom flask containing a solution of BH<sub>3</sub>.THF (34.0 mL, 34.0 mmol, 1.00M, 2.00 equiv) in THF was cooled to 0 °C. A solution of 1H-indene (**35**) (1.98 mL, 17.0 mmol, 1.00 equiv) in tetrahydrofuran (3.40 mL) was added and the mixture was warm to rt and stirred for 2 h. Water (3.40 mL) was added dropwise and the mixture was stirred for 3 h at rt. The mixture was concentrated in vacuo to remove the solvents except water. Ethyl acetate (50 mL) was added to the suspension and the mixture was washed with a sat. sol. of NaHCO<sub>3</sub> (50 mL) and brine (50 mL). The organic layers were combined, dried over MgSO<sub>4</sub>.(H<sub>2</sub>O)<sub>2</sub> and concentrated in vacuo. The crude oil was used directly in next step. To a round bottom flask (PFA) containing a solution of potassium hydrogen fluoride (6.64 g, 85.0 mmol, 5.00 equiv) in water (25.0 mL) were added the crude boronic acid (**36a**) and methanol (34.0 mL). The mixture was stirred at rt open to air for 2 h. The

-

<sup>&</sup>lt;sup>22</sup> Weng, W.-Z.; Liang, H.; Zhang, B. *Org. Lett.* **2018**, *20* (16), 4979–4983.

mixture was concentrated in vacuo, the wet solid obtained was further dried by co-evaporation with acetone (3 times). The resulting solid was diluted with acetone (30 mL) and was put on the rotavap at  $P_{atm}$  with the bath at 45 °C for 10 minutes. The solution was filtered with care to leave the remaining insoluble solid in the flask. This process was repeated 2 more times, the solution of acetone was concentrated in vacuo to 1/3 of the initial volume. The solution was left to cool to rt then  $Et_2O$  was added to induce precipitation (~40 mL). The solution was cooled to 0 °C and left for 15 min standing at this temperature. The solid was filtered, washed with  $Et_2O$  and dried in vacuo to afford potassium 2,3-dihydro-1*H*-inden-2-yl-trifluoroborate (11a) (1.38 g, 6.14 mmol, 36% yield) as a white solid.

<sup>1</sup>**H NMR** (400 MHz, Acetone) δ 7.07 (dd, J = 5.3, 3.3 Hz, 2H, ArH), 6.95 (dd, J = 5.5, 3.1 Hz, 2H, ArH), 2.75 (dd, J = 9.9, 3.6 Hz, 4H, C $H_2$ ), 1.29 (m, 1H, C $H_3$ ).

<sup>13</sup>**C NMR** (101 MHz, Acetone)  $\delta$  148.3, 125.6, 124.6, 36.8. One carbon is not resolved.

<sup>19</sup>**F NMR** (376 MHz, Acetone)  $\delta$  -146.34 (d, J = 95.0 Hz). Corresponds to the reported literature data. <sup>23</sup>

potassium 2,3-dihydro-1H-inden-2-yl-trifluoroborate (11c)

$$B(OH)_2$$
  $KHF_2$  (5.0 equiv)  $BF_3K$ 

Water:MeOH


11c

Following a reported procedure,<sup>24</sup> in a round bottom flask (PFA), cyclohexyl boronic acid (**36c**, 5.00 g, 39.1 mmol, 1.00 equiv) was dissolved in methanol (100 mL). Aqueous potassium hydrogen fluoride (50 mL, 4.5 M, 225 mmol) was then added. The resulting white slurry was stirred at room temperature for 30 min, concentrated in vacuo and dissolved in hot acetone. The mixture was filtered, the filtrate was concentrated in vacuo and the residue recrystallized from a minimal amount of ether, to afford potassium cyclohexyl trifluoroborate (**11c**, 1.20 g, 6.3 mmol, 16%).

<sup>1</sup>H NMR (400 MHz, DMSO) δ 1.63 – 1.51 (m, 3H, cyclic- $CH_2$ ), 1.51 – 1.40 (m, 2H, cyclic- $CH_2$ ), 1.19 – 0.95 (m, 3H, cyclic- $CH_2$ ), 0.88 (q, J = 12.4 Hz, 2H, cyclic- $CH_2$ ), -0.02 (bs, 1H, cyclic- $CH_2$ ).

 $^{13}$ C NMR (101 MHz, DMSO) δ 31.2, 29.4, 28.7, 28.0. Corresponds to reported literature data.  $^{24}$ 

## 3. Photochemical experimental set-up



<sup>23</sup> Huang, H.; Zhang, G.; Gong, L.; Zhang, S.; Chen, Y. J. Am. Chem. Soc. **2014**, 136 (6), 2280–2283.

<sup>&</sup>lt;sup>24</sup> Cazorla, C.; Métay, E.; Lemaire, M. *Tetrahedron* **2011**, *67*, 8615–8621.

**Figure S1.** Left: Scope scale reactions (photo taken with a filter applied to it). Middle: optimization scale. Right: Scope scale reactions after irradiation (with PC, same appearance for PC-free reactions without)

# 4. Optimization of the photomediated deoxygenationalkynylation

## 4.1. Optimization studies method B (Excited state PhEBX 1a)

Experimental procedure: an oven dried dram vial (2 mL), equipped with a magnetic stirrer, was charged with the solid components following table S1: cesium oxalate 3a, PhEBX (1a), CsOBz, Cs<sub>2</sub>CO<sub>3</sub>. The reaction vial was sealed with a septum. After 3 vacuum/N2 cycles (backfilling with Ar on the last cycle), dry degassed (freeze pump thaw) solvent was added, followed by the liquid additive THF or  $\gamma$ -terpinene (as specified) and the septum was replaced with a screw cap under a flux of Ar.<sup>25</sup> The reactions were placed between 2 x 440 nm Kessil lamps (unless specified otherwise) at ca. 10 cm distance from both lamps (no ventilation, T = ca. 50 °C, with ventilation T = ca. 30-35°C as specified) and stirred under irradiation for 18 hours or 24 hours (as specified). The reaction was filtered through a small celite plug which was washed with CH<sub>2</sub>Cl<sub>2</sub>. The reaction crude was concentrated *in vacuo*, diluted with CDCl<sub>3</sub> and 1 equiv of CH<sub>2</sub>Br<sub>2</sub> was added as internal standard for <sup>1</sup>H NMR analysis.

**Table S1.** Optimization of direct excitation strategy

Entry	1a (equiv)	Additive (equiv)	solvent (M)	T (°C)	λ (nm)	<sup>1</sup> H NMR yield (%)
1	1.5	-	MeCN (0.1 M)	50	440	4
2	1.5	-	MeCN:H2O (0.1 M)	50	440	6
3	1.5	-	DMSO- $d_6$ (0.1 M)	50	440	4
4	1.5	-	MeOH (0.1 M)	50	440	17
5	1.5	-	DCM (0.1 M)	30-35	440	50
6 <sup>a</sup>	1.5	-	DCM (0.1 M)	30-35	360 <sup>b</sup>	50
7 <sup>b</sup>	1.5	-	DCM (0.1 M)	30-35	460 <sup>c</sup>	nd
8	2.5	-	DCM (0.1 M)	30-35	440	57
9°	2.5	-	DCM (0.1 M)	30-35	440	67
10 <sup>c,d</sup>	2.5	-	DCM (0.1 M)	30-35	440	41
11 <sup>c,d</sup>	2.5	-	DCM (0.1 M)	30-35	427	43
12 <sup>c,d</sup>	2.5	-	DCM (0.1 M)	30-35	390	34
13 <sup>c,d</sup>	2.5	-	DCM (0.1 M)	30-35	467	34
14 <sup>c</sup>	2.5	Cs <sub>2</sub> CO <sub>3</sub> (0.5)	DCM (0.1 M)	30-35	440	20
15 <sup>c</sup>	2.5	CsOBz (1)	DCM (0.1 M)	30-35	440	10
16 <sup>c</sup>	2.5	THF (2)	DCM (0.1 M)	30-35	440	nd
17 <sup>c</sup>	2.5	γ-terpinene (2)	DCM (0.1 M)	30-35	440	50

 $<sup>^{25}</sup>$  Use of a screw cap or crimp cap is of great importance to prevent solvent evaporation as the irradiation causes an increase in temperature. When using a test-tube/septum set-up, the latter would fly off within an hour of irradiation. As shown in the optimization section DCE is not as good a solvent as CH<sub>2</sub>Cl<sub>2</sub>.

<sup>a</sup>Reaction was performed in Rayonet reactor, <sup>b</sup>Reaction was performed with blue LED strips, <sup>c</sup>Reaction was run for 24 hours, <sup>d</sup>Reaction was performed with 1 Kessil lamp of the corresponding wavelength

## 4.2. Optimization studies of the 4CzIPN photocatalyzed deoxyalkynylation

Experimental procedure: an oven dried dram vial (2 mL), equipped with a magnetic stirrer, was charged with the solid components following table S2: cesium oxalate 3a, PhEBX (1a), photocatalyst, additive (as specified). The reaction vial was sealed with a septum. After 3 vacuum/N2 cycles (backfilling with Ar on the last cycle), dry degassed (freeze pump thaw) solvent was added and the septum was replaced with a screw cap under a flux of Ar.<sup>25</sup> The reactions were placed between 2 x 440 nm Kessil lamps (at ca. 10 cm distance from both lamps (no ventilation, T = ca. 50 °C, with ventilation T = ca. 30-35°C as specified) and stirred under irradiation for 18 hours or 24 hours (as specified). The reaction was filtered through a small celite plug which was washed with  $CH_2Cl_2$ . The reaction crude was concentrated *in vacuo*, diluted with CDCl<sub>3</sub> and 1 equiv of  $CH_2Br_2$  was added as internal standard for  $^1H$  NMR analysis.

Table S2. Optimization of the photocatalytic strategy

Entry	Solvent (M)	Photocatalyst	Stoichiometry	¹H NMR yield
-		•	(3a: 1a)	(%)
1	DMSO (0.1 M)	<b>2</b> a	1:1.5	52
2	MeCN (0.1 M)	<b>2</b> a	1:1.5	40
3	DME/DMF (0.1 M)	<b>2</b> a	1:1.5	70
4	DME/DMF + $10 \text{ eq H}_2\text{O}$ (0.1 M)	2a	1:1.5	55
5	THF (0.1 M)	<b>2</b> a	1:1.5	22
6	DCE (0.1 M)	<b>2</b> a	1:1.5	67
7	DCM (0.1 M)	<b>2</b> a	1:1.5	75
8	DCM (0.1 M)	2b	1:1.5	75
9	DCM (0.1 M)	[Ir(dFCF <sub>3</sub> ppy) <sub>2</sub> (dtBBPY)]PF <sub>6</sub>	1:1.5	50
10	DCM (0.1 M)	DCA	1:1.5	55
11	DCM (0.1 M)	MesAcr.BF <sub>4</sub>	1:1.5	53
12	DCM (0.1 M)	[Ru(bpy) <sub>3</sub> ]PF <sub>6</sub>	1:1.5	<10% decomp
13	DCM (0.1 M)	[Ru(bpz) <sub>3</sub> ]PF <sub>6</sub>	1:1.5	20
14	DCM (0.1 M)	2a	1.2:1	45
15	DCM (0.1 M)	<b>2</b> a	1:1	64
16	DCM (0.1 M)	<b>2</b> a	1::1.2	56
17	DCM (0.1 M)	<b>2</b> a	1:1.8	70
18	DCM (0.1 M)	<b>2</b> a	1:2.5	75
19	DCM (0.5 M)	2a	1:1.5	75
20	DCM (0.05 M)	2a	1:1.5	73
21	DCM (0.02 M)	2a	1:1.5	55
<b>22</b> <sup>a</sup>	DCM (0.1 M)	<b>2</b> a	1:1.5	65

<sup>&</sup>lt;sup>a</sup>Performed with 0.3 equiv BIOAc as an additive

## 5. Photomediated Alkynylation Reactions:

## 5.1. General Procedures

5.1.1. General procedure F: Direct excitation of PhEBX for deoxy-alkynylation

An oven dried (7.5 mL) dram vial equipped with a magnetic stirrer was charged with the cesium salt 3a-x (0.30 mmol, 1.00 equiv) and ArEBX (1, 2.5 mmol, 2.5 equiv). The reaction vial was sealed with a septum. After 3 vacuum/N2 cycles (backfilling with Ar on the last cycle), dichloromethane (3.00 mL) was added and the septums were replaced with a screw cap under a flux of Ar. <sup>25</sup> The reactions were placed between 2 x 440 nm Kessil lamps at ca. 10 cm distance from both lamps (with ventilation, T = 30-35 °C) and stirred under irradiation for 24 hours. The reaction was filtered through a small celite plug which was washed with  $CH_2Cl_2$ . A solid deposit was prepared (ca. 2g SiO<sub>2</sub>). The compound was purified by column chromatography (SiO<sub>2</sub>, pentane:EtOAc).

#### 5.1.2. General procedure G: Decarboxylative alkynylation

All carboxylic acids were commercial, bought from commercial sources and used as such in the reactions.

Following a modified reported procedure,  $^{26}$  a dram vial, equipped with a magnetic stirring bar, was charged with **1a** (261 mg, 0.750 mmol, 2.50 equiv), **7** (0.300 mmol, 1.00 equiv) and cesium carbonate (196 mg, 0.600 mmol, 2.00 equiv). After 3 vacuum/nitrogen cycles, refilling with argon upon the last cycle, dichloromethane (4.5 mL, degassed by freeze-pump-thaw) was then added and the reaction was irradiated for 21 hours with 2 Kessil lamps PR160 440 nm. A solid deposit was then prepared of the crude on SiO<sub>2</sub> and was purified by column chromatography (SiO<sub>2</sub>, Pentane:EtOAc).

-

<sup>&</sup>lt;sup>26</sup> Zhou, Q.; Guo, W.; Ding, W.; Wu, X.; Chen, X.; Lu, L.; Xiao, W. *Angew. Chem. Int. Ed.* **2015**, *54*, 11196–11199.

## 5.1.3. General procedure H: Oxime fragmentation-alkynylation

Following a modified reported procedure,  $^{27}$  a dram vial, equipped with a magnetic stirring bar, was charged with **1a** (261 mg, 750  $\mu$ mol, 2.50 equiv), **9** (0.300 mmol, 1.00 equiv) and potassium carbonate (46 mg, 0.33 mmol, 1.10 equiv). After 3 vacuum/nitrogen cycles, refilling with argon upon the last cycle, 1,2-dichloroethane (2.00 mL, degassed by bubbling Ar) was then added and the reaction was irradiated for 3 h 50 min to 4 hours. A solid deposite of the crude was prepared and the compound was purified by column chromatography (SiO<sub>2</sub>, pentane:EtOAc).

## 5.1.4. General procedure I: Deboronative alkynylation

Following a modified reported procedure,  $^{23}$  an oven-dried (7.5 mL) dram vial equipped with a magnetic stirrer was charged with alkyl trifluoroborate (11, 0.30 mmol, 1.0 equiv), PhEBX (1a, 261 mg, 0.750 mmol, 2.50 equiv) and Na<sub>2</sub>CO<sub>3</sub> (64 mg, 0.60 mmol, 2.0 equiv). The vial was sealed with a septum. After 3 vacuum/N<sub>2</sub> cycles, CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) and water (1.5 mL) were added and the septum was replaced with a screw cap. The reaction was placed between 2 x 440 nm Kessil lamps at ca. 7 cm distance from both lamps with a fan and stirred under irradiation for 19 h. The layers were then separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 10 mL). The combined organic layers were dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. The crude was purified by flash chromatography (SiO<sub>2</sub>,pentane:EtOAc) affording the corresponding alkyne.

#### 5.1.5. Difunctionalization

\_

<sup>&</sup>lt;sup>27</sup> Le Vaillant, F.; Garreau, M.; Nicolai, S.; Gryn'ova, G.; Corminboeuf, C.; Waser, J. *Chem. Sci.* **2018**, *9*, 5883-5889.

Following a modified reported procedure, <sup>28</sup> an oven dried dram vial, equipped with a magnetic stir bar was charged with 1a (35 mg, 0.10 mmol, 1.0 equiv) and 19b (15 mg, 0.050 mmol, 0.50 equiv). After 3 vacum/nitrogen cycles refilling with Ar on the last cycle, degassed CH<sub>2</sub>Cl<sub>2</sub> (0.40 mL) was added followed by N-vinylpyrolidinone 13 (16.7 mg, 16.0 μL, 150 μmol, 1.50 equiv). The reaction was irradiated for 19 hours with 2 x 440 nm Kessil lamps. The reaction was concentrated in vacuo. An NMR sample of the crude was prepared with 1 equiv of CH<sub>2</sub>Br<sub>2</sub> (7.0 μL, 0.10 mmol, 1 equiv) in CD<sub>3</sub>CN. The <sup>1</sup>H NMR yield of **14** was determined using the signal at 5.53 ppm (dd, J = 8.6, 4.8 Hz, 1H, NCHCH<sub>2</sub>O): 35%

<sup>1</sup>**H NMR** (400 MHz, Acetonitrile- $d_3$ )  $\delta$  8.06 (dd, J = 7.9, 1.2 Hz, 1H, ArH), 7.81 (dd, J = 7.8, 1.7 Hz, 1H, ArH), 7.58 - 7.47 (m, 3H, ArH and PhH), 7.47 - 7.33 (m, 3H, PhH), 7.27 (td, J = 7.7, 1.8 Hz, 1H, ArH), 5.53 (dd, J = 8.6, 4.8 Hz, 1H, NCHCH<sub>2</sub>O), 4.64 (dd, J = 11.3, 8.6 Hz, 1H, NCHCH<sub>2</sub>O), 4.50 (dd, J = 11.2, 4.8 Hz, 1H, NCHC $H_2O$ ), 3.75 - 3.52 (m, 2H,  $CH_2$ ), 2.39 - 2.30 (m, 2H,  $CH_2$ ), 2.12 - 2.02 (m, 2H,  $CH_2$ ). Corresponds to the reported literature data. Error! Bookmark not defined.

#### 5.1.6. Deaminative alkynylation

Following a slightly modified reported procedure, <sup>29</sup> a mixture of 2,4,6-trimethoxybenzaldehyde (38, 196 mg, 1.00 mmol, 1.00 equiv) and tert-amyl amine (37, 0.30 mL, 2.6 mmol, 2.6 equiv) in toluene (10 mL, 0.1 M) was heated in a Dean-Stark apparatus to reflux overnight. The reaction was then cooled, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated affording crude imine N-tert-amyl-1-(2,4,6trimethoxyphenyl)methanimine (15, 220 mg, 0.580 mmol, 85% pure, 71%) as a light yellow solid used directly in the next step.

An oven dried dram vial (7.5 mL) equipped with a magnetic stirrer was charged with crude imine 15 (80 mg, 85%wt 0.26 mmol, 1.0 equiv), PhEBX (1a, 261 mg, 0.750 mmol, 2.9 equiv) and cesium carbonate (108 mg, 0.330 mmol, 1.3 equiv). After 3 vacuum/N<sub>2</sub> cycles CH<sub>2</sub>Cl<sub>2</sub> (6.0 mL) was added and the reaction was sealed with a screw cap under a flux of Ar. The reaction was then irradiated for 24 hours with 2 Kessil lamps (440 nm). The crude was purified by preparative TLC heptane:cyclohexane

<sup>&</sup>lt;sup>28</sup> Amos, S. G. E.; Nicolai, S.; Waser, J. Chem. Sci. **2020**, *11*, 11274-11279

<sup>&</sup>lt;sup>29</sup> Ashley, M. A.; Rovis, T. J. Am. Chem. Soc. **2020**, 142, 18310–18316.

(1:1) affording 3,3-dimethylpent-1-ynylbenzene (**16**, 25.0 mg, 145  $\mu$ mol, 57% yield) isolated with 2.25 eq of DCM and traces of 1,3-diphenylbutadiene.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.48 – 7.27 (m, 5H, Ar*H*), 1.52 (q, J = 7.5 Hz, 2H, C $H_2$ C $H_3$ ), 1.26 (s, 6H, C(C $H_3$ )<sub>2</sub>), 1.05 (t, J = 7.5 Hz, 3H, CH<sub>2</sub>C $H_3$ ).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  131.7, 128.9, 128.3, 127.5, 97.5, 80.5, 36.2, 32.2, 28.9, 9.9.

**IR** (v<sub>max</sub>, cm<sup>-1</sup>) 2924 (m), 2970 (m), 3055 (m), 3105 (m), 2858 (m), 3101 (m), 1361 (m), 1323 (m), 1041 (m).

**HRMS** (nanochip-ESI/LTQ-Orbitrap) m/z:  $[M + H]^+$  Calcd for  $C_{13}H_{17}^+$  173.1325; Found 173.1324.

#### 5.1.7. HAT

Following a modified reported procedure,  $^{30}$  an oven dried (7.5 mL) dram vial equipped with a magnetic stirrer was charged with MS 4Å (20 mg) and PhEBX (**1a**, 70 mg, 0.20 mmol, 1.0 equiv). The reaction vial was sealed with a septum. After 3 vacuum/N2 cycles (backfilling with Ar on the last cycle), THF (**17**, 4.00 mL) was added and the septum is replaced with a screw cap under a flux of Ar. The reactions were placed between 2 x 460 nm Kessil lamps at ca. 10 cm distance from both lamps (no ventilation, T = ca. 50 °C) and stirred under irradiation for 18 hours. The reaction was filtered through a small celite plug which was washed with  $CH_2CI_2$ . The reaction crude was concentrated in vacuo. An NMR sample of the crude was prepared with 1 equiv of  $CH_2Br_2$  (14.0  $\mu$ L, 0.200 mmol, 1 equiv) in  $CDCI_3$ . The  $^1H$  NMR yield of **18** was determined using the signal at 4.81 (dd, J = 7.2, 5.2 Hz, 1H,  $CH_xO$ ): 80%.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.45–7.41 (m, 2H, Ar*H*), 7.31–7.28 (m, 3H, Ar*H*), 4.81 (dd, J = 7.2, 5.2 Hz, 1H,  $CH_xO$ ), 4.04–3.99 (m, 1H,  $CH_xO$ ), 3.89–3.83 (m, 1H,  $CH_xO$ ), 2.29–2.19 (m, 1H,  $CH_x$ ), 2.15–2.04 (m, 2H,  $CH_x$ ), 1.99–1.90 (m, 1H,  $CH_x$ ). Corresponds to the reported literature data.**Error! Bookmark not defined.** 

#### 5.1.8. General procedure J: 4CzIPN catalyzed deoxyalkynylation

An oven dried (7.5 mL) dram vial equipped with a magnetic stirrer was charged with the cesium salt **3a-x** (0.30 mmol, 1.00 equiv), the EBX reagent (**1**, 1.5 mmol, 1.5 equiv) and 4CzIPN (**2a**, 0.015 mmol, 5 mol%). The reaction vial was sealed with a septum. After 3 vacuum/N2 cycles (backfilling with Ar on the last cycle), dichloromethane (3.00 mL) was added and the septums were replaced with a screw


<sup>&</sup>lt;sup>30</sup> Matsumoto, K.; Nakajima, M.; Nemoto, T. *J. Org. Chem.* **2020**, *85* (18), 11802–11811.

cap under a flux of Ar then the seal was wrapped with parafilm. Error! Bookmark not defined. The reactions were placed between 2 x 440 nm Kessil lamps at ca. 10 cm distance from both lamps (no ventilation,  $T = ca. 50 \, ^{\circ}C)^{31}$  and stirred under irradiation for 15-18 hours. The reaction was filtered through a small celite plug which was washed with  $CH_2Cl_2$ . A solid deposit was prepared (ca. 2g  $SiO_2$ ). The compound was purified by column chromatography (pentane:EtOAc).

## 5.2. Yields and characterization data

#### 5.2.1. Deoxyalkynylated products

(3,3-dimethylpent-1-yne-1,5-diyl)dibenzene (4a)



Direct excitation: **4a** was synthesized following general procedure F using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 0.110 g, 0.300 mmol, 1.00 equiv) and PhEBX (**1a**, 0.261 g, 0.750 mmol, 2.50 equiv) in degassed  $CH_2Cl_2$  (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded (3,3-dimethylpent-1-yne-1,5-diyl)dibenzene (**4a**, 0.045 g, 0.18 mmol, 60%) as a slightly yellow oil.

*Photocatalyzed:* **4a** was synthesized following *general procedure J* using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 0.110 g, 0.300 mmol, 1.0 equiv), PhEBX (**1a**, 0.157 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded (3,3-dimethylpent-1-yne-1,5-diyl)dibenzene (**4a**, 0.056 g, 0.23 mmol, 75%) as a slightly yellow oil.


Rf (pentane) = 0.4.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.45 – 7.39 (m, 2H, Ar*H*), 7.33 – 7.27 (m, 5H, Ar*H*), 7.26 – 7.16 (m, 3H, Ar*H*), 2.95 – 2.79 (m, 2H, ArCH<sub>2</sub>), 1.86 – 1.75 (m, 2H, ArCH<sub>2</sub>CH<sub>2</sub>), 1.36 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 142.9, 131.7, 128.6, 128.5, 128.3, 127.6, 125.8, 124.1, 97.0, 81.0, 45.7, 32.3, 32.0, 29.4.

IR  $(v_{max}, cm^{-1})$  3084 (m), 3060 (m), 3027 (m), 2968 (m), 2945 (m), 2910 (m), 2866 (m), 2224 (m), 1946 (m), 1878 (m), 1804 (m), 1748 (m), 1491 (m), 1265 (m), 1070 (m), 755 (s), 740 (s), 690 (s). HRMS (ESI/QTOF) m/z: [M + Ag]<sup>+</sup> Calcd for  $C_{19}H_{20}Ag^+$  355.0610; Found 355.0615.

(3,3-Dimethylbut-1-yn-1-yl)benzene (4b)



Direbt excitation: **4b** was synthesized following general procedure F using cesium (tert-butyl)oxy-2-oxoacetate (**3b**, 0.083 g, 0.30 mmol, 1 equiv) and PhEBX (**1a**, 0.261 g, 0.750 mmol, 2.50 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded (3,3-dimethylbut-1-yne-1-yl)benzene (**4b**, 0.067 g, 49% purity 0.17 mmol, 57%) as a slightly yellow oil.

Ī

<sup>&</sup>lt;sup>31</sup> The reaction temperature was measured with an internal thermometer on a model system using 5 mol% 4CzIPN in DCM.


*Photocatalyzed:* **4b** was synthesized following *general procedure J* using cesium *tert*-butoxyl-2-oxoacetate (**3b**, 0.083 g, 0.30 mmol, 1 equiv), PhEBX (**1a**, 0.157 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5 μmol, 5 mol%) in degassed  $CH_2Cl_2$  (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded (3,3-dimethylbut-1-yn-1-yl)benzene (**4b**, 0.051 g, 85% purity, 0.27 mmol, 91%) as a colorless oil. The compound could be partially purified from 1,4-diphenylbuta-1,4-diyne (major impurity) by preparative TLC (SiO<sub>2</sub>, glass plate, Heptane) allowing full characterization of **4b**.

Rf (pentane) = 0.8.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43 – 7.33 (m, 2H, Ar*H*), 7.32 – 7.20 (m, 3H, Ar*H*), 1.32 (s, 9H, C(C*H*<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 131.7, 128.3, 127.5, 124.2, 98.7, 79.1, 31.2, 28.1.

**IR** ( $v_{max}$ , cm<sup>-1</sup>) 3084 (m), 3054 (m), 2971 (m), 2903 (m), 2871 (m), 1780 (m), 1723 (m), 909 (s). **HRMS** (APPI/LTQ-Orbitrap) m/z: [M]<sup>+</sup> Calcd for  $C_{12}H_{14}$ <sup>+</sup> 158.1090; Found 158.1093.

((1-Methylcyclopentyl)ethynyl)benzene (4c)




Direct excitation: **4c** was synthesized following general procedure *F* using cesium 2-((1-methylcyclopentyl)oxy)-2-oxoacetate (**3c**, 91 mg, 0.30 mmol, 1.0 equiv) and PhEBX (**1a**, 0.261 g, 0.75 mmol, 2.50 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded ((1-methylcyclopentyl)ethynyl)benzene (**4c**, 57 mg, 42% purity, 0.16 mmol, 54%) with major impurity 1,4-diphenylbutadiyne.

Photocatalyzed: **4c** was synthesized following the *general procedure J* using cesium 2-((1-methylcyclopentyl)oxy)-2-oxoacetate (**3c**, 91 mg, 0.30 mmol, 1.0 equiv), PhEBX (**1a**, 157 mg, 0.450 mmol, 1.50 equiv) and 4CzIPN (**2a**, 12 mg, 0.015 mmol, 5 mol%). Column chromatography (SiO<sub>2</sub>, Pentane) afforded ((1-methylcyclopentyl)ethynyl)benzene (**4c**, 39 mg, 0.20 mmol, 69%) as a pale yellow oil.

Rf (pentane) = 0.6.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.39 - 7.36 (m, 2H, Ar*H*), 7.29 - 7.23 (m, 3H, Ar*H*), 2.01 - 1.95 (m, 2H, C*H*<sub>2</sub>), 1.90 - 1.80 (m, 2H, C*H*<sub>2</sub>) 1.75 - 1.66 (m, 2H, C*H*<sub>2</sub>), 1.62 - 1.51 (m, 2H, C*H*<sub>2</sub>), 1.35 (s, 3H, C*H*<sub>3</sub>) <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 131.7, 128.3, 127.4, 124.4, 98.6, 79.6, 41.8, 38.5, 27.6, 24.5. IR (ν<sub>max</sub>, cm<sup>-1</sup>): 3060 (m), 2960 (s), 2869 (m), 1742 (m), 1488 (m), 1451 (m), 1322 (m), 1186 (m). HRMS (APPI/LTQ-Orbitrap) m/z: [M]<sup>+</sup> Calcd for C<sub>14</sub>H<sub>16</sub><sup>+</sup> 184.1247; Found 184.1248.

2-(1-Methylcyclohexyl)ethynylbenzene (4d)



Direct excitation: **4d** was synthesized following general procedure F using cesium 2-(1-methylcyclohexan-1-yl)oxy-2-oxoacetate (**3d**, 95 mg, 0.30 mmol, 1.0 equiv) and PhEBX (**1a**, 0.261 g, 0.750 mmol, 2.50 equiv) in degassed  $CH_2Cl_2$  (3.0 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded ((1-methylcyclohexyl)ethynyl)benzene (**4d**, 0.063 mg (55% purity), 0.18 mmol, 61%) with major impurity 1,4-diphenylbutadiyne.

Photocatalyzed: **4d** was synthesized following *general procedure J* using cesium 2-(1-methylcyclohexan-1-yl)oxy-2-oxoacetate (**3d**, 0.095 g, 0.30 mmol, 1 equiv), PhEBX (**1a**, 0.157 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5 μmol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).


Column chromatography ( $SiO_2$ , pentane) afforded (1-methylcyclohexyl)enthynylbenzene (**4d**, 0.053 g (80% purity), 0.22 mmol, 72%) as a colorless oil. The compound could be partially purified from 1,4-diphenylbuta-1,4-diyne (major impurity) by preparative TLC ( $SiO_2$ , glass plate, Heptane) allowing full characterisation of **4d**.

Rf (pentane) = 0.7.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.45 – 7.37 (m, 2H, Ar*H*), 7.32 – 7.22 (m, 3H, Ar*H*), 1.84 – 1.55 (m, 8H, C $H_2$ ), 1.28 (s, 3H, C $H_3$ ), 1.27 – 1.09 (m, 2H, C $H_2$ ).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 131.7, 128.3, 127.5, 124.4, 96.9, 81.9, 39.7, 33.3, 30.4, 26.1, 23.6. Consistent with the reported NMR data.<sup>32</sup>

1-Methyl-1-(phenylethynyl)cyclododecane (4e)



*Direct excitation:* **4e** was synthesized following *general procedure F* using cesium 2-(1-methylcyclododecan-1-yl)oxy-2-oxoacetate (**3e**, 151 mg (purity 80%), 0.300 mmol, 1.00 equiv) and PhEBX (**1a**, 0.261 g, 0.750 mmol, 2.50 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3.0 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded ((1-methylcyclododecyl)ethynyl)benzene (**4e**, 0.062 mg (47% purity), 0.11 mmol, 37%) with major impurity 1,4-diphenylbutadiyne.

Photocatalyzed: **4e** was synthesized following the *general procedure J* using cesium 2-((1-methylcyclododecyl)oxy)-2-oxoacetate (**3e**, 121 mg (purity 80%), 0.240 mmol, 1.00 equiv), PhEBX (**1a**, 157 mg, 0.450 mmol, 1.9 equiv) and 4CzIPN (**2a**, 12 mg, 0.015 mmol, 6 mol%). Column chromatography (SiO<sub>2</sub>, Pentane) afforded 1-methyl-1-(phenylethynyl)cyclododecane (**4e**, 43 mg, 0.15 mmol, 63%) as a pale yellow oil.


Rf (pentane) = 0.6.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.40 – 7.36 (m, 3H, Ar*H*), 7.29 – 7.23 (m, 2H, Ar*H*), 1.46 – 1.29 (m, 22H, CH<sub>2</sub>), 1.23 (s, 3H, CH<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 131.7, 128.2, 127.4, 124.4, 98.4, 80.6, 35.0, 34.4, 27.5, 26.6, 26.3, 22.7, 22.3, 19.9.

IR  $(v_{max}, cm^{-1})$ : 3058 (w), 2936 (s), 2859 (m), 2226 (w), 1597 (w), 1479 (m), 1449 (m), 1273 (w). HRMS (ESI/QTOF) m/z: [M + Ag]<sup>+</sup> Calcd for  $C_{21}H_{30}Ag^+$  389.1393; Found 389.1390.

4-Methyl-4-(phenylethynyl)tetrahydro-2*H*-pyran (**4f**)



Direct excitation: **4f** was synthesized following general procedure F using ethyl (4-methyltetrahydro-2H-pyran-4-yl) oxalate (**3f**, 0.096 g, 0.30 mmol, 1.0 equiv) and PhEBX (**1a**, 0.261 g, 0.750 mmol, 2.50 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3.0 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded 4-methyl-4-(phenylethynyl)tetrahydro-2H-pyran (**4f**, 0.040 g (93% purity), 0.19 mmol, 62%).

<sup>32</sup> Gao, C.; Li, J.; Yu, J.; Yang, H.; Fu, H. *Chem. Commun.* **2016**, *52*, 7292–7294.

.

Photocatalyzed: **4f** was synthesized following the *general procedure J* using ethyl (4-methyltetrahydro-2H-pyran-4-yl) oxalate (**3f**, 96 mg, 0.30 mmol, 1.0 equiv), PhEBX (**1a**, 157 mg, 0.450 mmol, 1.50 equiv) and 4CzIPN (**2a**, 12 mg, 0.015 mmol, 5 mol%). Column chromatography (SiO<sub>2</sub>, 1% to 5% EtOAc in Pentane) afforded, 4-methyl-4-(phenylethynyl)tetrahydro-2*H*-pyran (**4f**, 40 mg, purity: 94%, 0.19 mmol, 67%) as a colorless oil.

Rf (pentane:EtOAc 95:5) = 0.4.


<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ: 7.44 – 7.39 (m, 2H, Ar*H*), 7.32 – 7.27 (m, 3H, Ar*H*), 3.90 – 3.77 (m, 4H, OC*H*<sub>2</sub>), 1.76 – 1.68 (m, 2H, C*H*<sub>2</sub>), 1.61 (ddd, J = 13.2, 11.2, 5.0 Hz, 2H, C*H*<sub>2</sub>), 1.35 (s, 3H, C*H*<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$ : 131.7, 128.4, 127.9, 123.8, 94.7, 83.0, 65.4, 39.4, 31.1, 30.2.

 $\textbf{IR} \; (v_{\text{max}}, \, cm^{\text{-}1}) \colon 3058 \; (m), \, 2959 \; (s), \, 2857 \; (m), \, 1746 \; (m), \, 1492 \; (m), \, 1448 \; (m), \, 1174 \; (s), \, 1107 \; (s).$ 

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M + H]^+$  Calcd for  $C_{14}H_{17}O^+$  201.1274; Found 201.1273.

#### 1-(3,3-Dimethyl-5-phenylpent-1-yn-1-yl)-4-methylbenzene (4g)



Direct excitation: **4g** was synthesized following general procedure F using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 0.110 g, 0.300 mmol, 1.00 equiv) and pTolEBX (**1b**, 0.271 g, 0.750 mmol, 2.50 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded (3,3-dimethylpent-1-yne-1,5-diyl)dibenzene (**4g**, 0.055 g, 0.21 mmol, 70%) as a slightly yellow oil.

*Photocatalyzed:* **4g** was synthesized following *general procedure J* using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 0.110 g, 0.300 mmol, 1.0 equiv), pTolEBX (**1b**, 0.163 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded (3,3-dimethylpent-1-yne-1,5-diyl)dibenzene (**4g**, 0.050 g, 0.19 mmol, 64%) as a colorless oil.

#### Rf (pentane) = 0.4


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 – 7.26 (m, 4H, Ar*H*), 7.25 –7.15 (m, 3H, Ar*H*), 7.12 – 7.07 (m, 2H, Ar*H*), 2.96 – 2.76 (m, 2H, PhC $H_2$ ), 2.34 (s, 3H, ArC $H_3$ ), 1.85 – 1.74 (m, 2H, PhCH<sub>2</sub>C $H_2$ ), 1.35 (s, 6H, C(C $H_3$ )<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 143.0, 137.6, 131.6, 129.1, 128.6, 128.5, 125.8, 121.1, 96.2, 81.0, 45.8, 32.3, 32.0, 29.4, 21.6.

IR  $(v_{max}, cm^{-1})$  2858 (m), 2924 (s), 2970 (s), 3028 (m), 1508 (s), 1454 (s), 818 (s), 741 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + H]^+$  Calcd for  $C_{20}H_{23}^+$  263.1794; Found 263.1793.

#### 1-Methyl-1-(phenylethynyl)cycloheptane (4i)



4i was synthesized following general procedure J using cesium 2-(1-methylcycloheptan-1-yl)oxy-2-oxoacetate (3i, 0.110 g, 0.300 mmol, 1.00 equiv), PhEBX (1a, 0.157 g, 0.450 mmol, 1.5 equiv), 4CzIPN (2a, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).

Column chromatography (SiO<sub>2</sub>, pentane) afforded (3,3-dimethylpent-1-yne-1,5-diyl)dibenzene (4i, 0.068 g, 75% purity 0.22 mmol, 74%) as a colorless oil. The compound could be partially purified

from 1,4-diphenylbuta-1,4-diyne (major impurity) by preparative TLC (SiO<sub>2</sub>, glass plate, Heptane) allowing full characterisation of **4i**.

#### Rf (pentane) = 0.7.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42 – 7.39 (m, 2H, Ar*H*), 7.31 – 7.24 (m, 3H, Ar*H*), 1.95 – 1.84 (m, 2H, C*H*<sub>2</sub>), 1.82 – 1.64 (m, 4H, C*H*<sub>2</sub>), 1.64 – 1.56 (m, 2H, C*H*<sub>2</sub>), 1.55 – 1.44 (m, 4H, C*H*<sub>2</sub>), 1.29 (s, 3H, C*H*<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 131.7, 128.3, 127.4, 124.5, 98.1, 81.1, 42.3, 36.1, 31.5, 28.4, 24.0.

IR ( $v_{max}$ ,  $cm^{-1}$ ) 3081 (w), 3054 (w), 2961 (m), 2925 (s), 2855 (m), 1598 (m), 1491 (m), 1460 (m), 1231 (m), 912 (m), 755 (s).

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M]^+$  Calcd for  $C_{16}H_{20}^+$  212.1560; Found 212.1558.

#### 1-(Phenylethynyl)adamantane (4j)



**4j** was synthesized following the *general procedure J* using cesium 2-(((1*S*,3*S*)-adamantan-1-yl)oxy)-2-oxoacetate (**3j**, 107 mg, 0.300 mmol, 1.00 equiv), PhEBX (**1a**, 157 mg, 0.450 mmol, 1.50 equiv) and 4CzIPN (**2a**, 12 mg, 0.015 mmol, 5 mol%).

Column chromatography (SiO<sub>2</sub>, Pentane) afforded 1-(phenylethynyl)adamantane (**4j**, 20 mg, 0.080 mmol, 28%) as a pale yellow oil.

#### Rf (pentane) = 0.5.


<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ: 7.44 – 7.32 (m, 2H, Ar*H*), 7.32 – 7.19 (m, 3H, Ar*H*), 2.07 – 1.97 (m, 3H, C*H*), 1.97 – 1.92 (m, 6H, C*H*<sub>2</sub>), 1.75 – 1.69 (m, 6H, C*H*<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 131.8, 128.2, 127.5, 124.2, 98.6, 79.5, 43.0, 36.6, 30.2, 28.2.

IR (v<sub>max</sub>, cm<sup>-1</sup>): 3060 (w), 2912 (s), 2853 (m), 1491 (m), 1450 (m).

**HRMS** (nanochip-ESI/LTQ-Orbitrap) m/z:  $[M]^+$  Calcd for  $C_{18}H_{20}^+$  236.1560; Found 236.1561.

#### (3-Ethyl-3-methylpent-1-yne-1,5-diyl)dibenzene (4k)



**4k** was synthesized following the *general procedure J* using cesium 2-((3-methyl-1-phenylpentan-3-yl)oxy)-2-oxoacetate (**3k**, 115 mg, 0.300 mmol, 1.00 equiv), PhEBX (**1a**, 157 mg, 0.450 mmol, 1.50 equiv) and 4CzIPN (**2a**, 12 mg, 0.015 mmol, 5 mol Column chromatography (SiO<sub>2</sub>, Pentane) affording (3-ethyl-3-methylpent-1-yne-1,5-diyl)dibenzene (**4k**, 57 mg, 0.22 mmol, 72%) as a pale yellow oil.


#### Rf (pentane) = 0.3

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.44 – 7.41 (m, 2H, Ar*H*), 7.32 – 7.27 (m, 5H, Ar*H*), 7.25 – 7.22 (m, 2H, Ar*H*), 7.21 – 7.17 (m, 1H, Ar*H*), 2.90 – 2.77 (m, 2H, ArC*H*<sub>2</sub>), 1.90 – 1.82 (m, 1H, C*H*<sub>2</sub>), 1.76 – 1.63 (m, 2H, C*H*<sub>2</sub>), 1.59 – 1.50 (m, 1H, C*H*<sub>2</sub>), 1.30 (s, 3H, C*H*<sub>3</sub>), 1.07 (t, J = 7.40 Hz, 3H, CH<sub>2</sub>C*H*<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 143.1, 131.8, 128.6, 128.5, 128.3, 127.6, 125.8, 124.3, 96.1, 82.2, 43.7, 36.2, 34.5, 31.9, 26.0, 9.5.

IR  $(v_{max}, cm^{-1})$ : 3062 (w), 3031 (m), 2969 (m), 2929 (m), 2858 (w), 1599 (m), 1493 (m), 1454 (m). HRMS (APPI/LTQ-Orbitrap) m/z: [M]<sup>+</sup> Calcd for  $C_{20}H_{22}^{+}$  262.1716; Found 262.1716.

#### (3,3,4-trimethylpent-1yn-1-yl)benzene (4l)



**4I** was synthesized following *general procedure J* using cesium (2,3-dimethylbutan-2-yl)oxy-2-oxoacetate (**3I**, 0.092 g, 0.30 mmol, 1.0 equiv), PhEBX (**1a**, 0.157 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).

Column chromatography ( $SiO_2$ , pentane) afforded (3,3,4-trimethylpent-1-yn-1-yl)benzene (**4I**, 0.053 g, 85% purity, 0.21 mmol, 72%) as a colorless oil. The compound could be partially purified from 1,4-diphenylbuta-1,4-diyne (major impurity) by preparative TLC ( $SiO_2$ , glass plate, Heptane) allowing full characterisation of **4I**.

#### Rf (pentane) = 0.75.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43 – 7.35 (m, 2H, Ar*H*), 7.32 – 7.22 (m, 3H, Ar*H*), 1.64 (hept, J = 6.8 Hz, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.25 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 1.03 (d, J = 6.8 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  131.7, 128.3, 127.4, 124.4, 97.0, 81.0, 38.0, 35.6, 27.1, 18.5.

**IR** (v<sub>max</sub>, cm<sup>-1</sup>) 3083 (m), 3055 (m), 2971 (s), 2939 (m), 2874 (m), 2228 (m), 1599 (m), 1489 (m), 1460 (m), 1369 (m), 1157 (m), 1061 (m), 911 (m), 755 (s), 691 (s).

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M]^+$  Calcd for  $C_{14}H_{18}^+$  186.1403; Found 186.1403.

#### 1-(2,2-Dimethyl-4-phenylbut-3-yn-1-yl)-4-methoxybenzene (4m)



**4m** was synthesized following *general procedure J* using cesium (1-(4-methoxyphenyl)-2-methylpropan-2-yl)oxy-2-oxoacetate (**3m**, 0.115 g, 0.300 mmol, 1.00 equiv), PhEBX (**1a**, 0.157 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).

Column chromatography ( $SiO_2$ , pentane:EtOAc 100:0 to 90:10) afforded 1-(2,2-dimethyl-4-phenylbut-3-yn-1-yl)-4-methoxybenzene (**4m**, 0.044 g, 0.17 mmol, 55%).

#### Rf (pentane:EtOAc 9:1) = 0.4.


<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.40 – 7.33 (m, 2H, Ar*H*), 7.31 – 7.21 (m, 5H, Ar*H*), 6.88 – 6.81 (m, 2H, Ar*H*), 3.80 (s, 3H, OCH<sub>3</sub>), 2.74 (s, 2H, ArCH<sub>2</sub>), 1.28 (s, 6H, (CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.4, 131.7, 131.6, 130.7, 128.3, 127.6, 124.2, 113.2, 97.2, 81.7, 55.4, 48.4, 33.1, 29.1.

IR  $(v_{max}, cm^{-1})$  3057 (m), 3034 (m), 2961 (m), 2933 (m), 2835 (m), 1786 (m), 1611 (m), 1512 (s), 1465 (m), 1302 (m), 1246 (s), 1177 (s), 1037 (s), 757 (s), 739 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Ag]^+$  Calcd for  $C_{19}H_{20}AgO^+$  371.0560; Found 371.0552.

#### 1-(2,2-Dimethyl-4-phenylbut-3-yn-1-yl)-2-fluorobenzene (4n)



**4n** was synthesized following *general procedure J* using cesium (1-(2-fluorophenyl)-2-methylpropan-2-yl)oxy-2-oxoacetate (3n, 0.112 g, 0.300 mmol, 1.00 equiv), PhEBX (1a, 0.157 g, 0.450 mmol, 1.50 equiv), 4CzIPN (2a, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).

Column chromatography ( $SiO_2$ , pentane) afforded 1-(2,2-dimethyl-4-phenylbut-3-yn-1-yl)-2-fluorobenzene (4n, 0.023 g, 0.091 mmol, 30%).

#### Rf (pentane) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl3) δ 7.43 (td, J = 7.6, 1.9 Hz, 1H, ArH), 7.38 – 7.36 (m, 1H, ArH), 7.35 (d, J = 2.0 Hz, 1H, ArH), 7.30 – 7.25 (m, 3H, ArH), 7.25 – 7.17 (m, 1H, ArH), 7.13 – 6.99 (m, 2H, ArH), 2.87 (d, J = 1.5 Hz, 2H, ArCH<sub>2</sub>), 1.33 (d, J = 1.0 Hz, 6H, C(CH<sub>3</sub>)<sub>2</sub>).

<sup>1</sup>**H NMR** {<sup>19</sup>**F**} δ 7.42 (dd, J = 7.6, 1.8 Hz, 1H, ArH), 7.39 – 7.32 (m, 2H, ArH), 7.31 – 7.18 (m, 4H, ArH), 7.13 – 7.01 (m, 2H, ArH), 2.87 (s, 2H, Ar $CH_2$ ), 1.33 (s, 6H, C(C $H_3$ )<sub>2</sub>).


<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 161.7 (d, J = 245 Hz), 133.1 (d, J = 5 Hz), 131.6, 128.3 (d, J = 8 Hz), 128.3, 127.7, 125.5 (d, J = 16 Hz), 124.1, 123.5 (d, J = 4 Hz), 115.2 (d, J = 23 Hz), 96.7, 81.5, 41.3, 33.3, 29.1.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -116.1.

IR  $(v_{max}, cm^{-1})$  3061 (w), 2969 (w), 2925 (w), 1489 (m), 1488 (m), 1467 (m), 1280 (m), 1183 (m), 752 (s), 721 (m).

**HRMS** (APPI/LTQ-Orbitrap) m/z: [M]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>17</sub>F<sup>+</sup> 252.1309; Found 252.1308.

#### 1-(((3,3-Dimethyl-5-phenylpent-4-yn-1-yl)oxy)methyl)-4-methylbenzene (40)



**4o** was synthesized following *general procedure J* using cesium (2-methyl-4-((4-methylbenzyl)oxy)butan-2-yl)oxy-2-oxoacetate (**3o**, 0.124 g, 0.300 mmol, 1.00 equiv), PhEBX (**1a**, 0.157 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).

Column chromatography ( $SiO_2$ , pentane:EtOAc 100:0 to 80:20) afforded 1-(((3,3-dimethyl-5-phenylpent-4-yn-1-yl)oxy)methyl)-4-methylbenzene (4o, 0.049 g, 0.17 mmol, 56%).

#### Rf(pentane:EtOAc 8:2) = 0.5.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37 – 7.29 (m, 2H, Ar*H*), 7.30 – 7.21 (m, 5H, Ar*H*), 7.17 – 7.11 (m, 2H, Ar*H*), 4.50 (s, 2H, ArC*H*<sub>2</sub>), 3.74 (dd, J = 7.6, 6.9 Hz, 2H, C*H*<sub>2</sub>), 2.34 (s, 3H, ArC*H*<sub>3</sub>), 1.89 – 1.81 (m, 2H, C*H*<sub>2</sub>), 1.32 (s, 6H, C(C*H*<sub>3</sub>)<sub>2</sub>).

 $^{13}\text{C NMR}$  (101 MHz, CDCl<sub>3</sub>)  $\delta$  137.3, 135.6, 131.7, 129.2, 128.3, 127.9, 127.6, 124.0, 96.7, 80.8, 73.0, 68.2, 42.6, 30.6, 29.9, 21.3.

IR  $(v_{max}, cm^{-1})$  3052 (m), 3033 (m), 2969 (m), 2907 (m), 2863 (m), 1960 (w), 1900 (w), 1715 (w), 1598 (m), 1490 (m), 1443 (m), 1361 (m), 1096 (s), 802 (s), 754 (s).

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M]^+$  Calcd for  $C_{21}H_{24}O^+$  292.1822; Found 292.1818.

#### tert-Butyl((3,3-dimethyl-5-phenylpent-4-yn-1-yl)oxy)dimethylsilane (4p)



**4p** was synthesized following the *general procedure J* using cesium 2-((4-((*tert*-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)oxy)-2-oxoacetate (**3p**, 127 mg, 0.300 mmol, 1.00 equiv), PhEBX (**1a**, 157 mg, 0.450 mmol, 1.50 equiv) and 4CzIPN (**2a**, 12 mg, 0.015 mmol, 5 mol%).


Column chromatography (SiO<sub>2</sub>, 5% DCM in Pentane) afforded (3- *tert*-butyl((3,3-dimethyl-5-phenylpent-4-yn-1-yl)oxy)dimethylsilane (**4p**, 55 mg, 0.18 mmol, 61%) as a yellow oil.

#### **Rf** (pentane:DCM 95:5) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.39 – 7.34 (m, 2H, Ar*H*), 7.30 – 7.25 (m, 3H, Ar*H*), 3.90 (t, J = 7.5 Hz, 2H, OC*H*<sub>2</sub>), 1.76 (t, J = 7.5 Hz, 2H, C*H*<sub>2</sub>), 1.31 (s, 6H, C(C*H*<sub>3</sub>)<sub>2</sub>), 0.91 (s, 9H, C(C*H*<sub>3</sub>)<sub>3</sub>), 0.08 (s, 6H, Si(C*H*<sub>3</sub>)<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 131.7, 128.3, 127.6, 124.1, 96.8, 80.7, 61.1, 45.8, 30.5, 29.9, 26.1, 18.5, -5.1.

IR ( $v_{max}$ , cm<sup>-1</sup>): 3668 (w), 2962 (s), 2901 (s), 1467 (m), 1393 (m), 1254 (m), 1092 (s), 1057 (s). HRMS (nanochip-ESI/LTQ-Orbitrap) m/z: [M + H]<sup>+</sup> Calcd for  $C_{19}H_{31}OSi^+$  303.2139; Found 303.2137.

#### tert-Butyl((3,3-dimethyl-5-phenylpent-4-yn-1-yl)oxy)diphenylsilane (4q)



**4q** was synthesized following the *general procedure J* using cesium 2-((4-((*tert*-butyldiphenylsilyl)oxy)-2-methylbutan-2-yl)oxy)-2-oxoacetate (**3q**, 164 mg, 0.300 mmol, 1.00 equiv), PhEBX (**1a**, 157 mg, 0.450 mmol, 1.50 equiv) and 4CzIPN (**2a**, 12 mg, 0.015 mmol, 5 mol%).

Column chromatography (SiO<sub>2</sub>, 5% DCM in Pentane) afforded *tert*-butyl((3,3-dimethyl-5-phenylpent-4-yn-1-yl)oxy)diphenylsilane (**4q**, 53 mg, 0.12 mmol, 41%) as a yellow oil.

**Rf** (pentane:DCM, 95:5) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.74 – 7.64 (m, 4H, Ar*H*), 7.44 – 7.31 (m, 6H, Ar*H*), 7.29 – 7.21 (m, 5H, Ar*H*), 3.96 (dd, J = 7.6, 6.8 Hz, 2H, OCH<sub>2</sub>), 1.82 (dd, J = 7.6, 6.8 Hz, 2H, CH<sub>2</sub>), 1.27 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 1.05 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 135.7, 134.1, 131.7, 129.7, 128.2, 127.8, 127.6, 124.0, 96.7, 80.8, 62.0, 45.5, 30.5, 30.0, 27.0, 19.3.

IR  $(v_{max}, cm^{-1})$ : 3668 (m), 3061 (m), 2966 (s), 2935 (s), 1478 (m), 1392 (m), 1258 (m), 1084 (s).

**HRMS** (nanochip-ESI/LTQ-Orbitrap) m/z:  $[M + Na]^+$  Calcd for  $C_{29}H_{34}NaOSi^+$  449.2271; Found 449.2269.

#### 1-(3,3-Dimethyl-5-phenylpent-1-yn-1-yl)-3-fluorobenzene (4r)

**4r** was synthesized following *general procedure J* using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 0.110 g, 0.300 mmol, 1 equiv), mFPhEBX (**1d**, 0.164 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M)

Column chromatography (SiO<sub>2</sub>, pentane) afforded 1-(3,3-dimethyl-5-phenylpent-1-yn-1-yl)-3-fluorobenzene (**4r**, 0.045 g, 0.17 mmol, 56%).

#### Rf (pentane) = 0.5.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 – 7.15 (m, 7H, Ar*H*), 7.10 (ddd, J = 9.6, 2.7, 1.4 Hz, 1H, Ar*H*), 6.98 (tdd, J = 8.3, 2.7, 1.2 Hz, 1H, Ar*H*), 2.87 – 2.79 (m, 2H, ArC*H*<sub>2</sub>), 1.84 – 1.75 (m, 2H, C*H*<sub>2</sub>), 1.35 (s, 6H, C(C*H*<sub>3</sub>)<sub>2</sub>).


<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.4 (d, J = 245.8 Hz), 142.6, 129.7 (d, J = 8.7 Hz), 128.4, 127.5 (d, J = 2.9 Hz), 126.1 – 125.3 (m), 118.4 (d, J = 22.5 Hz), 114.8 (d, J = 21.1 Hz), 98.0, 79.8, 45.4, 32.1, 31.9, 29.1. 2 carbons are not resolved.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -113.5 (d, J = 4.5 Hz).

**IR** ( $v_{max}$ , cm<sup>-1</sup>) 3087 (m), 3062 (m), 2972 (s), 2937 (s), 2911 (s), 1608 (s), 1580 (s), 1075 (s), 1056 (s), 909 (s), 873 (s), 784 (s).

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M]^+$  Calcd for  $C_{19}H_{19}F^+$  266.1465; Found 266.1473.

#### 1-(3,3-Dimethyl-5-phenylpent-1-yn-1-yl)-4-(trifluoromethyl)benzene (4s)



**4s** was synthesized following *general procedure J* using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 0.110 g, 0.300 mmol, 1 equiv),  $pCF_3PhEBX$  (**1e**, 0.187 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed  $CH_2Cl_2$  (3 mL, 0.1  $\mu$ M)

Column chromatography ( $SiO_2$ , pentane) afforded 1-(3,3-dimethyl-5-phenylpent-1-yn-1-yl)-4-(trifluoromethyl)benzene (**4s**, 0.055 g, 0.17 mmol, 58%).

#### Rf (pentane) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.58 – 7.46 (m, 4H, Ar*H*), 7.34 – 7.17 (m, 5H, Ar*H*), 2.88 – 2.79 (m, 2H, Ar*CH*<sub>2</sub>), 1.85 – 1.77 (m, 2H, C*H*<sub>2</sub>), 1.36 (s, 6H, C(C*H*<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 142.7, 132.0, 128.5 (m), 125.9, 125.2 (d, J = 3.9 Hz), 99.8, 80.0, 45.5, 32.3, 32.1, 29.2. 4 carbons not resolved.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -62.7.

**IR** (v<sub>max</sub>, cm<sup>-1</sup>) 3028 (w), 2975 (w), 2940 (m), 2859 (m), 2822 (w), 2239 (w), 1617 (m), 1505 (m), 1324 (s), 1168 (m), 1130 (s), 1066 (s), 910 (s), 766 (m), 743 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Ag]^+$  Calcd for  $C_{20}H_{19}AgF_3^+$  423.0484; Found 423.0479.

#### 1-(3,3-Dimethyl-5-phenylpent-1-yn-1-yl)-4-bromobenzene (4t)

4t was synthesized following general procedure J using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (3a, 0.110 g, 0.300 mmol, 1.00 equiv), pBrPhEBX (1f, 0.192 g, 0.450 mmol, 1.50 equiv), 4CzIPN (2a, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).

Column chromatography (SiO<sub>2</sub>, pentane) afforded 1-(3,3-dimethyl-5-phenylpent-1-yn-1-yl)-4-bromobenzene (**4t**, 0.044 g, 0.13 mmol, 45%).

#### Rf (pentane) = 0.3.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.45 – 7.38 (m, 2H, Ar*H*), 7.33 – 7.25 (m, 2H, Ar*H*), 7.29 – 7.21 (m, 3H, Ar*H*), 7.25 – 7.14 (m, 2H, Ar*H*), 2.87 – 2.78 (m, 2H, ArC*H*<sub>2</sub>), 1.83 – 1.74 (m, 2H, C*H*<sub>2</sub>), 1.34 (s, 6H, C(C*H*<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 142.8, 133.2, 131.5, 128.5, 125.9, 123.1, 121.7, 98.3, 80.1, 45.5, 32.3, 32.1, 29.3. 1 carbon is not resolved.

**IR** (v<sub>max</sub>, cm<sup>-1</sup>) 3086 (m), 3062 (m), 3026 (m), 2968 (m), 2920 (m), 2861 (m), 1485 (s), 1469 (m), 1312 (m), 1265 (m), 1070 (s), 1011 (s), 823 (s), 745 (s), 700 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Ag]^+$  Calcd for  $C_{19}H_{19}Ag^{79}Br^+$  432.9716; Found 432.9707.

#### 1-(3,3-dimethyl-5-phenylpent-1-yn-1-yl)-2-bromobenzene (4u)



**4u** was synthesized following *general procedure J* using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 0.110 g, 0.300 mmol, 1.00 equiv), PhEBX (**1g**, 0.192 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).

Column chromatography ( $SiO_2$ , pentane) afforded (3,3-dimethylpent-1-yne-1,5-diyl)dibenzene (**4u**, 0.071 g, 0.22 mmol, 72%).

#### Rf (pentane) = 0.3.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.57 (dd, J = 8.0, 1.2 Hz, 1H, ArH), 7.45 (dd, J = 7.7, 1.7 Hz, 1H, ArH), 7.33 – 7.18 (m, 5H, ArH), 7.22 – 7.14 (m, 1H, ArH), 7.12 (td, J = 7.7, 1.7 Hz, 1H, ArH), 2.96 – 2.87 (m, 2H, ArCH<sub>2</sub>), 1.87 – 1.78 (m, 2H, CH<sub>2</sub>), 1.38 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 142.8, 133.2, 132.3, 128.7, 128.5, 128.4, 126.9, 126.0, 125.7, 101.9, 79.7, 45.5, 32.3, 32.2, 29.1. 1 carbon is not resolved.

IR  $(v_{max}, cm^{-1})$  3062 (m), 3026 (m), 2968 (s), 2925 (m), 2865 (m), 2226 (m), 1466 (s), 1058 (m), 1047 (s), 1027 (s), 753 (s), 700 (s).

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M]^+$  Calcd for  $C_{19}H_{19}^{79}Br^+$  326.0665; Found 326.0676.

#### 1-(3,3-Dimethyl-5-phenylpent-1-yn-1-yl)-4-chlorobenzene (4v)



**4v** was synthesized following *general procedure J* using cesium 2-(methyl-4-phenylbutan-2-yl)oxy-2-oxoacetate (**3a**, 0.110 g, 0.300 mmol, 1.00 equiv), oClPhEBX (**1h**, 0.172 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5  $\mu$ mol, 5 mol%) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M).

Column chromatography ( $SiO_2$ , pentane) afforded 1-(3,3-dimethyl-5-phenylpent-1-yn-1-yl)-4-chlorobenzene ( $\mathbf{4v}$ , 0.066 g, 0.23 mmol, 78%).


#### Rf (pentane) = 0.3.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.48 – 7.35 (m, 2H, Ar*H*), 7.33 – 7.14 (m, 7H, Ar*H*), 2.95 – 2.86 (m, 2H, Ar*CH*<sub>2</sub>), 1.86 – 1.77 (m, 2H, C*H*<sub>2</sub>), 1.38 (s, 6H, C(C*H*<sub>3</sub>)<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 143.0, 136.0, 133.3, 129.3, 128.7, 128.6, 128.5, 126.4, 125.8, 123.9, 102.7, 78.0, 45.7, 32.4, 32.3, 29.3.

**IR** ( $v_{max}$ , cm<sup>-1</sup>) 2972 (m), 2901 (m), 1495 (w), 1406 (m), 1229 (m), 1075 (s), 905 (s), 729 (s). **HRMS** (APPI/LTQ-Orbitrap) m/z: [M]<sup>+</sup> Calcd for  $C_{19}H_{19}^{35}Cl^+$  282.1170; Found 282.1178.

(3R,3aS,6S,7R,8aS)-3,6,8,8-tetramethyl-6-(phenylethynyl)octahydro-1H-3a,7-methanoazulene (4w)



Direct excitation: **4w** was synthesized following general procedure F using cedrol derived cesium oxalate **3w** (0.128 g, 0.300 mmol, 1 equiv) and PhEBX (**1a**, 0.261 g, 0.750 mmol, 2.50 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded (3R,3aS,6S,7R,8aS)-3,6,8,8-tetramethyl-6-(phenylethynyl)octahydro-1H-3a,7-methanoazulene (**4w**) as a single diasteroisomer (0.077 g (48% purity), dr > 20:1, 0.15 mmol, 50%).

*Photocatalyzed:* **4w** was synthesized following *general procedure J* using cedrol derived cesium oxalate **3w** (0.128 g, 0.300 mmol, 1 equiv), PhEBX (**1a**, 0.157 g, 0.450 mmol, 1.50 equiv), 4CzIPN (**2a**, 0.012 g, 1.5 μmol, 5 mol%) in degassed  $CH_2Cl_2$  (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded (3*R*,3a*S*,6*S*,7*R*,8a*S*)-3,6,8,8-tetramethyl-6-(phenylethynyl)octahydro-1H-3a,7-methanoazulene (**4w**) as a single diasteroisomer (0.075 g (70% purity), dr > 20:1, 0.17 mmol, 58%). The compound could be partially purified from 1,4-diphenylbuta-1,4-diyne (major impurity) by preparative TLC (SiO<sub>2</sub>, glass plate, Heptane) allowing full characterisation of **4w**.

#### Rf (pentane) = 0.6.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42 – 7.35 (m, 2H, Ar*H*), 7.32 – 7.20 (m, 3H, Ar*H*), 2.18 – 2.10 (m, 1H, aliphatic-C*H* or C*H*<sub>2</sub>), 1.95 – 1.83 (m, 2H, aliphatic-C*H* or C*H*<sub>2</sub>), 1.85 – 1.76 (m, 1H, aliphatic-C*H* or C*H*<sub>2</sub>), 1.79 – 1.65 (m, 5H, aliphatic-C*H* or C*H*<sub>2</sub>), 1.60 – 1.50 (m, 1H, aliphatic-C*H* or C*H*<sub>2</sub>), 1.48 (s, 3H, C*H*<sub>3</sub>), 1.46 – 1.34 (m, 2H, aliphatic-C*H* or C*H*<sub>2</sub>), 1.28 (dtd, J = 11.8, 7.7, 6.0 Hz, 1H, aliphatic-C*H* or C*H*<sub>2</sub>), 1.22 (s, 3H, C*H*<sub>3</sub>), 1.03 (s, 3H, C*H*<sub>3</sub>), 0.87 (d, J = 7.1 Hz, 3H, C*H*<sub>3</sub>).


<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 131.6, 128.3, 127.3, 124.6, 100.0, 80.8, 59.0, 57.4, 54.2, 44.4, 44.0, 42.0, 39.1, 37.1, 34.9, 31.9, 29.8, 29.0, 28.5, 25.6, 15.7.

IR ( $v_{max}$ , cm<sup>-1</sup>) 3055 (m), 3010 (m), 2950 (m), 2870 (m), 2851 (m), 1648 (m), 1474 (m), 1442 (m), 1246 (m), 755 (s), 724 (m), 690 (s).


**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M]^+$  Calcd for  $C_{23}H_{30}^+$  306.2342; Found 306.2342.








#### **NOESY**





(1R,2R,5R)-5-isopropyl-2-methyl-2-(phenylethynyl)-6-oxabicyclo[3.2.1]octan-7-one (4x)

Direct excitation: 4x was synthesized following the general procedure F using Cesium (R)-2-((1-isopropyl-4-methylcyclohex-3-en-1-yl)oxy)-2-oxoacetate (3x, 107 mg, 0.300 mmol, 1.00 equiv) and PhEBX (1a, 261 mg, 0.750 mmol, 2.5 equiv). Column chromatography ( $SiO_2$ , 5% EtOAc in Pentane) afforded (1R,2R,5R)-5-isopropyl-2-methyl-2-(phenylethynyl)-6-oxabicyclo[3.2.1]octan-7-one (4x, 40 mg, dr > 20:1, 0.16 mmol, 47%) as a colorless oil.


Photocatalyzed: **4x** was synthesized following the *general procedure J* using Cesium (R)-2-((1-isopropyl-4-methylcyclohex-3-en-1-yl)oxy)-2-oxoacetate (**3x**, 107 mg, 0.300 mmol, 1.00 equiv), PhEBX (**1a**, 157 mg, 0.450 mmol, 1.50 equiv) and 4CzIPN (**2a**, 12 mg, 0.015 mmol, 5 mol%). Column chromatography (SiO<sub>2</sub>, 5% EtOAc in Pentane) afforded (1R,2R,5R)-5-isopropyl-2-methyl-2-(phenylethynyl)-6-oxabicyclo[3.2.1]octan-7-one (**4x**, 45 mg, dr > 20:1, 0.16 mmol, 53%) as a colorless oil.

#### Rf (pentane:EtOAc 95:5) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.44 – 7.37 (m, 2H, Ar*H*), 7.35 – 7.28 (m, 3H, Ar*H*), 2.65 (dd, J = 5.6, 1.7 Hz, 1H, CHCO<sub>2</sub>), 2.47 (d, J = 11.9 Hz, 1H, CO<sub>2</sub>CHCH $_{ax}$ ), 2.15 – 2.08 (m, 1H, CO<sub>2</sub>CHCH $_{eq}$ ), 2.07 – 2.00 (m, 1H, CCH<sub>3</sub>CH $_{ax}$ ), 2.00 – 1.91 (m, 1H, C(CH<sub>3</sub>)<sub>2</sub> $_{2H}$ ), 1.91 – 1.85 (m, 1H, COCH $_{ax}$ ), 1.84 – 1.77 (m, 1H, COCH $_{eq}$ ), 1.74 – 1.63 (m, 1H, CCH<sub>3</sub>CH $_{eq}$ ), 1.48 (s, 3H, CH $_{3}$ ), 1.01 (d, J = 6.8 Hz, 3H, CH(CH $_{3}$ )<sub>2</sub>), 0.97 (d, J = 6.9 Hz, 1H, CH(CH $_{3}$ )<sub>2</sub>).


<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 176.3, 131.8, 128.5, 128.3, 123.2, 93.1, 90.1, 82.6, 51.0, 37.4, 35.3, 34.7, 34.3, 27.3, 26.8, 17.2, 16.8.

IR ( $v_{max}$ , cm<sup>-1</sup>): 3059 (w), 2967 (m), 2881 (m), 1773 (s), 1593 (w), 1461 (m), 1171 (m), 930 (m). HRMS (APPI/LTQ-Orbitrap) m/z: [M + Na]<sup>+</sup> Calcd for  $C_{19}H_{22}NaO_2$ <sup>+</sup> 305.1512; Found 305.1512.



## 5.2.2. Decarboxylation alkynylation

#### 1,3-Diphenylprop-2-yn-1-one (8a)



**8a** was synthesized following *general procedure G* using phenyglyoxylic acid (**7a**, 45 mg, 0.30  $\mu$ mol, 1.0 equiv), PhEBX (**1a**, 261 mg, 750  $\mu$ mol, 2.50 equiv), Cs<sub>2</sub>CO<sub>3</sub> (195 mg, 600  $\mu$ mol, 2.0 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 0.05 M). Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 95:5) afforded 1,3-diphenylprop-2-yn-1-one (**8a**, 50 mg, 0.24 mmol, 81%) as a yellow solid.


Rf (pentane:EtOac 95:5) = 0.5.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 8.27 – 8.21 (m, 2H, Ar*H*), 7.72 – 7.68 (m, 2H, Ar*H*), 7.67 – 7.60 (m, 1H, Ar*H*), 7.56 – 7.47 (m, 3H, Ar*H*), 7.46 – 7.39 (m, 2H, Ar*H*).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  178.2, 137.0, 134.3, 133.2, 130.9, 129.7, 128.8, 128.8, 120.3, 93.3, 87.0.

Corresponds to reported literature data.<sup>26</sup>

#### 2-Cyclohexylethynylbenzene (8b)



**8b** was synthesized following *general procedure G* using cyclohexanecarboxylic acid (**7b**, 38 mg, 0.30  $\mu$ mol, 1.0 equiv), PhEBX (**1a**, 261 mg, 750  $\mu$ mol, 2.50 equiv), Cs<sub>2</sub>CO<sub>3</sub> (195 mg, 600  $\mu$ mol, 2.0 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 0.05 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded 1,3-diphenylprop-2-yn-1-one (**8b**, 35 mg, 0.15 mmol, 51%) as a yellow solid.


Rf (pentane) = 0.7.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39 (ddd, J = 8.0, 3.3, 1.4 Hz, 2H, ArH), 7.28 – 7.25 (m, 3H, ArH), 2.59 (tt, J = 9.3, 3.7 Hz, 1H, CH-alkyne), 1.89 (ddd, J = 15.6, 7.0, 3.3 Hz, 2H, cyclic-CH<sub>2</sub>), 1.76 (dtd, J = 12.2, 6.1, 2.3 Hz, 2H, cyclic-CH<sub>2</sub>), 1.62 – 1.47 (m, 4H, cyclic-CH<sub>2</sub>), 1.44 – 1.29 (m, 2H, cyclic-CH<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  131.7, 128.3, 127.5, 124.3, 94.6, 80.6, 32.9, 29.2, 26.1, 25.1.

Corresponds to reported literature data.<sup>26</sup>

Tert-butyl 4-(phenylethynyl)piperidine-1-carboxylate (8c)



**8c** was synthesized following *general procedure G* using 1-Boc-piperidine-4-carboxylic acid (**7c**, 38 mg, 0.30  $\mu$ mol, 1.0 equiv), PhEBX (**1a**, 261 mg, 750  $\mu$ mol, 2.50 equiv), Cs<sub>2</sub>CO<sub>3</sub> (195 mg, 600  $\mu$ mol, 2.0 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 0.05 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded 1,3-diphenylprop-2-yn-1-one (**8c**, 35 mg, 0.12 mmol, 41%) as a yellow solid.


Rf (pentane:EtOAc 9:1) = 0.4

<sup>1</sup>**H NMR** δ 7.46 – 7.36 (m, 2H, Ar*H*), 7.28 (dt, J = 4.6, 2.9 Hz, 3H, Ar*H*), 3.74 (ddd, J = 13.5, 6.7, 3.7 Hz, 2H, N(C $H_2$ )<sub>2</sub>), 3.25 (ddd, J = 13.5, 8.4, 3.5 Hz, 2H, N(C $H_2$ )<sub>2</sub>), 2.80 (tt, J = 8.0, 4.0 Hz, 1H, CH-alkyne), 1.85 (ddt, J = 13.7, 6.9, 3.6 Hz, 2H, cyclic-C $H_2$ ), 1.67 (dtd, J = 15.1, 7.3, 3.3 Hz, 2H, cyclic-C $H_2$ ), 1.47 (s, 9H, tBu).

Corresponds to reported literature data.<sup>33</sup>

## 5.2.3. Oxime fragmentation

Tert-butyl (cyanomethyl)(3-phenylprop-2-yn-1-yl)carbamate (**10a**)



**10a** was synthesized following *general procedure H* using **9a** (77 mg, 0.30 mmol, 1.0 equiv), PhEBX (**1a**, 261 mg, 750  $\mu$ mol, 2.50 equiv), K<sub>2</sub>CO<sub>3</sub> (46 mg, 0.33 mmol, 1.1 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 0.05 M). Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 20:1) afforded *tert*-butyl (cyanomethyl)(3-phenylprop-2-yn-1-yl)carbamate (**10a**, 60 mg, 0.22 mmol, 74%) as a yellow oil.


Rf (pentane:EtOac 20:1) = 0.35.

<sup>1</sup>H NMR H NMR (400 MHz, Acetonitrile- $d_3$ ) δ 7.46 (m, 2H, PhH), 7.37 (m, 3H, PhH), 4.34 (s, 2H, CH<sub>2</sub>), 4.27 (s, 2H, CH<sub>2</sub>), 1.49 (s, 9H, Boc).

 $^{13}$ C NMR (101 MHz, CD<sub>3</sub>CN) δ 154.9, 132.4, 129.7, 129.5, 128.7, 123.3, 117.6, 85.1, 84.5, 82.7, 36.1, 28.3.

Corresponds to reported literature data.<sup>27</sup>

Tert-butyl (1-cyano-5-phenylpent-4-yn-2-yl)carbamate (10b)



**10b** was synthesized following *general procedure G* using **9b** (86 mg, 0.30 mmol, 1.0 equiv), PhEBX (**1a**, 261 mg, 750  $\mu$ mol, 2.50 equiv),  $K_2CO_3$  (46 mg, 0.33 mmol, 1.1 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 0.05 M). Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 9:1 to 8:2) afforded *tert*-butyl (1-cyano-5-phenylpent-4-yn-2-yl)carbamate (**10b**, 59 mg, 0.21 mmol, 69%) as a yellow solid.

Rf (pentane:EtOac 8:2) = 0.3.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.51 – 7.38 (m, 2H, Ar*H*), 7.39 – 7.28 (m, 3H, Ar*H*), 4.92 (m, 1H, N*H*), 4.14 (m, 1H, C*H*NHBoc), 2.90 – 2.69 (m, 4H, C $H_2$ ), 1.46 (s, 9H, tBu).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 154.7, 131.6, 128.4, 128.3, 122.5, 116.9, 84.3, 83.3, 80.5, 46.3, 28.2, 24.5, 22.5.

Corresponds to reported literature data.<sup>27</sup>

.

<sup>&</sup>lt;sup>33</sup> Liu, X.-G.; Zhou, C.-J.; Lin, E.; Han, X.-L.; Zhang, S.-S.; Li, Q.; Wang, H. *Angew. Chem. Int. Ed.* **2018**, *57*, 13096–13100.

2-((3-Phenylprop-2-yn-1-yl)oxy)acetonitrile (10c)

**10c** was synthesized following *general procedure G* using **9c** (50 mg, 0.30 mmol, 1.0 equiv), PhEBX (**1a**, 261 mg, 750  $\mu$ mol, 2.50 equiv), K<sub>2</sub>CO<sub>3</sub> (46 mg, 0.33 mmol, 1.1 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 0.05 M). Column chromatography (SiO<sub>2</sub>, pentane:EtOAc 95:5) afforded 2--((3-phenylprop-2-yn-1-yl)oxy)acetonitrile (**10c**, 27 mg, 0.16 mmol, 53%) as an off-white oil.

Rf (pentane:EtOac 95:5) = 0.3.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.51 – 7.39 (m, 2H, Ar*H*), 7.39 – 7.30 (m, 3H, Ar*H*), 4.55 (s, 2H, C $H_2$ ), 4.44 (s, 2H, C $H_2$ ).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  131.9, 129.1, 128.4, 121.8, 115.6, 88.7, 82.1, 59.0, 54.1.

Corresponds to reported literature data.<sup>27</sup>

## 5.2.4. Deboronative alkynylation

#### 2-(Phenylethynyl)-2,3-dihydro-1H-indene (12a)



12a was synthesized following general procedure I using potassium 2,3-dihydro-1H-indenyl trifluoroborate (11a, 67 mg, 0.30 mmol, 1.0 equiv), PhEBX (1a, 261 mg, 0.750 mmol, 2.50 equiv), Na<sub>2</sub>CO<sub>3</sub> (64 mg, 0.60 mmol, 2.0 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub>:water (1:1) (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, 0 to 2% EtOAc in Pentane) afforded 2-(phenylethynyl)-2,3-dihydro-1H-indene (12a, 47 mg, 0.22 mmol, 72%) as a pale yellow solid.


Rf (pentane) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43 – 7.40 (m, 2H Ar*H*), 7.30 – 7.27 (m, 3H, Ar*H*), 7.25 – 7.21 (m, 2H, Ar*H*), 7.19 – 7.16 (m, 2H, Ar*H*), 3.49 – 3.40 (m, 1H, C*H*), 3.35 – 3.29 (m, 2H, C*H*<sub>2</sub>), 3.13 (dd, J = 15.2, 8.7 Hz, 2H, C*H*<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  142.2 131.8, 128.3, 127.8, 126.7, 124.5, 123.9, 93.2, 80.7, 40.5, 30.9.

Corresponds to reported literature data. 23

#### But-1-yne-1,4-diyldibenzene (12b)



**12b** was synthesized following *general procedure I* using potassium 2-phenylethyl trifluoroborate (**11a**, 64 mg, 0.30 mmol, 1.0 equiv), PhEBX (**1a**, 261 mg, 0.750 mmol, 2.50 equiv), Na<sub>2</sub>CO<sub>3</sub> (64 mg, 0.60 mmol, 2.0 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub>:water (1:1) (3 mL, 0.1 M). Column chromatography (SiO<sub>2</sub>, 0 to 2% EtOAc in Pentane) afforded but-1-yne-1,4-diyldibenzene (**12b**, 38 mg, 0.18 mmol, 61%) as a pale yellow oil.


Rf (pentane) = 0.4.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.39 - 7.36 (m, 2H, Ar*H*), 7.33 - 7.30 (m, 2H, Ar*H*), 7.31 - 7.27 (m, 5H, Ar*H*), 7.25 - 7.21 (m, 1H, Ar*H*), 2.93 (t, J = 7.5 Hz, 2H, CH<sub>2</sub>), 2.70 (t, J = 7.5 Hz, 2H, CH<sub>2</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 142.2, 131.2, 128.3, 127.8, 126.7, 124.5, 123.9, 93.2, 80.7, 40.5, 30.9. 1 carbon is not resolved.

Corresponds to reported literature data. 23

#### 2-Cyclohexylethynylbenzene (**12c** same structure as **8b**)



12c was synthesized following general procedure I using potassium cyclohexyl trifluoroborate (11c, 57 mg, 0.30 mmol, 1.0 equiv), PhEBX (1a, 261 mg, 750  $\mu$ mol, 2.50 equiv), Na<sub>2</sub>CO<sub>3</sub> (64 mg, 0.60 mmol, 2.0 equiv) in degassed CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 0.05 M). Column chromatography (SiO<sub>2</sub>, pentane) afforded 2-cyclohexylethynylbenzene (12c, 26 mg, 0.14 mmol, 47%) as a yellow solid.

Rf (pentane) = 0.7.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39 (ddd, J = 8.0, 3.3, 1.4 Hz, 2H, ArH), 7.28 – 7.25 (m, 3H, ArH), 2.59 (tt, J = 9.3, 3.7 Hz, 1H, CH-alkyne), 1.89 (ddd, J = 15.6, 7.0, 3.3 Hz, 2H, cyclic-CH<sub>2</sub>), 1.76 (dtd, J = 12.2, 6.1, 2.3 Hz, 2H, cyclic-CH<sub>2</sub>), 1.62 – 1.47 (m, 4H, cyclic-CH<sub>2</sub>), 1.38 – 1.25 (m, 2H, cyclic-CH<sub>2</sub>).

 $^{13}\text{C NMR}$  (101 MHz, CDCl<sub>3</sub>)  $\delta$  131.7, 128.3, 127.5, 124.3, 94.6, 80.6, 32.9, 29.2, 26.1, 25.1.

Corresponds to reported literature data.<sup>23</sup>

## 6. Mechanistic studies

## 6.1. Monitoring of the reaction by <sup>1</sup>H NMR

**Table S3.** Normalized <sup>1</sup>H NMR yields taken over 32 hours

Time (hours)	3a	1a	4a	5a	5b	1a	7	total oxalate	total alkyne
0	1	2.5	0	0	0	1	0	1	2.5
0.5	0.8	1.9	0.11	0.06	0.07	0.76	0.18	0.98	2.5
1	0.51	1.4	0.29	0.21	0.17	0.56	0.36	0.97	2.79
4	0.1	0.58	0.63	0.33	0.17	0.23	0.43	0.9	2.57
8	0.04	0.34	0.66	0.35	0.18	0.14	0.43	0.88	2.39
16	0.04	0.26	0.58	0.35	0.24	0.1	0.48	0.86	2.39
24	0.04	0.14	0.63	0.44	0.24	0.06	0.5	0.91	2.45
32	0.03	0.04	0.62	0.39	0.27	0.02	0.5	0.92	2.32

We attempted to study the evolution of iodobenzoate formation however, due to shift variations in the NMR that our concentration dependent and its insolubility in chloroform the results were non-conclusive. We attempted a study in DMSO- $d_6$  but the signal of trace DCM (reaction solvent) overlapped with the signals of **5a** and **5b**.




Figure S2. Evolution of 1a, 3a, 4a, 5a, 5b and 7 over 32 hours

## 6.2.<u>Side product formation and reaction with TIPS-EBX (1c) monitored by <sup>1</sup>H NMR</u>




Figure S3. Thermal degradation of PhEBX in presence of 3a




Figure S4. TIPS-alkynylation with PhEBX as a photooxidant

## 6.3. Synthesis and characterization of 5a, 5b and 4h

2-Oxo-2-phenylethyl 2-iodobenzoate (5a)

Following a reported procedure,<sup>34</sup> 2-iodobenzoic acid (**20**, 744 mg, 3.00 mmol, 1.00 equiv) and 2-bromo-1-phenylethanone (**39**, 657 mg, 3.30 mmol, 1.10 equiv) were dissolved in acetone (12.0 mL). DIPEA (2.6 mL, 15 mmol, 5.0 equiv) was then added and the reaction mixture was stirred overnight. The mixture was then diluted with EtOAc and washed with water. The organic layer was dried over

<sup>&</sup>lt;sup>34</sup> Speckmeier, E.; Zeitler, K. *ACS Catal.* **2017**, *7*, 6821–6826.

MgSO<sub>4</sub>, filtered and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography ( $SiO_2$ , 10% EtOAc in pentane, Rf = 0.4) obtaining 2-oxo-2-phenylethyl 2-iodobenzoate (**5a**, 660 mg, 1.80 mmol, 60% yield) as an off-white solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.06 (dd, J = 7.8, 1.7 Hz, 1H, ArH), 8.03 (dd, J = 8.0, 1.2 Hz, 1H, ArH), 8.00 – 7.94 (m, 2H, ArH), 7.68 – 7.59 (m, 1H, ArH), 7.56 – 7.49 (m, 2H, ArH), 7.45 (td, J = 7.7, 1.2 Hz, 1H, ArH), 7.20 (td, J = 7.7, 1.7 Hz, 1H, ArH), 5.60 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, CDCl3) δ: 191.8, 165.9, 141.6, 134.3, 134.2, 133.2, 131.8, 129.1, 128.2, 128.0, 94.6, 66.9. 1 Carbon atom is unresolved. Constitent with reported literature data.<sup>34</sup>

2-methyl-4-phenylbutan-2-yl (2-oxo-2-phenylethyl) oxalate (5b)

Following a modified reported procedure, 35 a solution of 2-methyl-4-phenylbutan-2-ol (26a, 0.85 mL, 5.0 mmol, 1.0 equiv) in Et<sub>2</sub>O (40 mL) was cooled to 0 °C. Oxalyl dichloride (0.90 mL, 10 mmol, 2.0 equiv) was then added dropwise. The mixture was warmed to room temperature after 10 min, and after an additional 1.5 h, oxalyl dichloride (0.44 mL, 5.0 mmol, 1.0 equiv) were added. After an additional 1h oxalyl dichloride (0.90 mL, 10 mmol, 2.0 equiv) was added and the reaction was stirred for another hour. The reaction was carefully quenched at 0 °C by the dropwise addition of H2O (30 mL) after addition of a vent needle. The mixture was stirred vigorously and warmed to room temperature. The layers were separated, and the aqueous layer extracted with Et<sub>2</sub>O (3 x 15 mL), and the combined organic layers dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure affording 2-(2methyl-4-phenylbutan-2-yl)oxy-2-oxoacetic acid as a clear oil (767 mg, 3.25 mmol, 65% yield), which was used directly in the next step. Following a modified reported procedure, 34 the crude oil of 2-(2methyl-4-phenylbutan-2-yl)oxy-2-oxoacetic acid (40, 767 mg, 3.25 mmol, 1.0 equiv) was dissolved in acetone (12 mL). DIPEA (2.4 mL, 15 mmol, 5 equiv) and phenacyl bromide (39, 597 mg, 3.00 mmol, 0.9 equiv) were then added. The reaction was stirred overnight. The reaction was quenched with water (5 mL), diluted with EtOAc (20 mL). The organic layer was washed with sat. aq. NH<sub>4</sub>Cl (3 x 10 mL), then brine (10 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford 2-methyl-4-phenylbutan-2-yl (2-oxo-2-phenylethyl) oxalate as a crude yellow oil (5b, 930 mg, 2.62 mmol, 87% yield, 52% yield over both steps).

•

<sup>&</sup>lt;sup>35</sup> Su, J. Y.; Grünenfelder, D. C.; Takeuchi, K.; Reisman, S. E. *Org. Lett.* **2018**, *20*, 4912–4916.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.96 – 7.89 (m, 2H, Ar*H*), 7.67 – 7.58 (m, 1H, Ar*H*), 7.50 (t, J = 7.7 Hz, 2H, Ar*H*), 7.29 (t, J = 7.5 Hz, 2H, Ar*H*), 7.25 – 7.17 (m, 3H, Ar*H*), 5.50 (s, 2H, C(O)CH<sub>2</sub>O), 2.77 – 2.69 (m, 2H, PhCH<sub>2</sub>), 2.23 – 2.14 (m, 2H, CH<sub>2</sub>), 1.65 (s, 6H, C(CH<sub>3</sub>)<sub>2</sub>.

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 190.1, 157.7, 156.2, 141.6, 134.2, 133.9, 129.0, 128.5, 128.5, 127.9, 126.0, 87.2, 67.6, 42.6, 30.3, 25.8.

IR  $(v_{max}, cm^{-1})$  2978 (s), 2904 (s), 1739 (m), 1705 (m), 1381 (m), 1242 (m), 1165 (s), 1111 (s), 1065 (s).

**HRMS** (ESI/QTOF) m/z:  $[M + Na]^+$  Calcd for  $C_{21}H_{22}NaO_5^+$  377.1359; Found 377.1363.

## (3,3-Dimethyl-5-phenylpent-1-yn-1-yl)triisopropylsilane (4h)

An oven dried dram vial (2 mL), equipped with a magnetic stirrer, was charged with cesium oxalate (3a, 0.036 g, 0.10 mmol, 1 equiv), TIPS-EBX (1c, 0.064 g, 0.15 mmol, 1.5 equiv) and PhEBX (1a, 0.026 g, 0.075 mmol, 0.75 equiv). The reaction vial was sealed with a septum. After 3 vacuum/N2 cycles (backfilling with Ar on the last cycle), dry degassed (freeze pump thaw)  $CH_2Cl_2$  was added and the septum was replaced with a screw cap under a flux of Ar. The reactions were placed between 2 x 440 nm Kessil lamps at ca. 10 cm distance from both lamps (with ventilation T = ca. 30-35°C as specified) and stirred under irradiation for 18 hours. The reaction was filtered through a small celite plug which was washed with  $CH_2Cl_2$ . The reaction crude was concentrated *in vacuo*, and purified by preparative TLC (SiO2, heptane), affording (3,3-dimethyl-5-phenylpent-1-yn-1-yl)triisopropylsilane (4h, 2 mg, 0.006 mmol, 6% vield)

**Rf** (pentane) = 0.55

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29 (d, J = 7.6 Hz, 2H, ArH), 7.23 – 7.14 (m, 3H, ArH), 2.85 – 2.75 (m, 2H, PhC $H_2$ ), 1.72 – 1.65 (m, 2H, C $H_2$ ), 1.26 (s, 6H, C(C $H_3$ )<sub>2</sub>), 1.13 – 0.98 (m, 22H, TIPS).

<sup>13</sup>C NMR (101 MHz, CDCl3) δ 143.0, 128.4, 128.4, 125.6, 116.2, 79.4, 45.8, 32.2, 29.7, 29.4, 18.7, 11.3.

**HRMS** (APPI/LTQ-Orbitrap) m/z:  $[M + Na]^+$  Calcd for  $C_{22}H_{36}NaSi^+$  351.2478; Found 351.2485.

#### 6.4.Control experiments

An oven dried dram vial (2 mL), equipped with a magnetic stirrer, was charged with the solid components following table S3: cesium oxalate **3a**, TIPSEBX (**1c**), PhEBX (**1a**), 4CzIPN (**2a**), **5a**, **5b**, BIOAc (**19a**), BIOH (**19b**). The reaction vial was sealed with a septum. After 3 vacuum/N2 cycles (backfilling with Ar on the last cycle),  $CH_2CI_2$  (3.0 mL) was added and the septum was replaced with a

screw cap under a flux of Ar.<sup>36</sup> The reactions were placed between 2 x 440 nm Kessil lamps (unless specified otherwise) at ca. 10 cm distance from both lamps (no ventilation, T = ca. 50 °C) and stirred under irradiation for 18 hours. The reaction was filtered through a small celite plug which was washed with  $CH_2Cl_2$ . The reaction crude was concentrated *in vacuo*, diluted with  $CDCl_3$  and 1 equiv of  $CH_2Br_2$  was added as internal standard for <sup>1</sup>H NMR analysis.

Table S4. Control reactions for the indetification of the photoactive species without photocatalyst

entry <sup>a</sup>	Reagent (1.5 equiv)	additive (equiv)	residual 3a (%)	<sup>1</sup> H NMR yield <sup>b</sup> (%)
1	1c	-	100	nd
2	1c	<b>1a</b> (0.05)	30	25
3	1c	<b>5a</b> (0.2)	98	2
4	-	<b>5a</b> (1.0)	100	-
5°	1a	<b>5b</b> (1.0)	-	$nd^d$
6	1c	<b>5b</b> (0.7)	>90	<5
7	1c	<b>19a</b> (0.2)	92	5
8	1c	<b>19b</b> (0.2)	92	5
9	-	<b>19a</b> (1.5)	100	-
10	-	<b>19b</b> (1.5)	90	-
11	-	<b>5b</b> (1.0)	>95	-
12	1c	<b>1a</b> (0.2)	80	16

<sup>&</sup>lt;sup>c</sup>No cesium salt was used. <sup>d</sup>No degradation of **6b** was observed, full decomposition of PhEBX. This suggests that **6b** is not a reaction intermediate.

## 6.5.UV-Vis absorption and fluorescence studies

Absorption and fluorescence studies of PhEBX 1a and the cesium oxalate 3a

A 5 mL 0.2 M stock solution of PhEBX (348 mg, 1.00 mmol) and a 2 mL 0.2 M stock solution of **3a** (147 mg, 0.4 mmol) were prepared in DMSO (from fresh ampoules, degassed and deuterated) were prepared in a 5 mL and 2 mL volumetric flask. The samples were prepared by dissolving 0.50 mL of stock solution with 0.5 mL of fresh DMSO, final concentration: 0.1 M. The samples were then submitted to UV-Vis, fluorescence and fluorescence excitation spectroscopy.

\_

 $<sup>^{36}</sup>$  Use of a screw cap or crimp cap is of great importance, the irradiation causes an increase in temperature causing the  $CH_2Cl_2$  to evaporate and an overpressure inside the vessel. When using a septum, the latter would fly off within an hour of irradiation. As shown in the optimization section DCE is not as good a solvent as  $CH_2Cl_2$ .




Figure S5. Absorption of PhEBX 2a, 0.1 M in DMSO




Figure S6. Absorption of 3a 0.1 M in DMSO

We checked for the presence of an EDA complex by combining 0.50 mL of both stock solutions of **2a** and **3a** and measuring the UV-Vis spectrum, no new band can be observed (Figure S7)





Figure S7. Absorption of a 1:1 mixture 2a:3a.



**Figure S8.** Normalized absorption, fluorescence (390 nm) and fluorescence excitation (485 nm) of **1a** (0.1 M) in DMSO

Absorption and Beer-Lambert linear regression at 420 nm and 440 nm of PhEBX (1a)

A 5 mL 0.14 M stock solution of PhEBX (1a, 243 mg, 0.700 mmol) in DMSO (from fresh ampoules, degassed and deuterated) was prepared in a 5 mL volumetric flask. Then 1 mL solutions were prepared following table S4, where C(1a) is the concentration of the stock solution, V(1a) is the volume of the stock solution used for the sample, V(DMSO) the volume of DMSO added for the dilution C<sub>f</sub>(1a) the final concentration of the sample. UV-Vis spectra of each sample were then measured. Reproducibility of the measure was verified by repetition of the analyses.

Table S5. Sample preparation table for UV-Vis analyses for the Beer-Lambert linear regression

C(1a) (M)	V(1a) (mL)	V(DMSO) (mL)	C <sub>f</sub> (1a) (M)
0.14	0	1.00	0
0.14	0.10	0.90	0.014
0.14	0.30	0.70	0.042
0.14	0.50	0.50	0.07
0.14	0.70	0.30	0.098
0.14	1.00	0	0.14

1.4 1.2 0.014 M 1 Absorbance 8.0 -0.042 M 0.07 M 0.098 M 0.4 **-**0.14 M 0.2 0 470 570 670 320 370 420 520 620 720 770 λ (nm)

Figure S9. Absorption spectra of 1a at concentrations from 0.014 M to 0.14 M in DMSO




Figure S10. Beer-Lambert linear regression for 420 nm and 440 nm

#### 6.6.Cyclic voltammetry of PhEBX (1a)

An Autolab potentiostat with a 3 electrode cell configuration: glassy carbon (working electrode), Pt wire as (control electrode), and Ag/AgCl (KCl, 3 M aq.) as (reference electrode) was used for the measures. Tetrabutyl ammonium hexafluorophosphhate (TBAP, 0.1 M in MeCN) was used as an electrolyte. PhEBX (1a, 3.5 mg, 0.01 mmol) was dissolved in a stock solution of TBAP (0.1 M, 10 mL in MeCN) and was degassed by bubbling Argon directly before measure. The redox couple E( $1a/1a^{*-}$ ) is defined as the potential E measured for  $\frac{I_{max}}{2}$ .




Figure S11. Cyclic voltammogram of 1a

$$\begin{split} I_{max} = 36~\mu\text{A}; ~ \frac{I_{max}}{2} = 18~\mu\text{A}~E = ~-0.87~V~vs~SCE~for~I = 18\mu\text{A} \\ E_{1/2}(\textbf{1a/1a^{\bullet-}}) = ~-0.87~V~vs~SCE \end{split}$$

 $E_{1/2}(1a^*/1a^*) = E_{0-0} + E_{1/2}(1a/1a^*)$ .  $E_{0-0}$  was determined experimentally by position of the long wavelength tail of the absorption spectrum at 460 nm (Figure S8).<sup>37</sup>

$$E = \frac{hc}{\lambda}$$
 
$$E_{0-0} = \frac{1240}{460} = 2.7 \text{ eV}$$
 
$$E_{1/2}(\mathbf{1a}^*/\mathbf{1a}^{\bullet-}) = E_{0-0} + E_{1/2}(\mathbf{1a}/\mathbf{1a}^{\bullet-}) = 2.7 - 0.87 = 1.83 = +1.8 \text{ V vs SCE}$$


# 7. NMR spectra of new compounds


٠

<sup>&</sup>lt;sup>37</sup> Buzzetti, L.; Prieto, A.; Roy, S. R.; Melchiorre, P. Angew. Chem. Int. Ed. **2017**, 56 (47), 15039–15043.

### Compound 1h


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






# Compound **26e**


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






# Compound 26f


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




 $^{13}\text{C NMR, CDCl}_3$ , 101 MHz




# Compound **26m**








# Compound **26n**













### Compound 28a


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






#### Compound 3a


<sup>1</sup>H NMR, D<sub>2</sub>O, 400 MHz






# Compound **3b**


<sup>1</sup>H NMR, DMSO, 400 MHz









#### Compound 28c









### Compound 3c


<sup>1</sup>H NMR, DMSO, 400 MHz






### Compound 28d


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






### Compound 3d


<sup>1</sup>H NMR, DMSO, 400 MHz






### Compound 28e

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





 $^{13}\text{C NMR, CDCl}_3$ , 101 MHz



### Compound 3e


<sup>1</sup>H NMR, DMSO, 400 MHz






### Compound 28f

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





 $^{13}\text{C NMR, CDCl}_3$ , 101 MHz




### Compound 3f

<sup>1</sup>H NMR, DMSO, 400 MHz






### Compound 28i









### Compound 3i


<sup>1</sup>H NMR, DMSO, 400 MHz






# Compound 28j


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






### Compound 3j (with 25% 28j)


<sup>1</sup>H NMR, DMSO, 400 MHz






### Compound 28k

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





 $^{13}$ C NMR, CDCl $_3$ , 101 MHz




### Compound 3k

<sup>1</sup>H NMR, DMSO, 400 MHz






### Compound 28I









### Compound 31

<sup>1</sup>H NMR, DMSO, 400 MHz









### Compound 28m


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






### Compound 3m

<sup>1</sup>H NMR, DMSO, 400 MHz










### Compound 28n

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz











### Compound 3n


<sup>1</sup>H NMR, DMSO, 400 MHz













### Compound 280


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






# Compound 3o


<sup>1</sup>H NMR, DMSO, 400 MHz






# Compound 28p


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






# Compound **3p**

<sup>1</sup>H NMR, DMSO, 400 MHz





<sup>13</sup>C NMR, DMSO, 101 MHz



# Compound 28q


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






# Compound 3q

<sup>1</sup>H NMR, DMSO, 400 MHz





<sup>13</sup>C NMR, DMSO, 101 MHz



# Compound 28w


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






# Compound 3w

<sup>1</sup>H NMR, DMSO, 400 MHz





<sup>13</sup>C NMR, DMSO, 101 MHz



# Compound 28x


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






# Compound 3x

<sup>1</sup>H NMR, DMSO, 400 MHz





<sup>13</sup>C NMR, DMSO, 101 MHz



# Compound 9a


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






# Compound 9c

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




 $^{13}$ C NMR, CDCl $_{3}$ , 101 MHz




# Compound 11a (previously reported)

<sup>1</sup>H NMR, Acetone, 400 MHz




# Compound **11c** (previously reported)


<sup>1</sup>H NMR, DMSO, 400 MHz



# Compound 4a










# Compound 4b

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz









Compound 4c

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





<sup>13</sup>C NMR, CDCl<sub>3</sub>, 101 MHz




## Compound 4d

#### <sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






## Compound 4e




<sup>13</sup>C NMR, CDCl<sub>3</sub>, 101 MHz




Compound 4f

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




<sup>13</sup>C NMR, CDCl<sub>3</sub>, 101 MHz




## Compound 4g

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




## $^{13}$ C NMR, CDCl $_{3}$ , 101 MHz




## Compound 4h

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





 $^{13}$ C NMR, CDCl $_3$ , 101 MHz



## Compound 4i


#### <sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






Compound 4j

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




 $^{13}\text{C NMR, CDCl}_3$  (with 1V% TMS), 101 MHz




Compound 4k

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





<sup>13</sup>C NMR, CDCl<sub>3</sub>, 101 MHz



# Compound 4I


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






## Compound 4m


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz







## Compound 4n


## <sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




## $^{13}$ C NMR, CDCl $_3$ , 101 MHz









## Compound 4o




 $^{13}$ C NMR, CDCl $_3$ , 101 MHz




## Compound 4p




<sup>13</sup>C NMR, CDCl<sub>3</sub>, 101 MHz



# Compound 4q





<sup>13</sup>C NMR, CDCl<sub>3</sub>, 101 MHz





## Compound 4r

## <sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz













## Compound 4s

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz











# Compound 4t

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





## $^{13}$ C NMR, CDCl $_3$ , 101 MHz



## Compound 4u


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz






## Compound 4v


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





 $^{13}\text{C NMR, CDCl}_3$ , 400 MHz




## Compound 4w











HMBC ( O1P = 55 ppm; SW = 80 ppm)





NOESY (O1P = 4 ppm, SW = 8 ppm)





## Compound 4x


<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz


















#### NOESY




## Compound 8a (previously reported)

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




#### Compound **8b** (previously reported)




## Compound **8c** (previously reported)

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




## Compound 10a (previously reported)




## Compound **10b** (previously reported)

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz




## Compound 10c (previously reported)




## Compound 12a (previously reported)

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





# Compound 12b (previously reported)



Compound 16

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





## Compound **5b**

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz

